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ABSTRACT 
As in other less developed countries in the region and elsewhere, cancers are becoming a 
major cause of morbidity and mortality in Jordan. Globally, colorectal cancer (CRC) is the 
second most common cancer in women and the third most common cancer in men. In 
Jordan, CRC is the second most common cancer in women and the most common in men. 
There is little known about survival from CRC in Jordan and few survival studies have 
been conducted in comparable Eastern Mediterranean countries.  
 
As the first study of its type in Jordan, this thesis aimed at estimating CRC survival among 
Jordanian patients and comparing them with survival estimates among other populations. 
The thesis explored the relationship between CRC and socio-demographic characteristics, 
clinical manifestations, treatment, diabetes mellitus – for which the prevalence in Jordan is 
very high - and treatment sites. The study augmented existing Jordan Cancer Registry data 
by gathering additional case mix information and completing missing fields. CRC was 
classified according to international classification of oncology (ICD-O third edition in 
addition to the International Classification of Diseases, ICD-10) as C18.0-C20.9. The vital 
status of the patients was ascertained from Civil Registration Bureau based on use of the 
unique National Identification number of the patients with follow-up to 31 December, 
2010. The survival duration of each case was determined as the time difference (in days) 
between the date of incidence (index date) and the date of death, date of loss to follow-up 
or the closing date for follow-up (31 December, 2010). Observed and relative CRC 
survival rates were calculated among a study population of 1,896 Jordanian colorectal 
patients aged 15 to 99 years of age, diagnosed with first invasive primary CRC from 
January 2003 to December 2007. The Kaplan-Meier method was used to determine the 
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observed survival probability over time. The logrank test was used to estimate whether the 
difference in survival estimates was statistically significant between the groups. The 
complete approach of estimation of observed survival probability was used. Cox 
proportional hazard regression was used to assess the effect of each variable after 
simultaneously controlling the effects of potential confounders.  
 
With half of the sample aged 60 years and above, males were predominant (55.5 percent) 
with the majority of the sample (75.4 percent) residing in the central part of Jordan. The 
vast majority of the cases (63.5 percent) were diagnosed with colon cancer, with regional 
metastasis present in 58.9 percent. No significant difference was found in the distribution 
of colon and rectum cancer by sex. Adenocarcinoma was the most commonly found tumor 
(84.4 percent) compared to mucinous tumors which was found in 7.8 percent of the 
patients. In addition, 62.7 percent of the cases were classified as moderate and 14.9 percent 
as poor. The percentages of rectum cancer patients with moderate and poor/anaplastic 
types of cancer were higher than in colon cancer patients. The majority of patients (77.9 
percent) underwent surgery, which was mostly elective (82.0 percent). A significantly 
higher occurrence of these elective surgeries was found among rectum cancer (87.7 
percent) than colon cancer patients (78.7 percent). Curative treatment was found to be a 
more common form of treatment for colorectal cancer patients (76.5 percent) than 
palliative (23.5 percent). Of those undergoing surgery, 4.8 percent has died within 30-days 
of resection, with a significantly lower mortality among patients aged ≤ 65 years (2.9 
percent) than the over 65 years age group (7.1 percent). Thirty days postoperative mortality 
was significantly higher among colon cancer patients (5.3 percent), patients with more 
advanced tumours and those who underwent emergency operations. 
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Results of this study revealed that the incidence of CRC in the Jordanian population to be 
low compared to developed countries. However, this low incidence is similar to CRC 
incidence rates in other countries in the region.  During the 5-year study period, the overall 
crude colorectal cancer incidence rate for males was 5.6 per 100,000 population, and 5.1 
per 100,000 populations in females. The overall Age Standardized colorectal incidence rate 
(ASR) among males was 15.5 per 100,000 populations compared to 12.5 per 100,000 
populations among females.  For colon cancer, the crude incidence rate was 5.4 per 
100,000 populations in males and 4.1 per 100 000 populations in females, while ASR for 
males was 11.1 and 8.4 for females. Alternatively, the crude incidence rate for rectum 
cancer was 3.0 per 100,000 population for males and 2.4 per 100,000 population for 
females, and the respective ASR incidence rates was 6.1 per 100,000 males and 4.9 per 
100,000 females. Unexpectedly, results showed a high percentage (13.8 percent) of CRC 
patients among the young age groups (i.e. less than 40 years of age) with insignificant 
differences between the sexes. The age specific incidence rates were found to increase with 
age.  
 
The study revealed that 5-year observed and relative survival probabilities for colorectal 
cancer to be 57.7 and 61.3 percent respectively, with higher probability for colon cancer. 
These results showed good survival estimates of colorectal cancer compared to developed 
countries as well as the most developed countries in the region and across the Asian 
continent. The slightly higher observed colorectal survival rates among females were found 
to be insignificantly different than those for males. Patients aged 45 through 59 years had 
the highest survival estimates among all age groups, and the 75 years and above age group 
the lowest. The highest survival estimates were found among patients living in the central 
parts of Jordan, and the poorest was significantly noted in the south. Moreover, the 
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observed and relative survival estimates were consistently highest during Year 1 and 
lowest during Year 5. 
 
Mucinous and serous tumors showed the poorest survival rates among the colorectal 
cancer, with higher 5-year relative survival rates among the mucinous and serous type of 
colon (52.4 percent) compared to rectum cancer (42.8 percent). With more than half of the 
colon patients (57.2 percent) and rectal patients (62 percent) having a regional spread; a 
higher proportion of colon cancers (24.1 percent) were found to have distant metastasis, 
than rectum cancer patients (20.5) and an equally low (11 percent) had localized CRC at 
diagnosis. Results also showed that observed and relative survival rates from localized and 
regional colon cancer were better than survival from rectum cancer in the same stages at 1, 
3 and 5-years of diagnosis. Results also indicated that observed survival became poorer 
with increasing age for both localized and regional tumours. This observation was 
applicable for both males and females.  
 
In recognizing appropriate surgery as the most important aspect of colorectal cancer 
treatment, the observed survival probability for colorectal cancer patients who underwent 
surgery was found significantly higher than that for patients who did not undergo surgery. 
This scenario was similarly observed for both colon and rectum. Conversely, the overall 
relative survival rates for patients who underwent surgery declined from 96.2 percent to 
62.6 percent between the first and fifth year and from 86.5 percent to 23.5 percent for 
patients who did not undergo surgery. In addition, no significant difference was found 
between colorectal survival estimates for patients who underwent elective surgery and 
those who underwent emergency surgery. This was held true for both colon and rectum 
cancer. 
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A multivariable analyses done to examine the adjusted odds of death within 30 days of 
surgery and selected variables revealed that the odds of dying were significantly higher 
among colorectal cancer patients older than 65 years (OR 2.3, 95percent CI: 1.3-4.1), those 
with distant tumors (OR 3.6, 95percent CI: 2.0-6.2); and those who were operated upon as 
an emergency (OR 2.3, 95percent CI: 1.2-4.1). 
 
Study findings indicated that colorectal cancer patients who received chemotherapy 
treatment had better survival for almost the first four years. However this was not a 
statistically significant result. Similarly, colon cancer patients who received chemotherapy 
treatment had better survival rates for nearly four years, compared to rectum cancer 
patients had better survival rates for the first two years from receiving chemotherapy. 
 
In terms of treatment sites (hospitals), results showed that 32.4 percent of cases were 
treated at public health facilities, 23.4 percent at King Hussein Cancer Center (KHCC), 
18.4 percent at the teaching hospitals, 16.8 percent at the private health facilities, and only 
9.1 percent at other sites.   The results of Cox proportional hazards ratios, after adjusting 
for age, extent of disease, place of residence, surgery, chemotherapy, radiotherapy and 
intent of treatment, have shown that patients who received treatment in private hospitals as 
well as in the King Hussein Cancer Center, had better survival rates compared to those 
who received their treatment in the public sector. 
Finally, this study revealed that the mean survival for colorectal cancer patients with 
diabetes mellitus was significantly lower than that for patients without diabetes (Log-Rank 
test, p=0.0359). The study also revealed a significant relationship between diabetes 
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mellitus and colon cancer survival, where diabetic patients with colon cancer were less 
likely to survive compared to non-diabetic patients with colon cancer. However, no 
significant association was observed regarding diabetic patients with rectum cancer. In 
addition, multivariate analysis identified diabetes mellitus as a significant predictor 
associated with lower observed survival, where diabetic patients were one and one-half 
times more likely to be at risk of dying compared to non-diabetic patients.  Age group 75 
years or older, regional and distant metastasis of disease were shown to be independent 
prognostic factors for observed survival in this multivariate analysis. 
 
The Cox proportional hazard model showed that age, place of residency, extent of disease, 
and morphology to be significant predictors for colorectal cancer survival. Colon cancer 
patients aged 75 years and above had 2.2 times higher risk of death than those aged 44 
years or less ( HR=2.2, 95percent CI: 1.5-3.1). Rectum cancer patients residing in the 
central region of the country had a 27 percent lower risk of death compared with those who 
resided in the North (HR=0.73, 95percent CI: 0.56-0.95). Colon and rectum cancer patients 
with regional metastasis had three times and one and the half times higher risk of death 
than those with localized disease respectively (Colon: HR=3.3, 95percent CI: 2.0-5.6); 
(Rectum: HR=1.6, 95percent CI: 1.1-2.5). Moreover, colon patients with distant metastasis 
had fourteen times higher risk of death and rectum cancer patients portrayed four and the 
half times higher risk of death than those with localized disease (Colon: HR=14.0, 
95percent CI: 8.0-23.8); (Rectum: HR=1.6, 95percent CI: 2.8-7.5). Colon patients with 
poor or anaplastic grade had almost twice the risk of death than those with well grade 
(HR=1.9, 95percent CI: 1.1-3.2). On the other hand, patients diagnosed with mucinous 
rectum cancer had 1.4 times higher risk of death than those with adenocarcinoma (HR=1.4, 
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95percent CI: 1.1-2.1). Sex, grade and year of diagnosis were insignificant predictors 
across all three models (CRC, colon and rectum).  
 
The main highlights of the study findings included a higher than expected incidence and a 
poorer than expected colorectal survival among the younger population, a large variation in 
survival rates based on the place of residency, and a significantly poorer survival among 
diabetic patients. Results of this study prompted a set of recommendations to assist 
national efforts in preventing and improving the survival of colorectal cancer in Jordan. 
These recommendations included various actions and measures to strengthen health service 
provision; assure provision of health care by expanding services; improve monitoring by 
promoting policy and research; and improve and strengthen data quality measures. 
Specifically, the study recommended screening to be made at a younger age in Jordan than 
in other developed countries as a result of the high percentage of CRC (13.8percent) 
among young age groups (<40 year) that was reported in the study. Conducting further 
research to investigate the reasons for poor survival rates among younger CRC patients is 
presented as a strong study recommendation.  
 
In addition, introducing managed clinical networks as an approach for reducing the 
variation in survival between the different hospitals was presented as a worthwhile 
recommendation. Undoubtedly, improving public health efforts to reduce the prevalence of 
Diabetes Mellitus, in addition to undertaking further research to explain the increased 
mortality among diabetic colorectal patients are presented as valuable recommendations in 
this study. Finally, the study recommended that the Jordan Cancer Registry play a major 
role in following-up with cancer patients to examine the quality of cancer services that they 
receive.  
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CHAPTER 1 – INTRODUCTION  
 
1.1 Overview 
This chapter aims at introducing the reader to the rationale, aims and objectives of this 
thesis. The chapter begins by providing an overview of the thesis and its organization by 
presenting the different chapters and a synopsis for each. This chapter moves on towards 
identifying the rationale, aims and objectives for undertaking this study. The chapter 
focuses on the significance of the study and the logical argument for conducting it.  
 
1.2 Thesis Overview  
This thesis is organized and presented as follows: 
 
Chapter 1 includes the rationale, the significance of the study, the study's general outline, 
the study’s aims, objectives and the research questions. This chapter provides the logical 
and systematic construction of the thesis. 
 
Chapter 2 provides a review of the literature starting with background information on 
Jordan where general information about Jordan’s geographical and population 
characteristics, health care system and mortality system is discussed. In addition, the 
chapter provides a discussion on the burden of diseases in general, as well as the burden of 
cancer. The chapter then proceeds to give an overview of cancer and present the problem 
of CRC with an emphasis on definition, epidemiology, symptoms, risk factors, screening 
and treatment. Research work describing the different factors that can influence CRC 
survival rates, namely: age; clinical characteristics of the tumour; type of treatment; 
comorbidity; country of residence, socio-demographic characteristics (i.e. race and 
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ethnicity, sex and socio-economic status); health services; and residence-related factors 
(i.e. country of residence and community-related factors) are depicted and discussed to 
explain the motivation for pursuing this thesis.  
 
Chapter 3 offers a discussion on the materials and methods used in conducting the study 
as well as a presentation of the procedures and study design. This chapter focuses on data 
sources, eligibility and inclusion criteria, study instruments and description of data 
collection, data quality control, data analysis techniques and procedures, terms and 
definitions, and human research ethical approvals are also included in this chapter.  
 
Chapter 4 - 9 present the main findings of the study in parallel with the main study 
objective. These chapters follow a similar presentation pattern where each provides an 
introduction, presentation of main results, summary and discussion of main findings. 
Following is a listing and description of these chapters. 
Chapter 4 includes a description of the study population in terms its socio-
demographic characteristics, as well as clinical and treatment 
characteristics. 
Chapter 5 presents incidence rates of CRC in the Jordanian population over the 
study period. The chapter also presents results of CRC survival 
analysis and findings associated with observed and relative survival 
rates related to patients’ characteristics: specifically, socio-
demographic characteristics, (age, sex, residency and year of 
diagnosis).  
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Chapter 6 presents and discusses the results of CRC survival analysis in relation 
to the clinical manifestations (site, histopathology, grade, stage) and 
treatment and the effect of these factors on the survival rate of CRC. 
Chapter 7 presents the results and discussion of CRC survival estimates and the 
effects of treatment sites on them. It presents differences of CRC 
survival estimates across treatment sites within Jordan and attempts to 
explain survival disparities detected between the treatment sites. 
 
Chapter 8 presents the results and discussion of colorectal survival and its 
association with diabetes mellitus in an attempt to detect the 
association of diabetes mellitus with CRC survival and rationalize its 
impact on patient outcome. 
 
Chapter 9 presents an overall discussion and a summary of the main results, 
implications and recommendations for further related research based 
on the main study findings. This chapter concludes the study and is 
followed by a list of references, annexes and appended material. 
 
1.3 Study Rationale  
Cancer is considered to be a disease of the developed countries, whereas Jordan, one of the 
low-middle-income countries, is experiencing an epidemiological transition where 
infectious diseases are declining and chronic diseases are becoming more predominant 
(1;2). Sedentary lifestyle, high fat diet, and smoking are becoming common in Jordan 
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(3;4). As in other less developed countries in the region and elsewhere, cardiovascular 
diseases (CVD) and cancer are the major causes of morbidity and mortality in Jordan. 
 
Communicable diseases have been the main diseases of the less developed countries. 
Recent development in less developed countries produced an increase in life expectancy 
together with changes in lifestyle leading to an epidemic of cancer (5;6). Based on current 
trends, it is estimated that 70 percent of the new cases of cancer will be diagnosed in 
people living in developing countries by the year 2020 (7). In addition, recent annotation 
by the World Health Organization (WHO) and the International Agency for Research on 
Cancer (IARC) indicated that 12.5 percent of all deaths in less developed countries are 
caused by cancer. Furthermore, cases in less developed countries are diagnosed with an 
advanced stage or terminal cancers at the time they are presented to the health system (7-
9).  
 
Cancer survival statistics are a means of quantifying the effectiveness of early detection 
strategies and treatment regimens at the population level (10;11). They are useful as 
comparative measures between different populations. It is these comparisons that help 
identify possible reasons for the differences and suggest targets for improvement and a 
means of monitoring progress towards them (12-14).   
 
Due to the tremendous impact of cancer on the health care system and the escalating cost 
of health care, strategies for cancer prevention and control are becoming increasingly 
important. Recently, Jordan launched the National Health Research Priorities Programme 
(2009-2012) in cooperation with the WHO, which included CRC at the top of its list of 
priorities (15). However, as other Eastern Mediterranean countries, Jordan still suffers 
from a scarcity of local studies that investigate the cancers’ survival.  
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Few survival studies have been conducted in developing countries (14;16-18), particularly 
in Eastern Mediterranean countries. Currently the situation is mainly described through the 
results of studies conducted in the developed countries (13;19-21). To the best of the 
author’s knowledge, survival statistics of CRC in Jordan are not available. Therefore, 
results of this study will support the crucial need to better understand the burden of CRC in 
Jordan, thus contributing to the implementation of the national efforts of cancer prevention 
and control. 
 
1.4 Study aims and objectives 
This is the first CRC survival study in Jordan. The study aimed to establish the estimates of 
survival among Jordanian patients with CRC and to compare them with survival estimates 
among other populations. The second major aim of this study was to investigate the 
possible influence of socio-demographic characteristics, clinical manifestations and 
treatment on the survival of CRC in Jordan. Another aim of this study was to explore 
possible survival differences of CRC across treatment sites that provide cancer treatment 
within Jordan. Finally, the study aimed at determining the possible effect of diabetes 
mellitus (one of the most prevalent comorbidities in Jordan) on CRC survival among 
Jordanian patients.  
 
1.4.1 Research questions  
Six research questions were formulated based on the review of the relevant literature and to 
address the gaps found in the literature. These questions were: 
RQ1: What are the observed and relative 5 years survival rates of CRC among Jordanian 
patients diagnosed in 2003-2007?  
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RQ2: Do survival rates from CRC differ between Jordan and other comparable countries, 
and if so, how can this be explained? 
RQ3: Do socio-demographic characteristics (e.g. age, sex, place of residency, etc.) affect 
the survival rate of CRC in Jordan? 
RQ4: Do the patient’s clinical manifestations (site, histopathology, grade, stage) and 
treatment of the tumour affect the survival rate of CRC in Jordan? 
RQ5: Are there differences of CRC survival estimates across treatment sites within Jordan 
and how could they be explained?   
RQ6: Does diabetes mellitus – which has very high prevalence in Jordan - affect the 
survival of CRC among Jordanian patients?  
 
1.4.2 Study objectives  
The Study objectives were developed to answer the research questions.  They are the 
following:  
Study objective 1: To produce estimates of observed and relative survival estimates for 
Jordanian patients diagnosed with CRC in 2003-2007.  
Study objective 2: To compare CRC survival among Jordanian patients with other 
comparable populations, and to explain the possible differences.   
Study objective 3: To investigate the possible influence of socio-demographic 
characteristics (e.g. age, sex, place of residency, etc.) on CRC survival estimates.  
Study objective 4: To investigate the effects of the clinical manifestations (e.g. site, 
histopathology, grade, stage, etc.) and treatment of CRC on survival estimates.   
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Study objective 5: To explore possible survival differences of CRC between treatment 
sites within Jordan, and explain the possible differences, if any.  
Study objective 6: To investigate the possible effect of diabetes mellitus (as a major co-
morbidity factor in Jordan) on CRC survival among Jordanian patients.  
 
1.5 Summary 
This chapter introduced the rationale and layout of the thesis as well as the research 
questions and study objectives. The primary gap in the literature (i.e. the lack of CRC 
survival statistics in Jordan) along with the deliberate need to focus on preventing and 
controlling cancer in Jordan were presented in this chapter as key logical elements for 
motivating the study research questions and study objectives. 
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CHAPTER 2 – LITERATURE REVIEW  
 
2.1 Introduction 
This chapter aims at providing relevant scientific evidence and background information 
needed to establish a theoretical base for the study. The chapter starts by providing the 
reader with an overview of Jordan, including a discussion of various characteristics of its 
health care system, while attempting to compare these characteristics with similar data 
from other countries.  The chapter introduces the reader to the burden of diseases in Jordan 
by providing a review and discussion on the significance of an epidemiological transition 
will particular emphasis on the burden of cancer.  
The chapter moves on to present a discussion on the development of colorectal cancer 
(CRC) in patients and its epidemiology. Variations in incidence rates across the globe and 
the region are compared, and risk factors are introduced with specific focus on the risk 
factors that are commonly shared with diabetes mellitus. In addition, this chapter discusses 
identification techniques and treatment of colorectal cancer cases and looks at different 
factors that can influence colorectal cancer survival rates. These include: age; clinical 
characteristics of the tumour; type of treatment; comorbidity; socio-demographic 
characteristics (i.e. race and ethnicity, sex and socio-economic status); health services; and 
residence-related factors (i.e. country of residence and community-related factors). 
 
The purpose of the literature review provided in this chapter is to help in the preparation of 
the study tools and to overcome difficulties that were highlighted by previous 
investigators, as well as provide material that supports the study objectives. The literature 
review was carried out using IARC library, PubMed, Medline and MSH data bases, 
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searching for peer-reviewed publications regarding CRC survival and its correlates. IARC 
library was also used to access many of the selected articles. Key words used in the search 
process were: "colorectal cancer" used independently or in combination with "survival", 
"socioeconomic", "social", "deprivation", "comorbidity", "treatment", "radiotherapy" and 
"chemotherapy".  
 
The search for pertinent references involved a systematic approach. The first step was to 
look at the title of the article to determine whether to include it or not. In case the title was 
not clear enough for such a decision, the abstract of the study was read thoroughly. 
Following the first two steps, relevant studies were saved into a Reference Manager data 
base. As a third step, a whole-article review was done to determine if the selected articles 
met the inclusion criteria.  
 
The inclusion criteria for the literature review were mainly studies that: 1) Estimated 
relative and observed survival rates of CRC; 2) Investigated the associations between 
survival rates of CRC and socio-demographic characteristics, clinical characteristics, type 
of treatment and comorbidities; 3) Included the C18-C20 classifications.  
 
Relevant information and reports were referenced through the Ministry of Health and the 
King Hussein Cancer Center. Many papers prepared by academic researchers were also 
accessed. Local websites with published and unpublished materials (such as annual reports, 
some studies) were also examined during the preparation of this review. 
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2.2 Country Profile 
This section presents important demographic and health information about Jordan. Specific 
information related to Jordan’s geography, population, health care system, health profile, 
and cancer registry is displayed in an attempt to define the study setting. 
 
2.2.1 Jordan’s geography and population 
Jordan is located in the Middle East region and bordered by Iraq, Syria, Saudi Arabia, the 
Occupied Palestinian Territory (depicted as West Bank) and Israel (Figure 1). As a small 
country with limited natural resources and a semi-arid climate, Jordan has a total land 
territorial area of 89,300 square kilometres, of which only 7.8 percent is arable land. 
Jordan's population of approximately 5.98 million are mostly Arabs with some Circassians, 
Chechens and Armenians. More than 92 percent of the population is Muslim and about 6 
percent are Christian. Administratively, the country is divided into 12 governorates, which 
are then grouped into three regions – the North region (Irbid, Jarash, Ajloun and Mafraq), 
the Central region (Amman, Zarqa, Balqa, and Madaba) and the South region (Karak, 
Tafielah, Ma’an and Aqaba). The major cities are Amman (the capital), Zarqa and Irbid 
(22) . 
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Figure 1: Map of Jordan 
 
From 2005 through 2008, Jordan’s death rate remained constant at less than one percent, 
while the birth rate continued to climb at nearly 3 percent annually. The significant rise in 
population growth has seen the national population density increase from 56 to 70 persons 
per square kilometres in the past decade(22;23). However, population density is far from 
uniform throughout Jordan.  The northern governorates (such as Irbid, Jarash and Ajloun) 
range from 320 to 660 persons per square kilometres; Amman, in the centre of the country 
has a population density of slightly less than 300 persons per square kilometres; and in the 
southern governorates of the country (such as Ma’an and Aqaba), population density is 
extremely low - between 4 and 19 persons per square kilometres. These figures, though, 
are strongly influenced by land size.  Compared with the whole of the kingdom, the area of 
the Northern Region represents 33 percent of the total; the Central Region comprises 16 
percent; and the Southern Region covers 51 percent of the kingdom (22;23). 
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The illiteracy rate for those aged 15 years or more is 6.7 percent overall, split as 9.9 
percent for females and 3.6 percent for males.  Some 41 percent of this age group has 
completed a secondary education or university; of those completing secondary education 
(17.7 percent of the group), females slightly outnumber males. The same is true for 
education of intermediate diploma-stage (8.2 percent of the group); but females more 
significantly outnumber the males, comprising 9.9 percent of the group versus 6.6 percent, 
respectively.  But this trend is reversed when it comes to completing a bachelor’s degree or 
more; where 14.7 percent of the group aged 15 years or greater have attained a university 
degree, with 13.7 percent females and 15.7 percent males (22). 
 
Jordan is undergoing a demographic transition. Results from the 2004 census indicate that 
the age structure of the Jordanian population has changed considerably since 1979 as a 
result of changes in fertility, mortality and migration dynamics. Consequently, the 
proportion of the population under 15 years of age declined from 51 percent in 1979 to 37 
percent by 2004, while life expectancy continues to increase reaching 74 years for females 
and 72 for males (1;22).  
 
The total fertility rate (TFR) is relatively high in Jordan, though it has declined steadily in 
recent years to reach 3.6 in 2009 (1;22). Available data from 2011 shows that the steady 
mortality rate (of 0.7 percent) combined with the steadily increasing birth rate (presently 
2.89 percent) yielded an average annual population growth rate of 2.2 percent in 2008 
(1;24). Figure 2 shows the age distribution of Jordan’s population in 2009 of 5.98 million 
total populations with 58 percent were less than 25 years of age. Furthermore, 36.9 percent 
were under 15 years of age; 59.6 percent were between 15 and 64 years of age; and 3.5 
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percent were over 65 years of age. The total population was divided into 50.4 percent 
males and 49.6 percent females.  
 
Figure 2: Age distribution of Jordan population, 2009 
 
Source:  Department of Statistics [Jordan] and ICF. 2010. Population and family 
health survey 2009. 
 
Over the next few years, Jordan’s demographics are expected to change significantly. The 
country’s population is growing rapidly, doubling over the last 20 years and likely to 
almost double again by 2035.  Jordan will see the relative size of its working age 
population more than double, leading to increased demand for infrastructure, quality 
education and health care. Policies are needed to reduce fertility rates, anticipate future 
retirement needs and address issues that influence health status and needs. The estimated 
population of Jordan at the end of the year 2008 was 5.85 million. By 2009, the population 
was estimated at 6.83 million. This significant increase shows not only the difficulties with 
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collecting complete statistics, but also the very large migrations related to conflicts in the 
region (1;2). 
 
Consequently, the relative size of Jordan’s population particularly that of the younger and 
middle aged group, will more than double in the coming two decades.  This denotes an 
expected sharp increase in the size of the at-risk population for non-communicable 
diseases, including cancer. Such an increase holds implications for primary and secondary 
prevention and health care resources needed for screening and treatment services. 
Therefore, policies are currently needed to reduce fertility rates; anticipate future health 
needs and health services, and address issues that might impede efficient management of 
chronic disease, including management of colorectal cancer.   
 
2.2.2 Overview of Health Care System in Jordan 
Significant achievements have been made in the health field over the last three decades 
making Jordan stand as one of the best countries in the region.  Jordan was ranked by the 
World Bank to be the number one medical tourism destination in the Middle East and 
North Africa region (MENA) and fifth in the world as a top medical tourism destination 
(25;26).  
 
Despite its modest resources, Jordan has developed an advanced record in terms of caring 
for the health of its citizens when compared to its neighbouring countries. Jordan’s basic 
health indicators have improved gradually and a variety of national health programmes 
have significantly cut the risk of infectious disease. For example, there have been no 
recorded cases of either polio or croup since 1995 and only 59 cases of measles were 
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recorded in 2008 compared to 1212 cases in 1979. Jordan achieved universal child 
immunization in 1988 and has made considerable progress in reducing the major health 
risks to infants and children. Since the early eighties; all national socioeconomic plans 
have emphasized the right to health and health care. Major progress was achieved in 
lowering the infant and child mortality rates (1.9 percent and 2.0 percent, respectively), as 
well as the maternal mortality rate (of 19 per 100,000 live births) (22;24). Currently, 
Jordan is one of the countries with the lowest infant and maternal mortality rates in the 
region (2).  Further comparisons of main health indicator reveals that in Jordan the Infant 
Mortality Rate (14.97 infant deaths per 1,000 live births) is not very far off from that of 
other developed countries with all their lifesaving technology, like the United Kingdom 
where the average is 4.56 infant deaths per 1,000 live births and the United States (6 per 
1,000 live births) (27).  
 
In reviewing the progress made towards achieving the Millennium Development Goal 
(MDG) targets, utilizing MDG Progress Index and data available from 2011, Jordan’s 
overall MDG progress score (4.5) indicated an overall improved performance  (Appendix 
1), ranking as top 33 from among 137 countries (28). 
 
2.2.2.1 Epidemiological Transition  
The last century has witnessed the most remarkable improvement in health in history for 
most nations. Life expectancy at birth has increased from a global average of 46 years in 
1950 to 66 years in 1998 (29). Socio-economic development has been long associated with 
the health status and disease profile of human societies. With industrialization, the major 
causes of death and disability in the more advanced societies, have shifted from a 
predominance of nutritional deficiencies and infectious diseases, to those classified as 
 
44
degenerative (i.e. chronic diseases such as cardiovascular disease/CVD, cancer and 
diabetes). This has come to be known as “the epidemiologic transition” (6). At any given 
time, different countries in the world or even different regions within a country are at 
different stages of the epidemiologic transition. This transition can occur between different 
disease categories (e.g., deaths from childhood diarrhoea and malnutrition giving way to 
adult chronic diseases), as well as within a specific disease category (e.g., rheumatic heart 
disease of the young giving way to chronic coronary artery diseases of middle age, 
degeneration and cancer of the elderly (30;31). 
 
Nowadays worldwide, the burden of non-communicable diseases (NCDs) is increasing 
posing a major current and future public heath challenge (32-34). Mortality, morbidity and 
disability attributed to NCDs account for about 60 percent of global deaths and nearly half 
of the global burden of disease (9;32;34;35).  Approximately 80 percent of deaths 
attributed to NCDs occur in low- and middle-income countries (33;34).  In 2005, deaths 
from all chronic diseases in 23 selected countries accounted to 61 percent of all deaths, it is 
estimated that this figure will rise to 66 percent in 2015 and to 71 percent in 2030.  These 
23 selected countries, including Egypt, Turkey, Pakistan and Iran, account for around 80 
percent of the total chronic disease mortality burden in developing countries (5). 
Furthermore, different studies in Colombia, Spain and Brazil indicated ascending trend in 
the mortality rate from colorectal cancer (36-38). As an example, in Spain the adjusted 
overall mortality rate of Andalusia increased from 7.7 to 17 deaths per 100,000 person-
year in men and 6.6 to 9 deaths/100,000 person-year in women (38). 
 
The Middle East and North Africa (MENA) region faces a dual burden of disease because 
of decreasing rates of communicable diseases and increasing rates of non-communicable 
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diseases. According to the World Health Organization (WHO) estimates, in 2010, 
communicable diseases accounted for 29 percent of the disease burden (down from 40 
percent in year 2000) and non-communicable diseases accounted for 53 percent (up from 
45 percent in 2000). By 2020, the respective figures are estimated to be 20 percent and 60 
percent. Results from the Global Burden of Disease Project 4 dispel the notion that non-
communicable diseases are related to affluence: premature mortality rates from non-
communicable diseases are higher in populations with high mortality and low income than 
in industrialized countries. Upper-income and urban areas in middle-income countries of 
the region are mainly burdened by non-communicable diseases, having largely controlled 
communicable diseases (38-40). 
 
Jordan is witnessing a demographic transition with expected increase in the elderly 
population (5 percent of the population by 2025 and 15 percent by 2050 (22), decrease in 
the burden of communicable diseases and concomitant increase in the burden of non-
communicable diseases (3;4). Currently, approximately half of deaths in Jordan are 
attributed to NCDs, namely, cardiovascular diseases, diabetes and cancer (41). Information 
from Jordan supports the theory that Jordan is experiencing an epidemiological transition 
from communicable to non-communicable diseases (3;4;15;41;42). Nowadays (in Jordan) 
Infectious disease accounted for less than 2 percent of all deaths; however NCDs 
accounted for more than 50 percent of all deaths in Jordan. Heart disease and stroke 
(International Statistical Classification of Diseases, 10th Revision, codes I00-I99) 
accounted for 35 percent of all deaths; malignant neoplasms (C00-C97) were responsible 
for 13 percent of deaths (15).  
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Results from the most recent (2007) Jordan Behavioural Risk Factor Survey on a national 
representative sample above 18 years of age showed that nearly one in three participants 
smoked cigarettes; two-thirds were overweight or obese; nearly one in five had been 
diagnosed with high blood pressure; and nearly one in ten had been diagnosed with 
diabetes mellitus; among participants of the medical evaluation, an estimated 11percent  
reported having been diagnosed with diabetes by a health professional, and 19 percent 
were diagnosed with diabetes according to laboratory testing (3). Furthermore, sedentary 
lifestyle, high fat diet and smoking are becoming common in Jordan (3;4;42-44). Crude 
projection estimates suggest that approximately 1 to 3 million people in Jordan will have 
diabetes, hypertension, or high blood cholesterol by 2050 according to changes in disease 
prevalence and the growth of the population (45).  
 
2.2.2.2 Governance of health system  
The healthcare system in Jordan comprises public, private and not for profit organizations, 
complemented by rising standards of living, housing, education, safe water supply and 
sanitation. The public sector consists of two major public programs that finance as well as 
deliver healthcare: the Ministry of Health (MOH) and Royal Medical Services (RMS). 
Other smaller public programs include several university-based programs, such as Jordan 
University Hospital (JUH) in Amman and King Abdullah Hospital (KAH) in Irbid. The 
extensive private sector includes 60 hospitals and many private clinics. Over 1.6 million 
Palestinian refugees in Jordan get access to primary care through the United Nations Relief 
Works Agency (UNRWA). Each of the health care sub-sectors has a financing and 
delivery system of its own. It is worth mentioning that MOH is responsible for all health 
matters in the country and, in particular, for maintaining public health by offering 
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preventive, treatment and health control services and organizing and supervising health 
services offered by both the public and private sectors (46;47). 
 
In addition, the majority of public hospitals are located in the central part of the country as 
well as the referral hospitals. Furthermore, the governance of MOH hospitals is highly 
centralized. Senior level executives at headquarters in Amman (the capital of the country 
which is located in the central region) decide all significant managerial, personnel, 
budgetary and procurement matters (25) . 
 
2.2.2.3 Health care financing 
In 2007, Jordan’s total Gross Domestic Product (GDP) per capita represented 3,022 U.S. 
Dollars.  This was considerably higher than the rate of the Lesser Developed Countries 
(576 U.S. Dollars), considerably less than the OECD Member States (34,092 U.S. Dollars), 
but in line with the World Bank’s set of Middle Income countries (2,923 U.S. Dollars) 
(48). 
 
In the same year, Jordan’s total health expenditure–-both public and private–-was 
estimated at 1,422 million U.S. Dollars, or 253 U.S. Dollars per capita. This was 
equivalent to 8.4 percent of GDP. The government share in the financing of health 
expenditures increased from 43 percent in 1998 to 59.8 percent in 2007. Jordan’s 
healthcare expenditure of 8.4 percent of GDP is similar to that of the U.K. (8.4 percent) 
and Australia (8.5 percent). When total healthcare expenditures are compared in terms of 
Purchasing Power Parity (PPP), Jordan’s expenditure per capita ($414) is much lower than 
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the U.K. ($3,007) and Australia ($3,314) but more favourable than Egypt ($259), Syria 
($177) and Iraq ($136) but similar to Tunisia ($469) (48). 
 
Secondary care, in Jordan like many other developing countries, takes up a 
disproportionately large share of public spending on health. During the period 1998-2007, 
the share of curative care increased from about 79 to 82 percent of the total health 
expenditure, while the proportion spent on primary health care remained below 20 percent 
(46;47).  
 
Overall spending has increased in nominal terms over the past six years and has grown 
slightly more rapidly than Gross Domestic Product (GDP). Nevertheless, Jordan's health 
spending, whether measured in per capita U.S. dollar terms or as a share of GDP, is high 
compared to other Middle East and North Africa Region (MENA) and middle-income 
countries (25). 
 
2.2.2.4 Health insurance 
About 79 percent of the population in Jordan is covered by formal health insurance. MOH 
is the largest health insurer (34 percent) followed by RMS (26 percent), private firms (9 
percent), UNRWA (8.5 percent) and university hospitals (1.3 percent) (49). In addition to 
its general public health functions, the MOH is responsible for administering the Civil 
Health Insurance Plan (CHIP) that covers civil servants and their dependents. Individual 
certified as poor, the disabled, children below the age of six years and blood donors, 
pregnant women and elderly above 60 are also formally covered under the CHIP. In 
 
49
addition some costly diseases are also insured according to special regulations determined 
by the Health Insurance bylaw, including cancer and its side effects (46).  
 
2.2.2.5 Health workers 
In 2008, the total number of health workers in Jordan was 91,756 (12 percent of the total 
employees in the public and private sectors). The country has 25 physicians, 38 nurses (all 
categories), 9 dentists and 13 pharmacists per 10,000 populations (46). The number of 
physicians per 10,000-population is similar to the numbers found in the U.K. (27), 
Australia (25) and the U.S. (24).  This makes Jordan’s rate considerably greater than the 
number of physicians per 10,000 population found in Syria (5), Iraq (7), Saudi Arabia (9), 
Tunisia (13) and Turkey (16). But, numbers for UAE (19.3) and Qatar (22.5) approach 
Jordan’s ratio of physicians to 10,000 population, while Egypt (28) exceeds it (50).  During 
the last ten years the number of most health professions and their percentages to population 
has been increasing (46). The nurse-to-doctor ratio in the health sector (i.e. 1.2 nurses to 
1.0 doctor) remains very low and is among the lowest group of countries in the world 
(46;47). E.g. Jordan’s ratio is the same as Mexico, but much lower than the ratios found in 
the U.K., France and the U.S. (i.e. 3.6, 2.5 and 4.2, respectively) and even lower than 
Russian Federation and Estonia (both at 1.9) and Poland (at 2.4) (48). 
 
2.2.2.6 Jordan Cancer Registry 
The Jordanian Cancer Registry (JCR) is a population based–cancer registry covering six 
million people at national level. Jordan initiated the Jordan Cancer Registry (JCR) in 1996 
in collaboration with National Cancer Institute (NCI-USA) and the Middle East Cancer 
Consortium (MECC). The main purpose of JCR is to assess the burden of cancer diseases 
by collecting data on all diagnosed malignancies from all related health facilities. The JCR 
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receives notification forms from different hospitals representing all health sectors 
distributed all over the country, (Public, Private, Royal Medical Services and the teaching 
hospitals). The JCR collects data by a combination of active and passive methods, 1) 
trained personnel abstract cancer data from patient files and complete notification forms 
before forwarding them to the JCR, and 2) JCR staff conduct site visits to medical facilities 
during which; JCR staff monitor the quality of data collection and search for missed cases 
and missing information (51).  
 
Since 1996 onwards, cancer registration in Jordan was performed in accordance with rules 
set out by the International Agency for Research on Cancer (52). The JCR started using a 
specially designed registration form and checking for duplication and consistency using the 
CANREG IV software developed by IARC specifically for cancer registration (53).  All 
cancer cases are coded using the 3rd revision the International Classification of Diseases 
for Oncology, 3rd edition (ICD-O3) (54), in addition to the International Classification of 
Diseases (ICD-10) (55).   
 
When Jordan joined the Middle East Cancer Consortium (MECC) in 1998, further quality 
control measures were applied and awareness was also raised on notifying staff about the 
existence and benefits of the registry (56). In 1998, completeness and reliability of The 
JCR data was assessed by external assessors and registrations were determined to be 88 
percent complete. Such a completeness rate was considered excellent for a newly establish 
registry (57). In 2003, the Jordan Ministry of Health updated its death certificate according 
to international standards. Improving of quality of death certificate and increasing coverage 
and utilization of medical death certificates allows mortality statistics to be used with 
greater confidence for causes of death. However, even mandatory death certification 
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requires basic additional information to enable verification of the causes of death statistics 
with other sources. Recently death certificates have been used as a reliable source of 
information in the JCR (41).   
 
Synopsis: Located in the Middle East Region, Jordan is divided into 12 governorates with 
a population of 5.85 million. Over the last three decades, Jordan underwent a demographic 
transition as a result of changes in fertility, mortality and migration dynamics. With a 
steady low mortality rate and an increasingly high birth rate and TFR, 58 percent of 
Jordan’s population are under 25 years of age. Over the next few decades, Jordan’s 
population is expected to double, leading to increased demand on health care and an 
expected sharp increase in the size of the at-risk population for non-communicable 
diseases, including cancer.  
 
Changes in Jordan’s health profile brought about significant improvements in health care 
services, placing Jordan among the top medical destinations in the region. Improvements in 
health care services in Jordan resulted in improvements in the population’s health status 
which was mainly marked by a reduction in infant mortality rate and maternal mortality. 
Such improvements were brought about by strengthening the structure and function of 
Jordan’s healthcare delivery system, which is comprised of public, private and non-profit. 
However, health care expenditure for Jordan remains high when compared to the region. 
Simultaneously, the demographic transition in Jordan introduced new challenges to health 
care, particularly the increasing burden of NCDs. Such a transition resulted in a shift in the 
population’s vital status where half of the deaths in Jordan are currently being attributed to 
NCDs, mainly cardiovascular diseases, diabetes and cancer. Given the evidence provided 
in the literature that supports the association between diabetes and the increased risk of 
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colorectal cancer, the change in disease profile in Jordan becomes of utmost importance for 
this study. Finally, as the main source for collecting data and assessing the burden of 
cancer diseases, the JCR is the sole population based–cancer registry in Jordan that 
provides quality data on all cancer cases.  
 
2.3 Overview  
This section provides an overview of cancer and its risk factors. The global and regional 
burden of cancer is presented herewith, with special notation colorectal cancer. Cancer 
incidence is presented with a focus on Jordan statistics both for cancers in general while 
explicitly concentrating on colorectal cancer among the Jordan population. 
 
2.3.1 The Global and Regional burden of cancer 
Examining the burden of cancer, both globally and regionally, can assist in describing and 
understanding the problem of cancer, its magnitude and its different correlates when 
focusing on Jordan. The GLOBOCAN published by the International Agency for Research 
on Cancer prepared a worldwide estimate of the incidence and mortality rates from 27 
cancers for 182 countries. Estimations showed that globally 12.7 million new cancer cases 
and 7.6 million cancer deaths occurred in 2008. Lung cancer remains the most common 
cancer in the world, both in term of cases (1.6 million cases, 12.7 percent of total) and 
deaths (1.4 million deaths, 18.2 percent), followed by breast cancer in terms of cases (1.4 
million cases, 10.9 percent) which ranks fifth as cause of death (458,000, 6.1 percent), 
followed in terms of incidence by colorectal cancer (1.2 million cases, 608,000 deaths) and 
stomach cancer (990,000 cases, 738,000 deaths) (7).  
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In West Asia and according to GLOBOCAN the most common cancer among males is 
lung cancer with an ASR of 30.7, followed by colorectal cancer with an ASR of 13.1, 
while bladder cancer ranks third with an ASR of 13.2. For females, breast cancer ranks 
first with an ASR of 32.5, followed by colorectal cancer with an ASR of 10.1, corpus uteri 
cancer comes next with an ASR of 5.5. As the cause of mortality among males, lung 
cancer ranks first with an ASR of 28.4, followed by stomach cancer with an ASR at 11.1, 
and then comes colorectal cancer with an ASR of 8.3. For females, the most common 
cause of mortality among cancers is breast cancer with an ASR of 14.3, followed by 
colorectal cancer with an ASR of 6.2 and stomach cancer at 5.8 (7). 
 
In Western Asia, Israel scored the highest age-standardized incidence rate (ASR) for both 
males (288.0) and females (270.7). In Jordan ASR for males was 132.5 per 100,000 
population; lower than in Israel, Turkey (190.6), Cyprus (188.0) and Bahrain (156.0), but 
higher than in Kuwait (119.9) and Oman (100.9). ASR for females in Jordan was 126.4 per 
100,000 population; lower than Israel, Cyprus (171.4), Bahrain (141.4) and Kuwait (127.2) 
but higher than Turkey (113.6) and Oman (86.5) (7).  
 
The Cancer in Five Continents (CI5) monograph series (published by the International 
Agency for Research) presents essential incidence data from populations all over the world 
(58). In CI5 I–IX, periods are generally about 5 years in length. It allows comparative 
studies between different populations (in terms of geography or ethnicity). In addition, the 
long-time series of data allows studying risk in different populations over time. Findings 
from 44 cancer registries in 15 countries in Asia were published as Cancer Incidence in 
Five Continents Volume IX (CI5 IX); in addition to three other registries (including 
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Jordan), findings were analysed to provide an overview on the incidence by country/region 
in Asia for the period 1998-2002 (Figure 3) (59).  
 
Figure 3: Number of person-years, crude and age-standardized cancer incidence rates 
by sex, 1998-2002  
 
*Source: Hai-Rim Shin, et al. Cancer in Asia- Incidence Rates Based on Data in Cancer Incidence in Five 
Continents IX (1998-2002), Vol 11, Asian Epidemiology Supplement, 2010 
 
Among countries of Eastern and South Eastern Asia, with predominantly Chinese 
populations, the highest rates for males were seen in the most developed countries of Hong 
Kong (259.6), Singapore (221.5) and Taiwan (254.3); Mainland China rates for males, 
though, were slightly higher (223.6) than the rate of Singapore. Females in the same 
countries fared much better: Hong Kong (190.7), Singapore (189.7), Taiwan (192.1) and 
Mainland China (161.7).  Males in the wealthy countries of Japan (270.7) and Korea 
(281.9) approached Israeli rates. While for females, Manila in the Philippines (205.0) had 
the ASR closest to the rate for females in Israel; females in Japan (166.3) and Korea 
(162.7) had considerably lower rates than both their male counterparts and Israeli females 
(59) .  
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2.3.2 Burden of Cancer in Jordan 
From the publication of the latest Jordan data, since establishment of the cancer registry (in 
1996) and until the end of 2005, there were 33,661 cases of cancer reported in Jordan, with 
16,981 male cases and 16,680 females. The highest crude incidence rate recorded for males 
was 74.7 per 100,000 in 1996, as for females the highest crude incidence rate recorded was 
75.2 per 100,000 in 1997. In this period of time lung cancer was the most common cancer 
among males (10.6 percent), followed by colorectal (9.8 percent), leukaemia (9.3 percent), 
urinary and bladder (8.6 percent) and prostate cancer (7.4 percent). As for females, breast 
cancer was the most common tumour (32.0 percent), followed by colorectal (9.0 percent), 
leukaemia (6.7 percent), thyroid (4.9 percent) and corpus uteri cancer (4.6 percent). The 
overall average of the Age Standardized Incidence Rate adjusted to the world standard 
population (ASRs) for all cancers was 119 per 100,000 adult males and 116 per 100,000 
adult females for the phase between 1996 and 2005 (60). 
 
GLOBOCAN estimates showed that the most common incident cancer among males is 
lung cancer at an ASR of 16.5, the second most common cancer among males in Jordan is 
colorectal at an ASR of 15.3, followed by prostate cancer at an ASR of 13. Among 
Jordanian females breast cancer comes first at an ASR of 42.2, next comes colorectal 
cancer at an ASR of 11.9 and leukaemia ranks third at an ASR of 8.5. However, the most 
leading cause of deaths from cancers among Jordanian males is lung cancer at an ASR of 
15.3, followed by colorectal cancer at an ASR of 11.4 and prostate cancer at an ASR of 
9.6. For Jordanian females the chief cause of death from cancers is breast cancer at an ASR 
of 22.2, followed by leukaemia at an ASR of 5.8 and thyroid cancer at an ASR of 3.3 
(Figure 4) (7).  
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More recent information (2009) from Jordan has shown the crude incidence rate and ASR 
for all cancers among Jordanians were increasing to reach 78.7 per 100,000 population (i.e. 
75.4 for males and 82.3 for females) and 135.1 per 100,000 population (i.e. 134.7 for males 
and 136.0 for females, respectively) (51). The Age-Standardized Incidence Rate of cancer 
has been found to be lower among Jordanians than people in developed countries for both 
males and females: the Age-Standardized Incidence Rate in the U.S.A. for males was 
371.7 and 284.5 for females; in New Zealand, the rate for males was 345.7 and 274.8 for 
females; in Canada the rate for males was 330.5 and 257.3 for females (51).  However, the 
Age-Standardized Incidence Rate of overall cancer for men in Jordan in 2008 was 134.7 
per 100,000 (51). In comparison to other countries in the Middle East and North Africa, it 
is higher than Kuwait (125.1) and Tunisia (113.0), but lower than Bahrain (162.2), Egypt 
(161.7), Qatar (165.5) and Lebanon (179.0). In comparison to many countries in Europe 
and North America, the Age-Standardized Incidence Rate of overall cancer for men is 
Figure 4: The top ten cancers among Jordanian population, 2008  
 
 
Source:  GLOBOCAN 2008.  Reproduced with permission of GLOBOCAN, 
2010. 
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lower than most of these countries, including Poland (201.0), Norway (328.0), Canada 
(330.5), Scotland (323.7) and white males in the U.S.A. (371.7), as well as New Zealand 
(345.7) (51). 
 
Among females, the Age-Standardized Incidence Rate of overall cancer in Jordan is 
slightly higher than for males at 136 per 100,000 (51). In comparison to many countries in 
the Middle East and North Africa, this is higher than Tunisia (89.0) and Egypt (120.8), 
similar to Kuwait (136.6), but lower than Bahrain (150.0), Qatar (164.5) and Lebanon 
(180.3). In comparison to countries in Europe and North America, it is higher than Poland 
(107.3), but still lower than Norway (271.0), Canada (257.3), Scotland (268.5) and the rate 
for white females in the U.S.A. (284.5), as well as New Zealand (274.8). The rank order of 
cancers for both males and females among Jordanian in 2008 was shown in the below 
(Figure 5).  
 
Figure 5: The percentage distribution of the most frequent types of cancer by sex in 
Jordan (all ages), 2008 
 
Source: Jordan Cancer Registry, Ministry of Health. Cancer Incidence in Jordan 2008. 
Amman (JO): Ministry of Health, Jordan; 2010 
 
 
58
It is noticed that breast and colorectal cancers are the leading cancers in Jordan in both 
sexes (51). For males, colorectal cancer at 14.5 percent ranks in the first place followed by 
lung cancer at 13.1 percent, urinary bladder cancers at 7.5 percent, prostate cancer at 7.2 
percent, leukaemia at 6.7 percent, Non-Hodgkin Lymphoma (NHL) at 5.1 percent, stomach 
cancer at 4.2 percent, brain and CNS cancers at 3.9 percent, cancer of the larynx at 3.8 
percent and Hodgkin’s Disease at 2.9 percent. However, among Jordanian females the 
most common cancers are still breast cancer at 36.7 percent, then colorectal cancer at 9.4 
percent, corpus uteri cancers at 5.4 percent, thyroid cancer at 4.7 percent, Non-Hodgkin’s 
Lymphoma at 4.6 percent, leukaemia at 4.0 percent, ovarian cancer at 3.6 percent, stomach 
cancer at 3.1 percent, brain and CNS cancers at 2.8 percent and lung cancer at 2.5 percent 
(51).  
 
Synopsis: Statistical data indicates that cancer is a predominant global health problem. 
Data collected from 182 countries in 2008 estimated that there were 12.7 million of new 
cancer cases and 7.6 million cancer deaths. Overall, the most common cancer in the world 
is lung cancer (1.6 million cases, 12.7 percent of total), followed by breast cancer (1.4 
million cases, 10.9 percent), then colorectal cancer (1.2 million cases, 9.4 percent). In 
addition, data collected from cancer registries allows comparison of different types of 
cancer between countries. Results from the GLOBOCAN 2008 project presented indicate 
that while females retained uniformity in incidence, males of the most developed countries 
of Asia had the highest rates of age standardized incidence rates of cancer. The Age-
Standardized Incidence Rate of cancer among Jordanians is lower than that in developed 
countries for both males and females. While breast cancer is the leading type of cancer 
among females in Jordan, colorectal cancers are more common among males. When 
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compared to other countries in the region, Jordan ranks among countries with relatively 
moderate Age-Standardized Incidence Rate of overall cancer (7). 
 
2.4 Colorectal Cancer  
This section defines colorectal cancer and introduces its aetiology, diagnosis, symptoms 
and epidemiological profile worldwide while specifically focusing on Jordan. Screening 
procedures for the early detection of colorectal cancer are discussed as a mechanism for 
decreasing mortality. In addition, different treatment modalities are presented, and a 
directed discussion is presented on type 2 Diabetes Mellitus as a major risk factor for 
colorectal cancer. 
 
Colorectal cancer is a disease in which cancerous growths (tumours) are found in the 
tissues of the colon and/or rectum. Because colon cancer and rectum cancer have many 
features in common, they are sometimes referred to together as colorectal cancer. 
Colorectal cancer usually develops slowly over a period of many years. Before a true 
cancer develops, it usually begins as a noncancerous polyp, which may eventually change 
into cancer. A polyp is a growth of tissue that develops on the lining of the colon or 
rectum. Certain kinds of polyps, called adenomatous polyps or adenomas, are most likely 
to become cancers, although most adenomas do not become cancerous. More than half of 
all individuals will eventually develop one or more adenomas. About 96 percent of 
colorectal cancers are adenocarcinomas, which evolve from glandular tissue. The great 
majority of colon and rectum cancers arise from an adenomatous polyp. Other types of 
colon cancer such as lymphoma, carcinoid tumours, melanoma and sarcomas are rare (61-
63).  
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2.4.1 Epidemiology of Colorectal Cancer  
As indicated previously, global statistics indicates that colorectal cancer is the second most 
common cancer in women (570,000 cases, 9.4 percent of the total) and the third most 
common cancer in men (663,000 cases, 10.0 percent of the total) with almost 60 percent of 
the cases occur in developed regions. The ASR for males was 20.4 versus 24.6 for females. 
Estimated deaths from colorectal cancer account for 8 percent of all cancer deaths making 
colorectal cancer the fourth most common cause of death from cancer (7). 
 
Incidence of colorectal cancer from cancer registries for 1983 through 1987 and 1998 
through 2002 show that colorectal cancer increased statistically significantly for both 27 of 
51 males and females. This rise in incidence mainly concerned economically transitioning 
countries in Eastern Europe, most parts of Asia and selected countries of South America. 
Increases in incidence were more frequent among men than among women. Considerable 
variations in colorectal cancer incidence trends were detected both within countries and 
among ethnicities (7;64).  
 
According to information abstracted from cancer registries (1998-2002), the highest 
worldwide colorectal ASR for males was in the Czech Republic at 59.1 followed by males 
in New Zealand at 49.3. For females the highest ASR was in New Zealand at 39.5, and 
followed by Australia (South) at 34.1. The lowest ASR for males was reported in India, 
Mumbai at 5.9, followed by Ecuador, Quito at 8.4. For females, the lowest ASR was also 
reported in India, Mumbai at 4.4, followed by Ecuador, Quito at 8.9 (58).   
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Regionally, using the same source of information, the Israeli non-Jews have the highest 
ASR of colorectal cancer for both males and females (i.e. 34 and 34.7, respectively). The 
lowest ASR of colorectal cancer for males was reported in Oman: Omani at 3.7 (57;58;65).   
 
In 2008, there were 548 colorectal cancer cases accounting for 11.9 percent of all newly 
diagnosed cases among Jordanians. Colorectal cancer ranked second among all types of 
new cancers, and ranked first among males (14.5 percent) and second among females (9.4 
percent), with a male to female ratio of 1.5: 1. The median age at diagnosis was: 61 years 
for both males and females; 62 years for the colon in the males and 59 for females; and 62 
years for the rectum in males and 59 for females. The highest (ASR) was found in the age 
group 80-84 years in both males (198.9/100,000) and females (128.4/100 000). The overall 
ASR was 20.9/100 000 for males and 13.9/100 000 for females (66). The trend of Age 
specific incidence rate (ASIR) and Age standardized Incidence Rate (ASR) for colorectal 
cancer in Jordan also showed an increase from 1996 through 2009.  In 1996, the ASIR was 
5.2 and the ASR was 10.1 per 100,000. Both of these trends increased gradually over time 
with some fluctuation (Figure 6). In 2009, the ASIR and ASR reached 9.3 and 17.3 per 
100,000, respectively (51). 
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Figure 6: Trend of ASIR (Age specific incidence rate per 100,000 population) & ASR 
(Age standardized rate) of colorectal cancer 1996-2009* 
*ASIR: Age Specific Incidence Rate per 100,000 population 
  ASR: a weighted mean of the age-specific rates; the weights are taken from population 
distribution of the standard population.  
Source: Jordan Cancer Registry, Ministry of Health. Cancer Incidence in Jordan 2009. 
Amman (JO): Ministry of Health, Jordan; 2011 
 
2.4.2 Symptoms of Colorectal Cancer 
The symptoms of colorectal cancer depend on the stage of the disease and the area of the 
colon that is involved. The problem with colorectal cancer is that it may present with no 
symptoms at all in early stages, or its symptoms are also found in other conditions such as 
ulcers, gallstones, haemorrhoids or reactions to certain foods - conditions far less serious 
than colorectal cancer. The majority of patients present either with abdominal symptoms 
such as abdominal discomfort, a persistent (6 weeks) change in bowel habits, particularly 
looser stools or increased frequency, vomiting, decreased appetite, cramping or gnawing 
stomach pain, or symptoms of anaemia such as weakness and fatigue, rectum bleeding 
(especially if it is not associated with anal symptoms such as itching, pain or soreness) or 
mucus discharge per rectum. Persons whose cancer involves the rectum may experience a 
feeling of rectal fullness, painful spasms, change in bowel movements, and change in the 
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diameter of stools. Pain, diarrheal or vomiting may be other symptoms of colorectal cancer 
(67-69). 
 
2.4.3 Aetiology and risk factors of Colorectal Cancer 
Although the exact cause of CRC is still unidentified, researchers have identified a set of 
variant risk factors. Being above the age 45 to 50 increases the chance of CRC among all 
groups.  The incidence rate of colorectal cancer is more than 14 times higher in adults 50 
years and older than in those younger than 50 years. Moreover, the mortality rates for CRC 
increases with age where 94 percent of deaths occur in individuals 50 years and older (70). 
CRC incidence and mortality rates are higher in men than in women. The reason behind 
this is not completely understood, but may can be partially explained by an inversely 
relation between oral contraceptive (OC) use and the risk of colorectal cancer (71;72). 
 
CRC has been associated with certain ethnic groups; e.g., African people(73-75). Among 
African Americans, incidence rates are more than 20 percent higher and mortality rates are 
about 45 percent higher than those in whites. This could be partially attributed to racial 
differences in the trends in the prevalence of risk factors for colorectal cancer and/or 
greater access to and utilization of recommended screening tests by whites, resulting in 
detection and removal of precancerous polyps (73).  
 
Incidence of CRC has been found to be higher in economically privileged countries 
(58;59;76-78). Furthermore, familial adenomatous polyposis, a family history of colon 
cancer (hereditary non-polyposis colorectal cancer or Lynch syndrome), a personal or 
family history of colorectal cancer and/or polyps, and being diagnosed with chronic 
inflammatory bowel disease, all predispose to colorectal cancer (79;80). On the other hand, 
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modifiable risk factors that have been positively associated with colorectal cancer included 
increased body mass index, increased caloric intake, diet rich in red or processed meat, 
insufficient intake of fruits and vegetables, sedentary lifestyle, prolonged cigarette 
smoking, and alcohol consumption (81-91).  
 
2.4.4 Diagnosis and staging of Colorectal Cancer  
Diagnosing CRC at an early stage has been associated with better survival rates compared 
to diagnosing the disease at a more advanced stage.  
 
Initial examination includes complete history, family history and laboratory tests including 
advanced stool and blood based tests. Up until the present, colonoscopy remains the main 
method for the diagnosis of colorectal cancer. The procedure allows for visual 
examination, while biopsies or polyp removal could be done at the same time. This 
procedure is preceded by other diagnostic blood tests (92-94). 
 
Another useful diagnostic method is the double contrast barium enema, being accurate in 
detecting more than 90 percent of colon cancer and polyps with a diameter of 6-10 mm. 
For the visual examination of the rectum and lower third of the colon, Flexible 
Sigmoidoscopy is also a widely used procedure (95). Moreover, Pan-body computed 
tomography (CT) is another important tool for diagnosing colorectal cancer (96;97). 
 
Colon cancer staging is an estimate of the amount of penetration of a particular cancer. It is 
performed for diagnostic and treatment purposes. Moreover, the staging system allows 
determining the prognosis. The systems for staging colorectal cancers depend on the extent 
of local invasion, the degree of lymph node involvement and whether there is distant 
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metastasis. Definitive staging can only be done after surgery has been performed and 
pathology reports reviewed. An exception to this principle would be after a colonoscopy 
polypectomy of a malignant pedunculated polyp with minimal invasion. Preoperative 
staging of rectum cancers may be done with endoscopic ultrasound. Adjunct staging of 
metastasis include Abdominal Ultrasound, Computed Tomography (CT), Positron 
Emission Tomography (PET) Scanning and other imaging studies (96;97). 
 
In 1932, Cuthbert Dukes introduced the first classification system (98). Dukes’ staining 
system has been modified many times over the years to include additional prognostic 
factors beyond the depth of tumour invasion and extent of lymph node metastases (99).  
The American Joint Committee on Cancer (AJCC) has developed the Tumour, Node, 
Metastasis (TNM) staging. The TNM staging system provides greater precision in 
identification of prognostic subgroups. The stage of a cancer is usually quoted as a number 
I, II, III, IV derived from the TNM value and grouped by prognosis; a higher number 
indicates a more advanced cancer and likely a worse outcome (100). Table 1 clarifies stage 
classifications of colorectal cancer.   
Table 1: Stage Classifications of Colon Cancer  
Duke’s Staging TNM Staging 
A – Limited to mucosa or sub mucosa.  Not 
invading muscularis.  No nodal involvement. I, TI,T2, N0, M0 
B – Invaded into muscularis and regional 
soft tissue.  No nodal involvement. II, T3, N0, M0 
C – Local metastatic spread to lymph nodes III, any T, N1, M0 
D – Distant metastases IV, any T, any N, M1 
 
2.4.5 Screening of Colorectal Cancer 
Risk assessment of CRC, and detecting the cancer at early stages are crucial in alleviating 
the mortality and morbidity associated with the disease. There are several screening 
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options available for the early detection of colorectal cancer. However, the recommended 
colon cancer-screening plan usually depends upon risk stage of the disease. The 
Gastrointestinal Consortium Panel has prepared a set of guidelines for screening average 
and high-risk individuals (93).  
 
Screening options for average risk individuals embrace faecal occult blood testing (FOBT) 
every year, flexible sigmoidoscopy every 5 years, a combination of FOBT and 
sigmoidoscopy, colonoscopy every 10 years, and double contrast barium enema (DCBE) 
every five years (101). 
 
Screening for colorectal cancer in high-risk individuals depends mainly on the associated 
risk factors. Individuals having a first-degree relative diagnosed with colon cancer or 
adenomatous polyps at age less than 60, or having two second-degree relatives diagnosed 
with colon cancer or adenomatous polyps at any age are recommended to have 
colonoscopy every five years starting at age 40 or 10 years younger than the earliest 
diagnosis in the family (102). In case adenomatous polyps are found, follow-up 
colonoscopy is to be done in the short term (102). If one or more of the polyps are 
malignant, or large and sessile, or if colonoscopy is not complete, if three or more polyps 
are found then follow- up colonoscopy is recommended in three years. If only one or two 
polyps with a diameter less than one centimetre is found, colonoscopy follow-up is 
recommended in five years. Individuals with Familial Adenomatous Polyposis (FAP) are 
advised to have genetic testing, in addition to flexible sigmoidoscopy starting at age 10-12. 
In case of Hereditary Nonpolyposis Colon Cancer (HNPCC), individuals are recommended 
to undergo genetic testing and colonoscopy every one to two years starting at age 20 to 25, 
or 10 years younger than the earliest case diagnosed in the family (103;104). Individuals 
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with a personal history of colorectal cancer should repeat colonoscopy in six months after 
resection if the colonoscopy was incomplete due to obstruction at time of diagnosis; 
otherwise, the colonoscopy is repeated in three years; and in case it was normal, repeated 
every five years. Moreover, individuals with inflammatory bowel disease are advised to 
have surveillance colonoscopy (93;94).  
 
2.4.6 Treatment of Colorectal Cancer 
Preoperative staging and treatment planning have evolved recently as crucial steps in CRC 
management (105). The disease is staged into: local disease, distant disease and 
synchronous colonic lesions.  
 
When diagnosis is made at an early stage, endoscopic mucosal resection and endoscopic 
sub-mucosal resection are performed for superficial colorectal cancers (106), while 
colonoscopy polypectomy can be applied for cancer found within polyps. Moreover, 
colonoscopy can be used as part of a surveillance program to remove missed or new 
adenoma. For rectum cancer, options include per-anal excision besides the conventional 
colonoscopic polypectomy (94). 
 
Until today, surgery continues to be the treatment of choice for CRC; five-year survival 
reaching 90 percent in Dukes A cancer and 75 percent in Dukes B (107). Exact surgical 
procedure is mainly determined by the preoperative staging (108). The aim of surgery is to 
adequately remove the cancerous lesion and ensure safe anastomosis, and at the same time, 
securing good vascularity and joining bowel ends under no tension (108). Rectum cancer 
survival, in particular, has improved immensely after the use of newly developed surgical 
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techniques, namely, total mesorectal excision (109). The use of laparoscopic procedures 
has shown less abdominal wall trauma and faster post-operative recovery than open 
surgical techniques (108). There is evidence from studies in the U.K., the U.S.A, and 
Europe that oncological outcomes in laparoscopic procedures are similar to those of open 
surgery (92). 
 
Almost 20 percent of CRC patients would have developed liver metastases at time of 
primary diagnosis, and only 20 percent of these are candidates for surgical resection 
involving both the primary tumour and liver metastases in, generally followed by 
neoadjuvant treatment. Although it is a general rule to avoid surgery for cases with 
metastases, it is considered an effective palliation in case of highly symptomatic primary 
tumour. Moreover palliative surgery includes surgical bypass, loop colostomy or loop 
ileostomy and stent placement (110). 
 
Adjuvant therapy such as chemotherapy or radiotherapy can be used along with surgical 
procedures in many cases (111). Chemotherapy is usually used to decrease the risk of 
disease relapse, cancer related death as well as for palliative purposes (112). The use of 
chemotherapy is still controversial in stage 2 (113). Drugs acting on novel targets or 
molecular markers are used in the treatment of advanced colon cancer, while cytotoxic 
agents, which are new innovations, are prescribed to patients with metastasis for improved 
results. Many drugs can be used for chemotherapy such as Fluorouracil, Capecitabine 
(Xeloda), Irinotecan (Camptosar), Oxaliplatin (Eloxatin), Cetuximab (Erbitux) and 
Evacizumab (Avastin) (112). 
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Preoperative adjuvant therapy such as combined modality therapy (i.e. chemotherapy and 
pelvic radiation) could help in the preservation of sphincter function (114). Radiotherapy 
in colon cancers may reflect postoperative adjuvant therapy in contrast to pre-operative 
treatment for rectum cancers. Furthermore, evidence indicated reduction of recurrence rate 
among rectum cancer cases after use of preoperative radiotherapy from 25 percent to 10 
percent; resulting in more favourable survival rates (115). 
 
2.4.7 Colorectal Cancer and Type 2 Diabetes Mellitus  
Diabetes mellitus - type 2 (formerly known as noninsulin-dependent diabetes mellitus 
(NIDDM) or adult-onset diabetes) and CRC share similar risk factors, including physical 
inactivity and obesity. Various studies have found a positive association between diabetes 
and increased risk of colorectal cancer in both men and women (116-118). Although the 
relationship between diabetes mellitus type 2 and colorectal cancer is still sometimes 
controversial (108;119), a positive association between diabetes and colorectal cancer has 
been found in studies that accounted for physical activity, body mass index and waist 
circumference (118;120-123).  
 
Extensive research published in 2012 showed additional shared modifiable risk factors for 
both colorectal cancer and type 2 diabetes mellitus. Out of 67 risk factors and risk factor 
clusters, only twelve were associated with colorectal cancer and/or diabetes mellitus. Of 
those twelve, seven were common to both colorectal cancer and type 2 diabetes mellitus; 
three were only associated with colorectal cancer and two only with type 2 diabetes 
mellitus (Table 2). Diet high in sugar-sweetened drinks was a newly reported risk factor 
for both diseases; diets low in milk, low in fibre and low in calcium were newly reported 
risk factors for colorectal cancer (124). 
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Table 2: Risk factors associated with CRC and type 2 DM  
Item # Modifiable risk factor CRC DM-2 
1 Smoking and second-hand smoke X X 
2 Alcohol – daily or binge X X 
3 High Body Mass Index X X 
4 Diet low in milk X  
5 Diet high in red meat X X 
6 Diet high in processed meats X X 
7 Diet high in sugar-sweetened drinks X X 
8 Diet low in fibre (all types: fruit, vegetable, grains, legumes, pulses) X  
9 Diet low in calcium (incl. milk, yoghurt, cheese) X  
10 Physical inactivity or low physical activity X X 
11 High fasting plasma glucose  X 
12 Diet low in whole grain  X 
Source: Lim, S. et al., The Lancet, 2012. 
 
The study and the literature show associations between type 2 diabetes and colorectal 
cancer (albeit more strongly with colon cancer).  These associations can be grouped by 
modifiable risk factor (Table 3). 
 
Table 3: Modifiable risk factors affecting both diabetes and CRC 
Risk factor 
International 
characteristics 
Jordanian statistics 
Obese or 
overweight 
High BMI ≥ 25 kg/m2 
 
Increased BMI  
Overweight:  
Males 62.3 percent; females 66.0percent; Total 
64.1percent (WHO 2008) 
Total 30.5percent (of n= 3 654 in 2007); (Al-Nsour 
et al. 2012) 
Obese: 
Males 24.0percent; females 36.4percent; Total 
30.0percent (WHO 2008) 
Total 36.0percent (of n= 3 654 in 2007); (Al-Nsour 
et al. 2012) 
Smoking Smoker  
Prolonged cigarette 
smoking  
Daily smoking: 
Males 48.8percent; females 4.1percent; Total 
27.1percent (WHO 2008) 
Total 29.0percent (of n= 3 654 in 2007); (Al-Nsour 
et al. 2012) 
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Table 3: Modifiable risk factors affecting both diabetes and CRC 
Risk factor 
International 
characteristics 
Jordanian statistics 
Alcohol 
consumption 
Excessive alcohol  
Alcohol consumption  
No literature found for Jordan. 
Unhealthy 
diet 
Increased caloric intake, 
diet rich in red or 
processed meat, 
insufficient intake of 
fruits and vegetables  
Number of fruit/vegetable servings daily: None = 
5.3percent; 1-4 = 78.1percent; ≥ 5 = 16.7percent 
(of n= 3 654 in 2007); (Al-Nsour et al. 2012) 
Physical 
inactivity 
Sedentary lifestyle  No data (WHO 2008) 
Engages in moderate physical activity: Total 
37.8percent (of n= 3 654 in 2007); (Al-Nsour et 
al. 2012) 
Positive 
association 
between 
diabetes and 
colorectal 
cancer 
Type 2 Diabetes Mellitus 
and colorectal cancer 
share similar risk factors 
when studies accounted 
for physical activity, BMI 
and waist circumference  
Raised cholesterol: 
Males 46.3percent; females 46.4percent; Total 
46.4percent (WHO 2008) 
Household survey 7.1percent (of n= 2 889 in 
2007); Medical exam 9.1percent (n= 765 in 
2007); (Al-Nsour et al. 2012) 
Raised blood glucose: 
Males 14.2percent; females 14.7percent; Total 
14.4percent (WHO 2008) 
Impaired fasting glucose found on medical exam 
23.9percent (n= 765 in 2007); (Al-Nsour et al. 
2012) 
Raised blood pressure: 
Males 31.4percent; females 25.9percent; Total 
28.8percent (WHO 2008) 
Household survey 16.4percent (of n= 2 889 in 
2007); Medical exam 23.0percent (n= 765 in 
2007); (Al-Nsour et al. 2012) 
Type 2 Diabetes: 
Household survey 9.4percent (of n= 2 889 in 
2007); Medical exam 11.5percent (n= 765 in 
2007); (Al-Nsour et al. 2012) 
Other chronic 
conditions 
 Heart disease: 
Household survey 8.2percent (of n= 2 889 in 
2007); Medical exam 7.5percent (n= 765 in 
2007); (Al-Nsour et al. 2012) 
Asthma: 
Household survey 6.6percent (of n= 2 889 in 
2007); Medical exam 7.7percent (n= 765 in 
2007); (Al-Nsour et al. 2012) 
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The increase in the prevalence rates of diabetes mellitus in Jordan can be attributed to 
behavioural changes rather than genetic or family history factors.  Developing countries 
adopting a Western lifestyle, characterized by decreased physical activity and 
overconsumption of energy-dense foods, have witnessed a substantial increase in the 
prevalence of obesity (3;4;125;126).  
 
The Jordanian diet, like other countries in the Mediterranean Region, would not be 
expected to be low in fibre and calcium/milk; at the same time, like other growing Middle 
Income countries, the Jordanian diet would also not be likely to be low in sugar-sweetened 
drinks. Results of the latest (2007) National Jordan’s Stepwise Surveillance survey 
conveyed the prevalence of a number of behavioural risk factors. E.g. smoking (33 
percent) and obesity are high in Jordan; approximately one-third of participants of the 
medical evaluation were either overweight (30 percent) or obese (36 percent) (3). These 
factors coupled with a high rate of physical inactivity (only 34.1 percent engaged in 
moderate or severe physical activity) and low consumption of vegetables and fruits (only 
some 15.9 percent of survey respondents reported having consumed five or more cups of 
fruits and/or vegetables) increase the risk of NCDs and constitute a substantial challenge to 
the health of Jordanians (3;4;125). 
 
The increased prevalence of rates of NCDs in Jordan have been linked to changes in 
lifestyle. Developing countries adopting a Western lifestyle characterized by decreased 
physical activity and overconsumption of energy-dense foods have witnessed substantial 
increased prevalence of obesity (4;127;128). Locally, the self-reported prevalence of type 2 
diabetes among Jordanian adults aged 18 years or above increased from 6.2 percent in 
2002, to 7.5 percent in 2004 and to 11 percent in 2007 (3;4;27;42;129) . However, in 2007, 
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19 percent of survey participants were diagnosed with diabetes according to laboratory 
testing or current use of insulin or an oral hypoglycaemic medication (3). 
 
The increase in the prevalence of diabetes is closely linked to obesity with about 90 
percent of acquired Type 2 diabetes being attributed to excess weight. Diabetic 
nephropathy accounted for over 29 percent of end-stage renal disease on haemodialysis in 
Jordan (130). The traditional diet in Jordan can be classified as a Mediterranean diet that is 
particularly rich in olive oil - monounsaturated oil). Such diet has been shown to offer 
protection against diabetes (131). People must be encouraged to return to their traditional 
diet and to increase their awareness of the role of such a diet in the prevention of diabetes.  
 
Prevention of NCDs requires changing the lifestyle of the general population, which can 
only be achieved through community mobilization and high political commitment.  As 
most of the needed interventions are outside the health sector, a multi-sectorial approach 
involving all governmental and nongovernmental stakeholders provides the basis for 
success.  In 2010, The World Health Organization adopted the WHO action plan for the 
prevention and control of NCDS to guide countries in their efforts to curb the escalating 
epidemic of NCDs (34).  The Global Status Report on NCD was developed as part of the 
implementation of the 2008–2013 Action Plan for the Global Strategy for the Prevention 
and Control of NCDs, which was endorsed by the World Health Assembly in 2008 (132). 
 
Synopsis: Colorectal cancer is one of the most common cancers worldwide including 
Jordan. It is a disease when cancerous growths are found in the colon and/or rectum. The 
majority of colorectal cancers arise from an adenomatous polyp. As the second most 
common cancer in women and third in men, colorectal cancer ranks as the fourth most 
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common cause of death from cancers worldwide. In Jordan colorectal cancer ranks as the 
second most common among all cancers, (first rank in males and second in females). 
During the last decade, the Age specific incidence rate (ASIR) and Age standardized rate 
(ASR) for colorectal cancer in Jordan increased, with a tendency to being mostly 
diagnosed later in life. With symptoms depending on the stage of the tumour, colorectal 
cancer can present itself with no symptoms during its early stages, or with symptoms of 
conditions that are less serious. With an unidentified exact cause, colorectal cancer has 
been associated with various risk factors, including: age (less than 50 years), sex, ethnicity, 
family history, and modifiable risk factors such as dietary habits, inactivity, smoking and 
others. 
 
Early diagnosis is important for improving colorectal survival. Furthermore, detecting 
colorectal cancer at an early stage affects its mortality and morbidity. Therefore, colon 
cancer-screening is recommended based on a set of guidelines that depends on risk stage of 
the disease with several screening options available for the early detection of colorectal 
cancer. With sigmoidoscopy as a commonly diagnostic procedure, prognosis of colorectal 
cancer is determined by staging the disease, which depends on the extent of local invasion, 
the degree of lymph node involvement and the presence of distant metastasis. Treatment 
regimen depends on the stage of the disease, which usually determines the surgical 
procedure and any adjunct radiotherapy or chemotherapy. Finally, the relationship between 
type 2 Diabetes Mellitus and colorectal cancer is widely reported in the literature with a 
reference to modifiable risk factors that are shared between these two diseases. 
 
2.5 Colorectal Cancer Survival and its Correlates 
This section presents available colorectal survival data in an attempt to describe the disease 
from a population perspective. The section discusses the effect of different factors on 
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colorectal cancer survival data including socio demographic factors, clinical 
characteristics, type of treatment, diabetes, health services and place of residence.   
 
Survival statistics are means of quantifying the effectiveness of early detection strategies 
and treatment regimens at the population level. Nowadays the cancer registry role has 
developed beyond providing cancer counts and incidence. Cancer registry is playing a 
major role in monitoring and evaluation of screening programmes and follow-up of cancer 
patients to examine the quality of cancer services they receive (10;133-135). Information 
about the survival rates will help the healthcare community take further preventive and 
control measures in order to improve the quality of cancer care patients receive. Survival 
data is an important tool to evaluate the effectiveness and efficiency of cancer health 
services (10;11).  
 
Understanding the different factors that influence the outcome of colorectal cancer is 
important for improving its relative survival. Accordingly, the literature identifies several 
aspects of health-care that could guide providers in the management of CRC. These 
include important prognostic factors that are related to patients as well as health-care 
providers. Although the literature widely addresses the association of colorectal survival 
outcome with patient and biological risk factors, few reports were found addressing 
providers’ characteristics. For example, a review discussing the impact of patient and 
provider characteristics on the treatment and outcomes of CRC, reported hospital 
characteristics such as surgeon experience and high hospital volume to be consistently 
reported in the literature as factors affecting the outcomes of cancer care (136).  
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The literature presents health insurance status as a main factor that is associated with 
differences in survival among CRC patients. For example, excess mortality among rectum 
cancer patients without private insurance was reported by a national hospital-based study 
done in the United States. An interesting finding of this study was the cancer survival 
disparities observed by race and area of residence that might indirectly denote geographic 
and transportation barriers that are simply related to socioeconomic status (137).  It is 
important to note that several nonmedical factors might influence patients’ compliance to 
treatment, such as: patient preference, cost barriers, mistrust in the health-care system, and 
communication with the health-care provider, all of which are key structural elements of a 
health-care treatment site (136;137).   
 
2.5.1 Socio-demographic characteristics and colorectal cancer survival 
Different factors can influence colorectal cancer survival rates. Age, clinical characteristics 
of the tumour, type of treatment, comorbidity, socio-demographic characteristics, health 
services and residence-related factors have been shown to affect cancer survival. 
Investigating the relationship between the different factors and CRC survival deepens the 
understanding of disease progress and elevates the quality level of provided services. In 
this review the effect of each factor on CRC survival is discussed. 
 
2.5.1.1 Age and colorectal cancer survival 
The correlation between colorectal cancer survival and age is still uncertain. Although 
worse prognoses of the disease in young patients were reported by many researchers (138-
143), analysing the data obtained from the Ontario (Canada) cancer registry, the relative 
odds of early death at 1-year increased by 85 percent in the age range of 65-69 years 
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compared with the age range of 40-49 years (144). Hazard ratios of death at 1-year for 
white and black patients registered in the national cancer data base increased by 37 percent 
and 38 percent, respectively, within the age range of 61-64 years compared with the age 
range of 18-49 years (145). On the other hand, the difference in survival rates among 
patients aged 40 years and younger and older patients aged more than 40 years was 
insignificant in a study conducted on 230 colorectal cancer patients of stage I-III and 
treated in a Beijing cancer hospital (140). An additional discrepancy was noticed in another 
study in which patients younger than 40 years old had poorer disease-free and cancer-
specific survival rates with respect to patients older than 80 years old (146).  
 
The tumour’s clinical characteristics, co-morbidity, treatment and patients’ demographics 
have been suggested as possible factors accounting for the higher survival in young 
patients despite the poor prognoses (147;148). Generally, advanced stage in diagnosis, 
poorly differentiated adenocarcinoma and presence of metastasis are characteristics of 
colorectal cancer tumours in young patients (141;146;147;149;150). Thus some researchers 
reported in their studies that poor survival in old patients is not related to the tumour 
characteristics (147). A study showed that survival for patients younger than 65 years of 
age improved over time compared with older patients. This improvement was attributed to 
an increase in the use of adjuvant treatment in younger patients as well as better tolerance 
to surgery (148). The effect of adjuvant therapy on improving cancer–related survival rate 
was also reported for patients younger than 50 years of age with rectum cancer. 
Furthermore, less co-morbidity and emergency operations, compared with older patients, 
were identified as possible factors (143).  More investigation is needed to explore if the 
tumour characteristics contribute to survival differences with age. 
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2.5.1.2 Sex and colorectal cancer survival 
The relationship between sex and colorectal cancer survival varies from one population to 
another and generally the investigation of this factor is not well established. Results of the 
CONCORD study showed that within most of the included regions, the survival rate of 
CRC patients was insignificantly affected by the patient’s sex. Better survival was found 
among females, but did not exceed five percent in most of the registries. The same study 
found differences between the two sexes in a few regions. In Malta, the 5-year relative 
survival rates for female patients were better than those of male patients by a difference of 
20 percent for colon cancer, 17.8 percent for rectum cancer and 19.8 percent for colorectal 
cancer. In the Navarre region, among the Spanish registries, the survival rate for females 
was higher by 15.4 percent for rectum cancer. Furthermore, better survival rates for male 
patients with rectum cancer were observed in the Ragusa, Italy registry and the 
Netherlands (South) registries where the differences were 12.5 percent and 12.9 percent, 
respectively (13).  
  
The impact of sex on survival following surgery was assessed in Scotland for 3,200 
patients who underwent resection surgery between 1 January 1991 and 31 December 1994. 
In this study, the 5-year overall survival for females (55.2 percent) was significantly higher 
than that of males (49.1 percent) (p<0.001) (151).  
 
In another study, the effect of sex on survival rate was investigated for 52,822 patients with 
metastatic colorectal cancer from 1988-2004. Patients were registered in the Surveillance, 
Epidemiology and End results (SEER) programme. Young women less than 45 years of 
age had better overall survival rates than men of the same age by 20 percent at the 
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seventeenth month, whereas the rates became worse for women more than 55 years of age 
compared with men of the same age (152). 
 
Rectum surgery is technically more difficult in men, so local spread and nodal clearance 
may be inadequate. Reasons of better survival rates in younger females when compared to 
men of the same age need further investigation.  Many researchers have suggested that 
oestrogen inhibits CRC progression and thus better survival was observed in pre-
menopause status (153-155). Studies indicated that a decline in oestrogen results in loss of 
oestrogen receptor beta that is associated with the survival differences between the two 
sexes. An accompanying research finding stated that the loss of oestrogen receptor beta is a 
mediator for oestrogen-dependent tumour progression (156), and it may cause an increase 
in proliferation and decrease differentiation of the colonic mucosa (157). Furthermore, 
selective loss of this receptor was detected in malignant tissues of colon cancer (158). 
Another supportive finding is the inverse correlation of contraceptives containing 
oestrogens with colorectal cancer risk (156-158). 
 
2.5.1.3 Socio-economic status 
Findings of many researchers showed that shorter CRC survival is associated with lower 
socioeconomic status after controlling for potential other risk factors (144;145;159-163). 
Many factors including stage at diagnosis, psychological support, differences in tumour 
biology, effect of treatment on the patient, quality of treatment, access to health care, 
access to diagnostic aids and/or burden of comorbid diseases, may partially contribute to 
the effect of socioeconomic status on survival (145;164;165).  
 
80
Data on patients diagnosed with CRC between 1990 and 1997 and living in Ontario was 
analysed to investigate the effect of socioeconomic status on CRC survival. Probability of 
death within 30 days was 1.37 for the lowest socioeconomic status compared with the 
highest socioeconomic status (145). The five-year relative survival of colon cancer patients 
ranged, depending on socioeconomic status, from 40 percent to 46 percent for males and 
45 percent to 55 percent for females diagnosed during 1994-2003 in Denmark (162).  
 
2.5.1.4 Race and ethnicity 
Race and ethnicity are important population characteristic that are widely used in 
epidemiologic and public health research. Understanding race and ethnicity and their 
influence on health is important for determining health outcomes. The literature debates 
the definition of race as a concept that has long been used as a marker to define the 
biological difference between population groups, hence giving it a biological context. 
Caution over using race as a biological concept has been criticized in the literature due to 
misuse, and a societal context for race has been increasingly adopted, bringing in the 
concept of ethnicity as a synonym for race (166).   
 
Many researchers explored the influence of race on CRC survival in the U.S. Generally, 
results showed lower survival among blacks compared to whites for both sexes 
(13;73;167;168), and lower survival among Hispanic compared to non-Hispanic whites 
(169). 
 
CRC survival variation was also detected in Denmark among Danish and immigrants 
(162), in Hawaii among Hawaiian and other ethnic groups including Japanese, Caucasian, 
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Chinese and Filipino (170), and among indigenous and non-indigenous people in New 
Zealand and Australia (77;171).  
 
Disparities of survival from one race to another may be explained by cancer stage at 
diagnosis, access to health services, and quality of treatment, tumour biology, 
demographics or socioeconomic characteristics (161;167;168;172).  
 
2.5.2 Clinical characteristics and colorectal cancer survival 
2.5.2.1 Stage of tumour 
Stage of tumour at diagnosis is the most important predictor of survival. Patients' survival 
from CRC was estimated for the different stages (i.e. Stage I through IV) of tumour at 
diagnosis (12;73;137;144;171;173-175). Findings indicated that survival rates became 
shorter as the cancer spread beyond the origin site. Thus, the highest survival rate was 
found for patients with localized tumour stage (Stage I) and the lowest for the distant 
tumour stage (Stage III). This result was found regardless of patient's race (73;137), quality 
of health care services (173), treatment type (174), and site of tumour (175).  In a cohort 
study to examine the prognostic factors in CRC patients, the 5-year survival rates of CRC 
were 68 percent for Stage II, 44 percent for Stage III and 2 percent for Stage IV (176). 
Others found that the 5-year survival of CRC patients were 89 percent for Dukes’ Stage A, 
75 percent for Dukes’ Stage B, 49 percent for Dukes’ Stage C and 12 percent for Dukes’ 
Stage D (177).  
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2.5.2.2 Cancer grade and morphology 
Cancer grade also plays an important role in predicting survival. Survival rate decreases 
with poorer cell differentiation (137;171). Hazard ratio for death at 5-years among non-
elderly patients in the U.S. National Cancer Data Base ranged from 1 to 2.53, as the cancer 
grade became higher (137). 
 
The different histological types of colorectal cancer tumours were investigated. It was 
reported that patients with rectum cancers rose from polyp or adenoma, and carcinoid had 
5-year survival rates ranging from 85 percent to 90 percent--the highest rate among various 
histological types. In the same study, the poorest 5-year survival rates (i.e. less than 30 
percent) were estimated for small cell and adenosquamous of colon cancer, whereas for 
rectum cancer, the poorest 5-year survival rates were for undifferentiated, small cell and 
melanoma histological types (178). Another study demonstrated that patients with: 
different papillary adenocarcinoma had the best survival; moderately differentiated and 
mucinous adenocarcinoma had moderate survival; and poorly differentiated 
adenocarcinoma had poor prognosis (179). In addition, mucinous tumours were found to 
have worse survival when compared with non-mucinous tumours; their 5-year survival 
rates were 51 percent and 69 percent, respectively, while signet ring tumours were worse 
(for both mucinous and non-mucinous tumours) with a 5-year survival rate of 27 percent 
(180).  
 
2.5.2.3 Tumour site 
Effect of tumour site varied among the different studies. One study estimated the survival 
rate of patients with colon and rectum cancer in different sub-sites (i.e. cecum, appendix, 
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ascending, hepatic flexure, transverse, splenic flexure, descending, sigmoid, overlapped 
and colon NOS) for colon cancer, as well as recto sigmoid and rectum for rectum cancer. 
Researchers found that five-year survival rates between sub-sites or between colon cancer 
and rectum cancer were insignificantly different (64.0 percent for colon cancer and 62.7 
percent for rectum cancer), but the other two sub-sites (overlapping and NOS) had much 
poorer survival outcomes. Distinct difference was shown for patients with stage II 
colorectal cancer where the 5-year survival rate was 82.7 percent and 69.7 percent for 
colon and rectum cancers, respectively (178). In another study, the survival rate for colon 
cancer was significantly higher than rectum cancer (181). In a recent study in which the 
survival rates of colon and rectum cancers were investigated at different survival times, 
patients with colon cancer had the worse 1-year survival rate, while they had better 2-, 3-, 
4- and 5-year survival rates compared with patients with rectum cancer (182). 
 
A study in New Zealand reported that the hazard ratio was 1.11 for right-sided tumours 
compared with the left-sided, indicating better survival for patients with left-sided tumours 
(171). Similar results were reported by a study conducted in the Hospital of Larissa, 
Greece (175). Other research, though, suggested higher survival associated with right-sided 
tumours (0.3 and 0.4 hazard ratio for females and males, respectively) compared with left-
sided tumours (0.45 and 1.08 hazard ratio for females and males, respectively) (183). 
 
2.5.3 Type of treatment and colorectal cancer survival 
Definitive surgery and adjuvant chemotherapy were found to contribute to variations in 
colon cancer survival of New Zealanders. Hazard ratio reduced significantly to 0.24 for 
patients who underwent definitive surgery and to 0.55 for patients who received adjuvant 
chemotherapy (171).  
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Three types of treatment were investigated in CRC in the state of Ohio, in the U.S. 
Palliative care, surgery plus chemotherapy treatment and surgery treatment only. 
Compared to palliative treatment, hazard ratio was 0.56 when surgery treatment was used 
alone and 0.76 when surgery combined with chemotherapy were used (184).  
 
In a study done to evaluate laparoscopic surgery versus open colectomy in colorectal 
cancer patients, no significant differences were observed in the 5-year survival rates 
between the two methods. Depending on cancer stage, 5-year survival rates ranged from 0 
to 100 percent for the laparoscopic method and 0 to 89.7 percent for the open surgical 
method (185). Other studies supported this finding, whereas no statistical difference was 
observed when the two methods were compared regarding their impact on survival 
(108;114).  
 
In a randomized clinical trial done in Brussels to investigate the impact of combining 
chemotherapy with preoperative and/or postoperative radiotherapy on rectum cancer 
survival, found that adding Fluorouracil-based chemotherapy to radiotherapy 
preoperatively and/or postoperatively did not have any effect on survival (114).  
 
A Swedish rectum cancer trial concluded that preoperative radiotherapy has beneficial 
effects on survival of rectum cancer patients undergoing surgery. The improvement in 13- 
years’ survival rate was not significant for Stages 2 and 3 of rectum cancer. Risk of 
recurrence was found to be reduced after receiving preoperative radiotherapy, and this 
reduction could have contributed to the improvement of survival (174). 
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2.5.4 Comorbidity and colorectal cancer survival 
The presence of concurrent illness is common in colorectal cancer patients and it 
significantly affects survival (161;162;171;172;186-191). Hazard ratio for death at 1- year 
for colorectal cancer patients in the U.S. National Cancer Data Base 2003-2005 was 
estimated according to the number of comorbid conditions. The hazard ratio increased with 
the number of comorbid conditions: by 12-48 percent in white patients having one or more 
comorbid conditions; whereas in black patients, hazard ratios increased significantly with 
three or more comorbid conditions (190).  
 
The Charlson comorbidity index is used to predict the 10-year mortality for a patient with 
comorbidities; i.e. it is used as a measurement of the effects of the presence of 
comorbidities.  A Charlson comorbidity index score of one or more was found to be 
associated with lower 5-year survival rates of male colon and rectum cancer patients in 
Denmark, whereas similar results were found for Danish females, with a score of two or 
higher (162).   
 
In a retrospective cohort study done to assess the impact of comorbidity on colon cancer 
patient survival among New Zealand colon cancer patients, the number of comorbid 
conditions, as well as the Charlson comorbidity index scores, was found to be associated 
with the survival of patients. The hazard ratio increased by 32 percent and by 48 percent 
for Charlson score 1-2 and 3 or higher, respectively. Also, hazard ratio increased by 23 
percent when two comorbidities were present, and by 33 percent when three or more 
comorbidities were present (191). 
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The impact of combinations of comorbidities on survival from colorectal cancer was 
difficult to predict. The effect of multiple comorbidity conditions had variable patterns 
depending on the type of the combined comorbidities (191;192).  
 
Diabetes mellitus was identified as a prognostic factor as well as being comorbidity 
associated with colorectal survival rate. Inconsistency of results was noticed in the 
literature. Zhou Zhong-guo et al. investigated the effect of diabetes mellitus on the survival 
of colorectal cancer patients who underwent resection in Stages II and III. Researchers 
found that patients with diabetes mellitus experienced worse disease-free survival rates 
than those without diabetes mellitus. However, the overall survival rate was not affected by 
the presence of diabetes mellitus (193). The same result was found in research that aimed 
to investigate the impact of diabetes mellitus on colorectal cancer survival rates for patients 
who underwent resection in the First Affiliated Hospital of Sun Yat-sen University in 
China. The five-year survival rate was 34.2 percent for diabetic patients and 55.1 percent 
for non-diabetic patients (187-189;191;192). Another study conducted on colorectal cancer 
patients who underwent surgery at Korea Cancer Center Hospital showed that both the 
disease-free survival rate and the overall survival rate were not affected by the presence of 
diabetes mellitus, while both the five-year disease-free rate and overall survival rate 
significantly decreased in the presence of diabetes mellitus during a study on patients with 
Stage II and III colon cancer (194).  
 
In a 2003 cohort study throughout the United States, 3 759 patients with high-risk stage II 
and stage III colon cancer were treated in a randomized adjuvant chemotherapy trial 
between 1988 and 1992. Within the cohort, 287 patients were identified as having diabetes 
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mellitus. “At 5 years, patients with diabetes mellitus, compared with patients without 
diabetes, experienced a significantly worse disease-free survival (DFS; 48 percent 
diabetics versus 59 percent non-diabetics; P < .0001), OS (57 percent versus 66 percent; 
p<0.0001). Median survival was 6.0 years and 11.3 years for diabetics and non-diabetics, 
respectively.” (122). The decrease in 5-year overall survival rate with the presence of 
diabetes mellitus was also observed in patients who underwent curative resection at 
Levanger Hospital in Norway. In the same study, there were no differences observed in 
cancer-specific survival rates regardless of diabetes status (119). However, in a study of 
colon cancer survival in diabetic patients and segregated by stage of colon cancer, both 
overall survival rate and cancer-specific rate decreased in diabetic patients with Stage II 
colon cancer. I.e. patients with diabetes had worse CSS (HR = 1.24, P = 0.013) when 
compared to those without, but it was only significant for patients with stage II cancers. 
The impact of diabetes on CSS was attenuated in both early (Stage I) and advanced stages 
(III and IV) (120). The effect of diabetes mellitus on colorectal cancer outcomes is 
associated with hyperinsulinemia and insulin-like growth factor-1 (IGF-1) (121;193;195).  
 
2.5.5 Health services and colorectal cancer survival 
Quality of health services provided to patients is strongly related to cancer survival. 
Perhaps the best model to describe this notion is Donabedian’s famous framework for 
assessing quality of care which is built on three concept elements: structure, process and 
outcome. This framework links the structure and process of care to patient outcome and 
suggests a direct relationship between the structure (organizational structure, material 
resources and human resources), process (organization and performance of clinical tasks 
and processes) and outcome of care (clinical results, their effect and patient satisfaction 
(196). 
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In a study of cancer survival in developing countries, survival in two groups of countries 
was analysed. One of the groups (Group A) included Turkey and Singapore where health 
services are well developed. The other group (Group B) included India, Philippines and 
Thailand where health services are less developed. The five-year relative survival rate in 
Group A countries versus Group B countries was 64.1 versus 49.8, 45.7 versus 32 and 8.6 
versus 2.4 for local, regional and distant colorectal cancer, respectively. The higher 
survival in Group A countries reflects well established screening programs, accessibility to 
health facilities as well as developed treatment practices, after controlling for potential 
confounders e.g age, sex, stage and treatment (14). 
 
Health insurance is one of the health services that affect colorectal cancer survival. For 
patients registered with the U.S. national cancer data base from 2003 to 2005, the hazard 
ratio for death at 1-year was increased for patients without private insurance (i.e. patients 
who have Medicare or Medicaid insurance in addition to uninsured patients) (137). The 
same result was found for the relationship between insurance status and survival among 
nonelderly rectum cancer patients registered by the U.S. national cancer data base from 
1998 to 2002 (190).  Comorbidity accounted partially for the increase of poorer survival of 
patients without private insurance, and it is expected that difference in the receipt of 
treatment may also lead to poorer survival (190). Many other studies showed variation in 
the relationship between colorectal cancer survival and insurance status (197-201).  
 
Different type of surgeons (general, specialist, and trainee) as well as different treatment 
facility types (e.g. secondary public, teaching public and private hospitals) are other factors 
of disparities in colorectal cancer survival as shown in a study carried out in New Zealand 
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(171). Early death was not found to be associated with distance to clinic, though, as shown 
in a study conducted in Ontario, Canada (145). 
 
2.5.6 Residence-related factors and colorectal cancer survival 
2.5.6.1 Country-related residential factors 
Wide variation is observed when colorectal cancer survival rates are compared among 
different countries. This fact is supported by the results of a global cancer survival study 
for 31 countries distributed across the five continents (CONCORD study). Researchers 
analysed the data for patients diagnosed with primary invasive malignant colorectal cancer 
during 1990 through 1994 in order to estimate the 5-year relative survival rate. The results 
showed that colorectal cancer’s 5-year relative survival rate was generally greater than 55 
percent for both sexes in Japan, France, U.S.A., Canada and Australia, reaching 61.1 
percent for males in Japan and 61.5 percent for females in France. Colorectal cancer’s 5-
year relative survival rate was generally lower in Algeria (male 22.5 percent, female 22.6 
percent) and Poland (male 28.6 percent, female 30.6 percent) (13).  
 
In Europe, large gaps in colorectal cancer survival rates were observed across the different 
European countries (12;13). In general, survival was lower in Eastern European countries 
compared to the Western European countries. In the CONCORD study the range of 5-year 
relative survival rate among the European registries was 25.7-57.8 percent for males and 
22.5-64.2 percent for females.  
 
Variations in survival rates across the Western European countries were also observed. In 
England and Scotland, survival rates were found to be 42.3 percent and 44.6 percent, 
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respectively for males, and 44.7 percent and 47.7 percent respectively for females. Yet, the 
rate exceeded 50 percent for both sexes in France, Germany and Italy with France reaching 
61.5 percent for females (13).  Moreover, in France, a population-based study was 
conducted on data from patients who were diagnosed between 1989 and 1997. The results 
provided age standardized 5-year relative survival rates among males and females, which 
were 55 percent and 57 percent, respectively (202).  
 
Another study which compared the survival differences between European and U.S. 
patients diagnosed between 1990 and 1991 showed that 3-year relative survival ranged 
from 67 percent in Modena, Italy to 44 percent in Thames, U.K. Comparing European with 
U.S. patients, 3-year relative survival was found to be 69 percent in the U.S. and 57 
percent in Europe (12). The CONCORD study also showed higher survival rates in the 
U.S. compared with Europe (13). 
 
In a report on cancer survival in developing countries, survival analysis was performed for 
patients diagnosed with disease from 1990 to 2001 (11). As in other studies, results 
demonstrated large discrepancies between the different regions. Furthermore, a five-year 
relative survival was reported to be greater than 50 percent in Singapore, Turkey and South 
Korea; ranging from 28 percent to 44 percent in India, Thailand, Philippines and China; 
whereas it didn't exceed 8 percent in Uganda and Gambia (14;17;173). 
 
2.5.6.2 Community-related residential factors 
Residents in rural areas were found to have lower colorectal cancer survival compared with 
those living in urban areas, as shown by the results obtained from studies conducted in 
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India, China, and New Zealand. Place of residence is associated with many factors such as 
life style, early detection, awareness and access to health services (13;171;173). 
 
Other reports demonstrated that distance from treatment centres is associated with the 
survival rate of colorectal cancer. In Australia, a study conducted in Queensland found that 
mortality risk of patients with rectum cancer increased by 6 percent for each 100 km 
increment in distance from radiotherapy facility (203). 
 
The association between colorectal cancer survival rate and access to healthcare was 
investigated in a study conducted in the U.S. state of Texas (159). Results showed a 
significant association between the spatial access to treatment and survival rate only in 
rural areas but not in urban areas; this was attributed to the greater concentration of 
oncologists in metropolitan areas.  
 
Synopsis: Examining different factors that might influence survival of colorectal cancer is 
important for determining disease progress. Survival statistics presented in this section 
indicated that colorectal cancer survival differs with age with a tendency of older patients 
to have poorer survival. Although the literature seems to be inconsistent in defining the 
link between sex and colorectal cancer survival, the survival rate of colorectal cancer 
patients is remains mostly insignificantly affected by the patient’s sex. Furthermore, there 
seems to be a consistent agreement in the literature for the association of lower 
socioeconomic status with a shorter colorectal cancer survival, as well as variations of 
survival by ethnicity or race. These variations may be explained by cancer stage at 
diagnosis, access to health services, quality of treatment, tumour biology, demographics or 
even risk factors such as obesity.  
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Evidence indicates that the stage of tumour at diagnosis is the most important predictor of 
survival with survival rates getting shorter with the spread beyond the site of origin. In 
addition, cancer grade also plays an important role in predicting colorectal cancer survival, 
where survival rate decreases with poorer cell differentiation. Alternatively, the literature 
provides controversial viewpoints on the effect of tumour site on colorectal cancer 
survival. Similarly, surgery and adjuvant chemotherapy were reported to contribute to 
variations in colorectal cancer survival with a tendency to have a lower survival among 
patients who underwent surgery compared to those who received adjuvant chemotherapy. 
Other important predictors conveyed through the literature include the presence of 
comorbidities in colorectal cancer patients which tend to significantly decrease survival. In 
this aspect, the literature emphasizes the effect of Diabetes Mellitus on colorectal survival 
with a tendency to support a decreased survival rate with the presence of Diabetes 
Mellitus.  
 
The literature provides strong evidence to support the relationship between the quality of 
health services and cancer survival. In addition, the literature identifies the availability of 
health insurance as a predictor to a decreased cancer survival, which might be partially 
related to the presence of other comorbidities that tend to decrease survival of patients 
without insurance. In addressing variations in colorectal cancer survival between countries 
the literature identifies large discrepancies between different regions with survival rates 
being lower in developing countries. Other factors identified in the literature as being 
associated with survival of colorectal cancer include residential factors, where residents in 
rural areas were found to have lower colorectal cancer survival compared with those living 
in urban areas.  
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2.6 Summary of the Literature Review 
There are demographic concerns for Jordan.  Its population will nearly double by 2035; the 
majority of the population will be 40 years of age or more by then and also represent a 
greater risk of developing cancer. As non-communicable diseases play a greater role in the 
overall disease burden of countries experiencing economic improvement. It is likely that 
Jordan’s future economic development positions the broadest segment of the population 
(i.e. those 40 years of age or more) to be especially at risk for developing cancer.   
 
However, it could be said that Jordan’s health care system is somewhat more robust than 
that of its neighbours as well as other wealthier countries.  Jordan has a considerably 
greater number of physicians per 10,000 population than its close neighbours and slightly 
more than the wealthier countries of U.A.E. and Qatar.  Jordan has made significant strides 
in provision of health care services to its population placing it on a par with the U.K. and 
Australia in terms of total health care expenditure as a percentage of GDP. Curative care 
takes up approximately 80 percent of health care expenditure while primary care remains 
less than 20 percent. 
 
As the chapter discussed, on a global basis, there are differences in the epidemiology of 
colorectal cancer.  While colorectal cancer globally is the third most common cancer in 
males, in Jordan it is the most common cancer among newly diagnosed male patients. 
Among females, colorectal cancer is the second most common cancer in Jordan, as well as 
globally. Throughout the world, as GDP increases, the incidence of colorectal cancer also 
climbs. The only country to witness a decline in incidence has been the U.S.   
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On a worldwide basis, colorectal cancer accounts for 9.4 percent of all cases.  While 
Jordan’s colorectal cancer rates of 9.8 percent for males and 9.0 percent for females are not 
dissimilar to worldwide rates, they are lower than the rates of most Arab countries (whose 
economic development have been slower than that of Jordan).  This fact also suggests, 
though, the possibility that Jordan’s population may experience a more rapid rise in new 
cases than countries outside the region that share similar levels of economic growth as 
Jordan. 
 
The incidence rate in Jordan has been lower than that of other middle-income countries, 
but not unlike the (relatively) lower rates across the Eastern Mediterranean Region.  
Despite the differences in incidence rates, a common set of variant risk factors have been 
identified; these include being older than 45 to 50 years, being male versus female, having 
a specific ethnicity (or familial history), et al. Other modifiable risk factors exist (e.g. high 
blood pressure, high BMI, impaired fasting glucose, high cholesterol) that are also 
common in patients with diabetes mellitus. This section discussed, Jordan is already 
witnessing the impact on its population of increased experience of the modifiable risk 
factors. However, survival rates for colorectal cancer are possibly most affected by early 
presentation and localized staging. These types of differences form part of the framework 
for comparison of Jordan’s colorectal survival rates with those of other countries.  
 
Due to gaps in the literature, the question remains of whether: i) Jordan has better, or 
worse, survival than other countries; and ii) whether it can be explained by known risk 
factors. In order to address these gaps, six Study objectives have been designed (Section 
1.4.2). Table 4a shows how the study objectives map against a summary of the known risk 
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factors discussed in the literature review; Table 4b shows how Study objectives map 
against survival statistics found in the literature. The column headed “Impact of the risk 
factors on populations outside Jordan” highlights pertinent data describing other countries; 
the column headed Jordanian metrics shows reciprocal data for Jordan.  The scarcity of 
Jordanian data provides more specific detail to describe the Literature gaps.  
 
As the chapter showed, differences between countries may be a result of differences in 
known risk factors (e.g. later presentation, older populations, poorer treatment) or some 
other country-specific factors.  While the literature gives some indications of how Jordan 
compares with other countries, gaps in the literature prevent definitive comparisons being 
made between survival rates in Jordan and other countries.  
 
 In addition, variation of colorectal cancer survival across the different countries can be 
attributed to socioeconomic status (SES), the screening programmes and the quality of 
treatment practices (12;13;173;204). Cancer survival is also an indicator for the country’s 
capability to control the disease (13;21;76;205). Apart from efforts to prevent cancers, 
improvements making early diagnosis and treatment more accessible could be major 
challenges in the developing countries. 
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Table 4a: Summary of literature review related to risk factors 
General risk factors 
Primary risk 
factor 
Secondary 
risk factor Impact of the risk factors on populations outside Jordan Jordanian metrics 
Age  Being >45-50 yrs. old. Incidence rate is more than 14 times higher in 
adults 50 years and older than in those younger than 50 years. Mortality 
rates increase with age; 94percent of deaths occur in individuals 50 years 
and older  
To be addressed via Study objective 3. 
Clinical 
characteristics 
of the 
tumour*: 
Stage of 
tumour 
Stage at Dx is single most important predictor of survival. Result constant 
regardless of race, quality of health services, treatment type and tumour 
site. Survival highest for localized tumours, lowest for distant.  Duke’s 
Staging and TNM Staging both showed that least advanced cancers 
(Duke’s Stage A and TNM Stage I) had highest survival rates  
To be addressed via Study objective 4. 
 Cancer grade/ 
morphology 
Survival rates worsen as cells become less differentiated. Higher cancer 
grades increased Hazard Ratio in non-elderly. Highest 5-yr. survival rates 
for rectum cancers from polyp/adenoma and carcinoid; poorest rates for 
small cell & adenosquamous types of colon cancer and rectum cancer with 
undifferentiated, small cell & melanoma types.  Mucinous vs. non-
mucinous tumours had the lower survival and signet ring was worse for 
both rectum & colon. 
To be addressed via Study objective 4. 
 Tumour site Effect of tumour site varies considerably among various studies. To be addressed via Study objective. 
Type of 
treatment* 
 Preoperative radiotherapy improved survival for rectum cancer patients, 
but otherwise little conclusive evidence of improved survival with surgery 
vs. chemotherapy. Some evidence of better 5-year survival for 
laparoscopy vs. open surgery. 
To be addressed via Study objectives 4 and 5. 
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Table 4a: Summary of literature review related to risk factors 
General risk factors 
Primary risk 
factor 
Secondary 
risk factor Impact of the risk factors on populations outside Jordan Jordanian metrics 
Comorbidity*  Concurrent illness is common in colorectal cancers and significantly affects 
survival.  Multiple comorbidities had variable patterns depending on 
combination of types. 
Presence of Diabetes Mellitus was both a prognostic factor and comorbidity 
associated with survival rate. Disease-free survival rates were lower in 
patients with Stages II or III colorectal cancer than those without diabetes. 
The effect of diabetes mellitus on colorectal cancer outcomes is associated 
with hyperinsulinemia and IGF-1. 
To be addressed via Study objectives 4 and 6. 
Socio-
demographic 
characteristics: 
Race/ethnicity Higher incidence rates among Ashkenazi Jews and African Americans. 
Lower survival rates among U.S. blacks vs. whites and among Hispanics 
vs. non-Hispanics. Lower number of comorbid conditions increased hazard 
ratios in white patients than in blacks. Variations in survival can be seen in 
local vs. immigrant populations in Denmark and Hawaii and between 
indigenous and non-indigenous population in Australia and N.Z.. 
Jordan has a multi-ethnic society.  Additional 
aspects of race/ethnicity will be addressed via 
Study objective 3. 
 Sex Incidence and mortality rates are higher in men than in women. One large 
study of metastatic colorectal cancer patients found that women <45 years 
had better survival rates than men, yet women > 55 years had worse 
rates than similarly aged men. 
To be addressed via Study objective 3. 
 Socio-
economic 
status 
Many researchers found lower socio-economic status to be positively 
associated with shorter survival. Many other factors (e.g. stage at Dx, 
quality of treatment, comorbidities) may play a role. 
Considerable inequalities in obesity by socio-
economic status exist in Jordan. Additional 
impacts of socio-economic status will be 
addressed via Study objective.  
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Table 4a: Summary of literature review related to risk factors 
General risk factors 
Primary risk 
factor 
Secondary 
risk factor Impact of the risk factors on populations outside Jordan Jordanian metrics 
Health services  Quality (i.e. degree of development) of health services is strongly related 
to survival. Adequate health insurance coverage also affects survival rate. 
Levels of surgeon’s skills as well as various type of treatment hospital 
affect survival rates. Distance to clinics was not related to early death in 
Canada.  
Health care expenditure in Jordan (8.4percent 
of GDP) is similar to rates found in the U.K. 
and Australia. Some 79 percent of Jordan’s 
population is covered by insurance. Jordan was 
ranked world’s fifth most popular medical 
tourism destination in 2008.  Additional 
impacts of health services will be addressed via 
Study objectives 2, 3 and 5. 
Residence-
related factors: 
Country of 
residence 
Incidence rate is higher in wealthier countries. Survival rates vary greatly 
across countries, per CONCORD study. CONCORD showed differences 
between European countries (e.g. higher survival in France, lower survival 
in Poland, better in the U.K. but still lower than France and Italy) and 
between Europe and the U.S. (higher survival in the U.S. and lower 
survival in Europe); Asian countries showed generally lower rates but 
representative of general economic status. Variation across countries is 
attributed to success of screening programmes. 
To be addressed via Study objectives 3 and 5. 
 Community-
related factors 
Residents in rural areas have lower survival rates than patients living in 
urban areas.  
To be addressed via Study objectives 3 and 5. 
Other 
modifiable risk 
factors: 
  To be addressed via Study objectives 1, 2, 3 
and 6. 
Non-modifiable Family/ 
personal 
history 
Adenomatous polyposis; hereditary non-polyposis colorectal cancer or 
Lynch syndrome, history of colorectal cancer and/or polyps; being 
diagnosed with chronic inflammatory bowel disease. 
No literature found for Jordan. 
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Table 4b: Summary of literature review related to CRC survival statistics 
Survival statistics CRC survival statistics and populations outside Jordan 
CRC survival statistics related to 
Jordanians 
Independent of risk 
factors: survival 
statistics for CRC in 
Jordan 
Not applicable. Literature gap to be filled by Study objective 1 (Section 1.4.3). 
Independent of risk 
factors: survival 
statistics for CRC in 
countries outside of 
Jordan 
Country Period/Year of the study: reference 
Literature gap to be filled by Study objective 
2 (Section 1.4.3). 
 Worldwide incidence of new CRC cases = 1.2 million cases 2008  
Literature related to 
Jordan 
Period/Year of 
the study: 
reference 
 8percent of all cancer deaths worldwide are from CRC  
Estimate for Jordan: CRC 
ASR of: 15.3 for males; 
11.9 for females 
GLOBOCAN 
2008 
 West Asia CRC ASR of: 13.1 for males; 10.1 for females GLOBOCAN 2008 
Jordan 2008: 548 new 
cases CRC; 11.9percent 
of all new Jordanian 
cases; male-to-female 
ratio 1.5:1 
 
 
Highest ASR for CRC: males: 
Czech Rep 59.1; NZ 49.3; 
For females: NZ 39.5; South 
Australia 34.1 
Between 1998-2003  
 
Lowest ASR for CRC: males: 
Mumbai, India 5.9; Quito, 
Ecuador 8.4; 
For females: Mumbai India 
Between 1998-2003  
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Table 4b: Summary of literature review related to CRC survival statistics 
Survival statistics CRC survival statistics and populations outside Jordan 
CRC survival statistics related to 
Jordanians 
4.4; Quito Ecuador 8.9 
 
ASIR of overall cancer in 
Jordan: 134.7 per 100 000 
for males; 136.0 per 100 000 
for females 
  2009   
 In region:  
 
Highest ASR for CRC: Israeli 
non-Jews: males 34.0 & 
females 34.7 
1998-2003  
 Lowest ASR for CRC: Oman males 3.7   
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CHAPTER 3 – MATERIALS AND METHODS 
 
3.1 Introduction 
This chapter describes the general methodological issues and introduces the reader to the 
subjects and methods used to fulfil the study objectives and answer the research questions 
(concerning colorectal cancer survival statistics in Jordan for the 2003 through 2007 
timeframe). The methodological approach included review of documents and other 
published materials. A study instrument was developed for capturing all pertinent data. 
 
The chapter starts with a description of the methods used for conducting the literature 
review as well as the source of data that has been utilized. The study instrument 
(questionnaire) is described in detail. The data collection procedures are also explained in 
detail. Data quality control measures, data analysis and human research ethical approvals 
were discussed, as well. At the end of this chapter, the main terms and conditions that have 
been used in the study are addressed.  
 
The main source of the study data was Jordan Cancer Registry. The vital status of patients 
was ascertained using the data of the Jordan National Civil Registration Bureau.  The 
researcher completed the missing data and collected additional information from hospitals 
by reviewing medical records and laboratories from both governmental and non-
governmental bodies. 
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The study was carried out at the national level: the Jordan Cancer Registry (JCR), 
hospitals, and laboratories from both governmental and non-governmental bodies were 
accessed.  
 
3.2 Study methods  
This is a descriptive study carried out to estimate the observed and relative colorectal 
cancer survival rates among the study population during the period 2003 (01 January) 
through 2007 (31 December). The survival rates were described in relation to many 
variables (such as age, sex, residency, extent of cancer, site, morphology, treatment and 
presence of diabetes mellitus type 2).  
 
3.3 Data sources  
The study was carried out at the national level: the Jordan Cancer Registry (JCR), 
hospitals, and laboratories from both governmental and non-governmental bodies were 
accessed. The vital status of patients was ascertained using the data of the Jordan National 
Civil Registration Bureau.   
 
Data from JCR was collected and coded in accordance with the International Classification 
of Diseases for Oncology, 3rd edition (ICD-O3) (54), in addition to the International 
Classification of Diseases (ICD-10) (55).  In addition to the use of routine JCR records, 
hospital records were reviewed and pathological laboratory reports at national level were 
used to complete any missing information. Field visits were conducted and data was 
collected from public health hospitals, King Hussein Cancer Center, military (i.e. Royal 
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Medical Services), teaching hospitals and hospitals in the private sector. In addition to 
these sites, data was also collected from pathology laboratories.  
 
It should be mentioned that the Civil Registration Bureau (CRB) in Jordan is a centralized 
system. Overseen by the Ministry of Interior, the CRB is responsible for the civil 
registrations in the country. Its main role is to register all vital events experienced by 
Jordanian citizens, living in the country or abroad, as well as other nationalities resident in 
Jordan. The CRB provides certificates for vital events, registers Jordanian families, issues 
family books and provides national IDs for all Jordanian citizens.  
 
3.4 Eligibility and inclusion criteria  
Only Jordanian colorectal patients, aged 15 through 99 years of age, diagnosed with first 
invasive primary colorectal cancer during the period 01 January 2003 through 31 
December 2007, verified by histopathology report and registered in Jordan Cancer Registry 
were included in the study. Non-Jordanian nationals, those Jordanians who were diagnosed 
before 01 January 2003 or after 31 December 2007 or any case with no histological report 
were all excluded from the study. The CRC cases were categorized according to ICD-10 
site codes (C18-C20-9).  
 
3.5 Study instrument 
The study instrument (Annex 1) was developed for capturing information from JCR, 
medical records, the histopathology report as well as CRB.  The study instrument was 
designed to gather information on socio-demographic characteristics, clinical and 
histopathology information, treatment, co-morbidities and information about the patients’ 
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vital status.  Sections 3.5.1 through 3.5.5 describe more fully each relevant section of the 
study instrument.  
 
3.5.1 Socio-demographic information 
This section of the study instrument collected data that identified the patient serial number, 
sex, age, date of birth, place of residency (i.e. governorate), occupation, level of education, 
and main source of medical services.  
 
3.5.2 Clinical and pathological information  
This section identified date of diagnosis, site of the tumour, morphology, staging and 
grade.  Further information about tumour size and number of positive lymph nodes was 
partially extracted from pathology reports.  
 
3.5.3 Treatment  
Treatment information included the type of treatment, whether palliative or curative, 
information about surgery (type, date and procedure) and information about chemotherapy 
as well as radiotherapy (date and frequency) was collected.  
 
3.5.4 Co-morbidity 
This section focused on the major co-morbidities in Jordan: diabetes mellitus, 
hypertension, raised cholesterol and obesity.  
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3.5.5 Vital status  
This section determined the vital status of the patient: whether alive, dead or unknown; 
time passed from date of diagnosis to date of death or to date of last visit, and the cause of 
death, if available.   
 
3.6 Data collection 
3.6.1 Preparatory Phase  
The preparatory phase was comprised of literature review, preparation of study tools, 
finalization of administrative steps and conducting a pilot study.  
 
3.6.1.1 Administrative steps 
Preparatory administrative communication with key personnel was made to facilitate 
implementation of the study. Official letters were addressed to the Ministry of Health in 
order to get required information. As a result, written permissions from the JCR, the 
Ministry of Health, King Hussein Cancer Center, Royal Medical Services Hospitals, 
private hospitals and laboratories, and the Civil Registration Bureau – CRB (under 
jurisdiction of the Ministry of Interior) were obtained (Annex 2).  
 
3.6.1.2 Pilot study  
A pilot study was conducted to test the instrument and to check the validity of the data 
collection techniques. The pilot study was conducted in Al-Bashir Hospital (a Ministry of 
Health hospital), the King Hussein Cancer Center, one teaching hospital and one private 
hospital. For each site ten forms were filled out. The study instrument was modified 
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accordingly. The pilot study confirmed the feasibility of conducting the study and the 
commitment of the Jordan Cancer Registry and other sites to support the study. On the 
other hand, the results of the pilot study showed variation in the quality of medical records 
across different hospitals. The pilot study also showed that some of the patients received 
treatment at different sites during their treatment plan.  
 
3.6.2 Implementation phase (Data collection and follow up)  
3.6.2.1 Jordan Cancer Registry  
Data from the JCR was obtained for patients diagnosed with the colorectal cancer during 
the 2003 through 2007 study period. A prerequisite step to this was to discuss and present 
the study protocol to the JCR and to the Jordan Ministry of Health before gaining their 
permissions. JCR provided CRC data on 2,093 records, according to the study eligibility 
and inclusion criteria. Data was supplied based on the anatomical location of colorectal 
cancer coded to the tenth revision of the International Classification of Diseases (ICD-10) 
or the third revision of the International Classification of Diseases for Oncology (ICD-O-
3); colon (ICD-10 C18.0–C18.9), rectosigmoid junction (C19; ICDO-3 C19.9), and rectum 
(C20; ICD-O-3 C20.9) excluding anus and anal canal (ICD-10 C21).  Data was collected 
for age, sex, date of presenting, residency, date of diagnosis, anatomical site, morphology, 
grade and stage at diagnosis. There was no available information about occupation, level of 
education and treatment.  
 
3.6.2.2 Medical records  
In addition to using the routine JCR data base, active strategies for collecting more clinical 
information on treatment, co-morbidity, the site of receipt of health care services were 
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followed by reviewing hospital records and pathological laboratory reports at the national 
level. Furthermore, the medical records and pathological laboratory reports were used to 
compensate for the missing clinical information such as the site, stage and grade of the 
cancer.  
 
3.6.2.3 Vital status  
The vital status of the patients was ascertained from CRB based on use of the unique 
National Identification (ID) number of the patients with follow-up to 31 December 2010. 
The outcome of interest was whether colorectal cancer cases were alive, dead or unknown. 
The survival duration of each case was determined as the time difference (in days) between 
the date of diagnosis (index date) and the date of death, date of loss to follow-up, or the 
closing date for follow-up (31 December 2010). 
 
Data collection took place between February 2010 and December 2010 after getting 
official permissions to conduct the study. 
 
3.7 Quality control  
3.7.1 Data processing  
As mentioned earlier, JCR provided CRC data on 2,093 subjects according to the study 
eligibility and inclusion criteria. After checking the data that was received, 46 duplicate 
records were excluded. Duplication of data was avoided by using the patient’s unique 
national ID number and their full names (i.e. use of four elements: name of patient, father, 
grandfather and family name). Seven records indicating patients’ age of less than 15 years 
and above 99 years were excluded as well as 47 records for non-Jordanian patients, 38 
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records with anal cancer (C 21) and two records with other types of cancer. Also excluded 
were the records of 20 patients whose tumours were benign (behaviour code 0), of 
uncertain or borderline malignancy (1), or metastatic (6) to the index organ from elsewhere 
(e.g. Lymphoma in large intestine: 9590, 9591, 9680 and 9731). Furthermore, another 37 
patients were excluded because of the lack of availability of any kind of follow-up 
information as of 31 December 2007. No cases were found based on information from 
death certificate only (DCO). Records with invalid codes, impossible sequences of dates or 
improbable combinations of tumour site and morphology were revised and checked with 
the JRC. Corrected records were integrated in the study. As a result, there were 1,896 
records included in the study. Figure 7 shows the corresponding data processing procedure.  
Figure 7: Data processing of colorectal cancer records (2003-2007) 
 
2093 records with CRC registered by JCR
197 records were excluded 
from analysis
7 records with inelligable  age 46 duplicate records
47 Non‐Jordanians cases 2 records with other types of cancer
38 records with anal cancer 37 records without any kind of follow up
20 records with not invasive or 
metastatic beviour 
1896 records were 
included in the analysis
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3.7.2 Vital Status and follow up time 
Identifying the vital status of the included patients was ascertained from the CRB through 
the use of the unique National Identification numbers (IDs) of the patients. In case no ID 
was present, the vital status was identified through a search of full four-element names 
(patient, father, grandfather and family name) and of three–element names (patient, father 
and with the third name element being the family name) and then comparing the results to 
the data in the CRB. In both of the above scenarios, names were matched with age and sex. 
Another source of identifying vital status was discharge data from the hospital assuming 
the date of discharge to be the date of the last visit of the patients. As a result, the vital 
status was identified through National Identification Numbers (IDs) for 1,499 cases, 
through checking with four-element names for 241cases, and through checking with three-
element names (the third name being the family name) for 20 cases. Medical records were 
used to follow up only 136 cases (from the date of diagnosis and the last day of the study 
(i.e. 31 December 2010). Figure 8 illustrates the procedure used for following up with vital 
status. 
Figure 8: Vital status follow up for CRC cases 
 
1896 cases were 
eligible for follow up
Cases with ID 
(CRB) : 1499 
Cases with four digit names 
but without ID (CRB): 241 
Cases with three digit 
names  but without ID 
(CRB):20 
Cases followed up by the medical records 
only: 136
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3.8 Statistical Analyses  
3.8.1 Incidence of colorectal cancer 
To better understand the CRC in Jordan, the crude and age–specific incidence rates (ASIR) 
per 100,000 population for each year were estimated for both males and females. The 
overall crude incidence rate was estimated using the total population in the period of the 
study corresponding to the sum of the populations for each year between 2003 and 2007. 
Standardization is necessary when comparing several populations that differ with respect 
to age because age has a powerful influence on the risk of cancer. The Age Standardized 
Rate (ASR) is a weighted mean of the age-specific rates; the weights are taken from the 
population distribution of the standard population. Similar to the crude incidence rate, the 
age-standardized incidence rate is expressed as the number of new cases per 100,000 
persons in a given year. The most frequently used standard population is the World 
Standard Population that we used in this study. World Age Standardized  Rates (ASR), 
using the Jordanian national population age-specific estimates, were calculated using the 
methods proposed by Segi and modified by Doll et al (78;206). To allow comparisons with 
different countries, the CRC age-specific incidence rates were aggregated by 5-year age 
groups (aged 15-74 years) as described by the International Agency for Research on 
Cancer (58). 
 
3.8.2 Survival probability  
The Kaplan-Meier method was used to determine the observed survival probability over 
time. Kaplan-Meier provides for calculating the proportion surviving to each point in time 
when death occurs. Thus it was used to measure the length of time people remain living 
after being diagnosed with colorectal cancer (207). An important advantage of the Kaplan–
Meier method is that it can take into consideration types of censored data, particularly 
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right-censoring, which occurs if a patient withdraws from a study (i.e. is lost from the 
sample before the final outcome, death, is observed. The Kaplan-Meier method and life 
table method give identical results in the absence of withdrawals (207;208). Kaplan-Meier 
was used in a univariate analysis to identify the potentially important prognostic variables-
effect of different predictors on survival rate (e.g. age at diagnosis, sex, stage, site, grade 
and type of treatment).  
 
The logrank test was used to estimate if the difference between the groups is statistically 
significant (P <0.05). The logrank test matches estimates of the hazard functions of the two 
groups at each observed event time. It is created by computing the observed and expected 
number of events in one of the groups at each observed event time and then adding these 
together to obtain an overall summary across all time points in which an event occurs 
(209;210) .  
 
In this study we used the complete approach of estimation of observed survival probability, 
implemented in the open-source program Strs with the statistical package Stata (version 
10.1) (211). The complete approach includes all subjects who are diagnosed as incidents of 
colorectal cancer cases until the closing date of the follow up. Cases with complete follow 
up of five years as well as those who had incomplete follow up of less than five years were 
both included (173;212;213). This approach allows for inclusion of all patients in the study 
period (2003-2007).   
 
Expected survival was estimated from the general population of Jordan, which was 
extracted from the National life tables (Department of Statistics/DOS estimation) of death 
rates by sex, single year of age and calendar year 2000. In this study, expected survival 
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probabilities were estimated according to the Ederer II method (173;212-214). The 
advantage of the Ederer II method is that calculations of the expected survival rates for 
patients under observation at each point of follow-up are made so that the matched 
individuals are considered to be at risk until the corresponding cancer patient dies or is 
censored (173;212;213;214). 
 
Relative survival is the standard approach for population-based cancer survival. It is 
interpreted as observed survival adjusted for other cases of background mortality (expected 
survival) (173;213). 
 
To compare the results with other countries, age-standardized relative survival was 
calculated using the International Cancer Survival Standards (ICSS) to correspond to the 
age distribution of cancer patients (215). These categories were derived from discriminant 
analysis to find the smallest number of sets of standard age weights that enable adequate 
standardization of survival. Each standard provides age-standardized survival estimates 
that are not too different from the unstandardized estimates. 
 
Observed and relative survival estimates at 1-, 3- and 5-years were estimated separately for 
each of the age groups 15–44, 45–54, 55–64, 65–74, and 75–99 years for both sexes.  
 
Cox proportional hazard regression was used to assess the net effect of each variable after 
simultaneously controlling the effects of potential confounders. This model, which takes 
into account the effect of censored observations, was chosen because it is recommended 
when the time of an event has particular interest (216;217). Since the Cox proportional 
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hazards model relies on the hazards to be proportional, i.e. that the effect of a given 
covariate does not change over time, it was very important to verify that the covariates 
satisfy the assumption of Proportionality (216-218). In our study the assumption of 
Proportionality was tested by assumption of Proportionality and including Time Dependent 
Covariates in the Cox Model techniques.  
 
Multivariable analyses were used to examine the adjusted odds of death within 30 days of 
surgery. The adjusted odds ratios for CRC thirty-day postoperative mortality for sex, age, 
place of residence, extent of disease, topography, operation type, and treatment site were 
calculated using the logistic regression modelling procedure. 
 
In addition to the Kaplan-Meier and Cox approaches, multivariate analysis was made by 
analysing Poisson Regression of relative survival. Both approaches yielded similar results.  
However, it was decided to present Kaplan-Meier and Cox approaches since the Cox 
Proportional Hazards Model is the most commonly applied model in medical time-to-event 
studies. Moreover, researchers from Jordan and the region are more familiar with the 
Kaplan-Meier/Cox approach rather than Poisson regression and thus the methods presented 
are more likely to be reproduced. The Poisson method is potentially more statistically 
powerful as it is a parametric approach; however, it assumes that the baseline hazards are 
constant over time.  The Cox approach does not make this assumption and as a non-
parametric method is potentially weaker.  However, baseline hazards do vary over time in 
colorectal cancer patients and it was felt that the Cox approach was the better one.  In 
practice, however, both approaches yield extremely similar results.  
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3.9 Human research ethical approvals 
Data was handled in compliance with the principles of the Data Protection Act 1988. In 
particular, only data that is required to answer the research questions was obtained; data 
was only used for the intended purposes. Secure encrypted electronic storage media was 
used to handle data, which was made anonymous prior to analysis by removing all 
sensitive data such as names and address and replacing them with computer-generated 
numbers. Using the data was approved by the national health ethical review board (ERB), 
Jordan ministry of health as well as by the institutional review board (IRB) of King 
Hussein Cancer Center. Furthermore, the study protocol was approved by the ethics 
committees of Glasgow University as well as the International Agency for Research on 
Cancer (IARC).  As patients were not directly contacted or involved, the principal ethical 
consideration in this study was to avoid disclosure of personally identifiable information. 
After completing the data analysis according to the Study objectives, the data was provided 
to the JCR.  Study approvals are annexed (Annex 2).  
 
3.10 Terms and definitions  
3.10.1 Colorectal cancer  
Colorectal cancer was classified according to international classification of oncology (ICD-
O third edition, in addition to the International Classification of Diseases, ICD-10) as 
(C18.0-C20.9) which include cancers of the colon (i.e. appendix C18.0, cecum C18.1, 
ascending colon C18.2, hepatic flexure of colon C18.3, transverse colon C18.4, splenic 
flexure of colon C18.5, descending colon C18.6, sigmoid colon C18.7, overlapping lesion 
of colon C18.8, colon, NOS C18.9), recto-sigmoid junction C19.9, rectum (rectum, NOS C 
20.9) (54;55).  
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3.10.2 Differentiation and grading 
According to ICD-O third edition, colorectal cancer grades were divided into four 
categories: well differentiated, moderately differentiated, poorly differentiated, 
undifferentiated anaplastic, and grade and differentiation not unknown (54).  
 
3.10.3 Stage definition 
In Jordan, the JCR uses Surveillance Epidemiology and End Results (SEER) Staging. 
However, a number of staging conventions had been used by treating doctors, as 
documented in the records of patients in this project, including Tumour, Nodes and 
Metastasis (TNM) scores, American Joint Committee on Cancer (AJCC) Staging Scores (I 
– IV) and Dukes (A-D) Scores (100). To compensate for the missing data by JCR, with 
assistance of Jordan cancer tumour registrar (CTR) in the JCR, scores of AJCC, TNM and 
Dukes scoring systems were converted into SEER scores, namely localized disease, 
regional spread and distant metastasis based on Summary Stage Book 2000 of colorectal 
cancer as shown in the reference table in AJCC for TNM staging system (100). Coding 
conventions used to derive a SEER score from the actual TNM, AJCC and Dukes scores 
were developed using commonly accepted cut points. 
 
3.10.4 Morphology type  
The type of histopathology includes adenocarcinoma (M8140), mucinous adenocarcinoma 
(M8480), carcinoma, and (M8010) other morphology according to the international 
classification of oncology ICD-O third edition (54).  
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3.10.5 Comorbidities  
For this study comorbidity, namely diabetes mellitus, hypertension, hypercholesterolemia 
and obesity were included in the study instrument. Information about these comorbidities 
was ascertained from the medical records of each patient. Due to the poor quality of 
medical records, poor comorbidities documentation, unavailability of electronic hospital 
discharge records and the fact that diabetes mellitus poses a high burden on the Jordanian 
population, justify investigating diabetes mellitus as the only factor in relation to colorectal 
cancer survival in this study.  
  
3.11 Summary 
This is a descriptive study carried out to estimate the observed and relative colorectal 
cancer survival rates among the study population during the period 2003 (01 January) 
through 2007 (31 December). The survival rates were described in relation to many 
variables (such as age, sex, residency, extent of disease (stage of cancer), site, morphology, 
treatment and presence of diabetes mellitus type 2). Only Jordanian colorectal patients, 
aged 15 through 99 years of age, diagnosed with first invasive primary colorectal cancer 
during the study period, verified by histopathology report and registered in Jordan Cancer 
Registry were included in the study. Colorectal cancer was classified according to 
international classification of oncology (ICD-O third edition in addition to the International 
Classification of Diseases, ICD-10) as C18.0-C20.9.  
 
The study was carried out at the national level: the Jordan Cancer Registry (JCR), 
hospitals, and laboratories from both governmental and non-governmental bodies were 
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accessed. In addition to the use of routine JCR records, hospital records were reviewed and 
pathological laboratory reports at the national level were used to complete any missing 
information. The study instrument was designed to gather information on socio-
demographic characteristics (e.g. sex, age, date of birth, place of residency), clinical and 
histopathology information (e.g. site of the tumour, morphology, staging and grade), 
treatment (e.g. type of treatment, information about surgery, chemotherapy and radiology), 
co-morbidities (e.g. diabetes mellitus) and information about the patients’ vital status.  
Field visits were conducted and data was collected from various hospitals.  In addition to 
these sites, data was also collected from pathology laboratories. A pilot study was 
conducted to test the instrument and to check the validity of the data collection techniques.  
 
The vital status of the patients was ascertained from CRB based on use of the unique 
National Identification number (ID) of the patients with follow-up to 31 December 2010. 
The outcome of interest was whether colorectal cancer cases were alive, dead or unknown. 
The survival duration of each case was determined as the time difference (in days) between 
the date of incidence (index date) and the date of death, date of loss to follow-up or the 
closing date for follow-up (31 December 2010). 
 
The data was checked and revised. Data with invalid codes, impossible sequences of dates 
or improbable combinations of tumour site and morphology was revised and checked with 
the Jordan Cancer Registry. Corrected records were integrated in the study. As a result, 
there were 1 896 records included in the study. 
 
The Kaplan-Meier method was used to determine the observed survival probability over 
time. The logrank test was used to estimate if the difference between the groups was 
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statistically significant. The complete approach of estimation of observed survival 
probability was used. Cox proportional hazard regression was used to assess the net effect 
of each variable after simultaneously controlling the effects of potential confounders. The 
crude and World Standardized incidence rates (ASR) were also calculated.  
 
Use of the data was approved by the national health ethical review board (ERB) and the 
Jordan Ministry of Health as well as by the institutional review board (IRB) of King 
Hussein Cancer Center. Furthermore, the study protocol was approved by the ethics 
committees of Glasgow University as well as the International Agency for Research on 
Cancer (IARC).  Data was only used for the intended purposes. Secure encrypted 
electronic storage media was used to handle data, which was anonymised before analysis 
by removing all sensitive data such as names and address and replacing them with 
computer-generated numbers.   
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CHAPTER 4 – SAMPLE DESCRIPTION 
 
4.1 Introduction 
This chapter describes the sample in terms of its socio-demographic characteristics (age, 
sex, place of residence, and year of diagnosis), clinical characteristics (extent of disease, 
morphology, and topography), and treatment characteristics (type of treatment, type of 
surgery, chemotherapy and radiotherapy). The chapter also examines cancer site by socio-
demographic, clinical characteristics, and treatment characteristics. 
 
4.2 Socio-demographic characteristics 
The study population consisted of 1,896 patients, with socio-demographic characteristics 
as seen in Table 5. Over half of the patients were men (55.5 percent). About one third of 
the patients were in the age group 45-59 (32.3 percent) and only 10 percent in the age 
group of 75 years or older. Three-quarters of the patients lived in the central region of 
Jordan compared with only 3.5 percent who lived in the south (Table 5).   
 
With one-fourth of the patients diagnosed during 2007, one-fifth was diagnosed in 2006 
and around 18 percent in each year from 2003 through 2005. Additional information 
showed that among all included cases, 1,132 (59.7 percent) patients were alive and 764 
(40.3 percent) patients had died on the closing day of the study. There were more deaths 
among male patients, where 442 (57.9 percent) of deaths being males and 322 (42.1 
percent) females. More than half of the deaths (54.2 percent) were patients aged 60 years 
and above, with the majority (41.2 percent) being in the age group of 60 to 74 years old 
(information not shown in the table).  
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Table 5: Percent distribution for socio-demographic 
characteristics of patients diagnosed with colorectal 
cancer during 2003-2007, Jordan 
Variable Number Percent 
Sex:   
Male  1053 55.5 
Female 843 44.5 
Age group:   
15-44 327 17.3 
45-59 613 32.3 
60-74 764 40.3 
>=75 192 10.1 
Region:   
North 390 20.6 
Middle 1430 75.4 
South 67 3.5 
Unknown 9 0.5 
Year of diagnosis:   
2003 350 18.5 
2004 339 17.9 
2005 338 17.8 
2006 392 20.7 
2007 477 25.2 
 
4.3 Clinical characteristics  
With regard to colorectal site for cancer, 1,204 (63.5 percent) of patients had colon cancer 
and 36.5 percent (692 cases) had rectum cancer. Table 6 shows that more than half of the 
patients (58.9 percent) had regional metastasis, 22.8 percent had distant metastasis, and 
11.2 percent had localized CRC at diagnosis. Only 7.1 percent of the cases were found 
with an unknown extent of the disease.   
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Table 6: Percent distribution for clinical characteristics 
of patients diagnosed with colorectal cancer during 
2003-2007, Jordan 
Variable Number Percent 
Colorectal site   
Colon (C18) 1,204 63.5 
Rectum(C19-20) 692 36.5 
Sum stage   
Localized 212 11.2 
Regional 1,118 58.9 
Distant 432 22.8 
Unknown 134 7.1 
Morphology   
Adenocarcinoma 1,598 84.4 
Mucinous 148 7.8 
Carcinoma, NOS 82 4.3 
Others 55 2.9 
Missing 11 0.6 
Grade   
Well 125 6.6 
Moderate 1,189 62.7 
Poor/anaplastic 282 14.9 
Unknown 300 15.8 
 
Adenocarcinoma was the most common form of CRC as it was found in 84.4 percent of 
cases, followed by mucinous tumours that were found in 7.8 percent of the patients; and 
neoplasms and NOS were found in 4.3 percent of the patients. Other types of morphology 
were found in 2.9 percent of the patients, while unknown morphology was only found in 
less than one percent of the patients.  In terms of grade, only 6.6 percent were classified as 
well, while more than half (62.7 percent) were classified as moderate, 14.9 percent as poor 
and 15.8 percent as unknown (Table 6). 
  
To better understand the relationship between mucinous adenocarcinoma and other 
variables, this study explored this morphological variable by selected potential factors. 
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Table 7 shows that mucinous adenocarcinoma was equally present among male and female 
patients. With three quarters of the mucinous adenocarcinomas occurring in the colon, 61.5 
percent of them were present among those who were 50 years of age or older. Moreover, 
the majority of the mucinous cancers were of a moderate grade (61.6 percent) and with a 
regional extent (64.86 percent).  
 
Table 7: Percent distribution of mucinous cases 
by selected variable  
Variable Patients (n) Percent 
Sex   
Male 75 50.7 
Female 73 49.3 
Age at diagnosis   
<=50 57 38.5 
>50 91 61.5 
Grade of tumour   
Well 10 8.9 
Moderate 69 61.6 
Poor/anaplastic 33 29.5 
Extent of disease   
Localized 9 6.1 
Regional 96 64.9 
Distant 37 25.0 
Site of tumour   
Colon 111 75.0 
Rectum 37 25.0 
 
 
Table 8 illustrates the topography of CRC in Jordanian patients. For colon cancer (C18); 
20.2 percent were located in the sigmoid (C18.7), 12.9 percent were located in the colon 
(i.e. colon, NOS), 7.2 percent and 6.1 percent were respectively located in the ascending 
(C18.2) and descending (C18.6) colons, 6 percent were located in the cecum (C18.1)and 
3.9 percent were located in the transverse colon (C18.4). 
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Almost similar percentages (2.4 percent) were located in the splenic flexure (C18.5), the 
overlapping (C18.8) (2.3 percent) and the hepatic flexure (C18.3) (2.1 percent), while only 
0.5 percent was located in the appendix (C18.0). While for rectum cancer (C19-20); 11.3 
percent were located in the recto-sigmoid (C19.9), and 25.1 percent were located in the 
rectum (C20.9).  
 
Table 8: Topography of colorectal cancer in Jordan (2003-2007) 
Topography* Frequency  Percent 
Colon (C18)  63.6 
Ascending (right) colon (C18.2) 136 7.2 
Descending (left) colon (C18.6) 116 6.1 
Colon, NOS (C18.9) 245 12.9 
Overlapping (C18.8) 43 2.3 
Sigmoid (C18.7) 383 20.2 
Appendix (C18.1) 10 0.5 
Cecum (C18.0) 114 6.0 
Hepatic flexure (C18.3) 40 2.1 
Splenic flexure (C18.5) 46 2.4 
Transverse colon (C18.4) 74 3.9 
Rectum (C19-20)  36.4 
Rectosigmoid (C19.9) 214 11.3 
Rectum (C20.9) 475 25.1 
* Shown with ICD-0-3 topography codes 
 
 
4.4 Cancer site by selected characteristics 
Cancer site (colon and rectum) was examined by selected socio-demographic (age, sex, 
place of residence, and year of diagnosis,) clinical characteristics (distance of disease, 
grade, and morphology) and treatment characteristics that included type of treatment, type 
of surgery, and intent of treatment.  
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Differences in the percentages of cancer site within the categories of each of the selected 
characteristics were examined for their significance by checking chi-square values and 
their pertinent p-value. Differences were considered statistically significant if a chi square 
p-value was lower than 0.05. 
 
4.4.1 Cancer site and socio-demographic characteristics 
Table 9 displays the percent distribution of colon and rectum cancers and by socio-
demographic characteristics (age, sex, place of residence, and year of diagnosis). 
Differences in the percentage of cancer site by these socio-demographic characteristics 
were examined for statistical significance.  
Results showed a statistically significant difference in the percentage distribution of age 
categories between rectum and colon cancer patients (p-value <0.001). The percentages of 
rectum cancer patients aged (15-44 and 45-59) were higher (20.8 percent and 35.6 percent 
respectively) than the percentages of colon cancer patients in these age categories (15.2 
percent and 30.5 percent respectively). Contrary, the percentages of colon cancer patients 
for the older age groups (60-74, and ≥75) were higher (42.6 percent and 11.7 percent 
respectively) than those for rectum cancer patients (36.3 percent and 7.4 percent 
respectively).  
 
No significant differences were found between the colon and rectum cancer patients in 
terms of their distribution by sex, place of residence, and year of diagnosis.  
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Table 9: Percent distribution of colon and rectum cancers by 
selected socio-demographic variables, Jordan (2003-2007) 
Variable Colon Rectum P-value No.  (percent) No.  (percent) 
Sex     0.305 
Male 658 54.7 395 57.1  
Female 546 45.3 297 42.9  
Age     < 0.001 
15-44 183 15.2 144 20.8  
45-59 367 30.5 246 35.6  
60-74 513 42.6 251 36.3  
>=75 141 11.7 51 7.4  
Place of residence      0.128 
North  234 19.4 156 22.5  
Middle 920 76.4 510 73.7  
South  42 3.5 25 3.6  
Unknown  8 0.7 1 0.1  
Year of diagnosis      0.189 
2003 236 19.6 114 16.5  
2004 207 17.2 132 19.1  
2005 204 16.9 134 19.4  
2006 243 20.2 149 21.5  
2007  314 26.1 163 23.6  
 
4.4.2 Cancer site and clinical characteristics 
Table 10 illustrates the percent distribution of colon and rectum cancer patients by their 
clinical characteristics (distance of disease, grade, and morphology). Differences in the 
percentage distribution of cancer site by these clinical characteristics were examined for 
their significance.  
 
Results showed a statistically significant difference in the percentage distribution of the 
grade of cancer between colon and rectum cancer patients (p-value=0.005).  The 
percentages of rectum cancer patients with moderate and poor/anaplastic types of cancer 
were higher (65.2 percent and 16.8 percent respectively) than colon cancer patients with 
the same type of disease grade (61.3 percent and 13.8 percent respectively). Alternatively, 
the percentage of well differentiated grade of cancer was higher among colon cancer (7.3 
percent) than rectum cancer patients (5.4 percent).  
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No significant differences were found between the colon and rectum cancer patients in 
terms of their extent of disease and morphology distribution.  
 
Table 10: Percent distribution of colon and rectum cancers by 
selected clinical characteristics, Jordan (2003-2007) 
Variable Colon  Rectum P-value No.  (percent) No.  (percent) 
Extent of disease     0.125 
Localized  133 11.1 79 11.4  
Regional  689 57.2 429 62.0  
Distant metastasis  290 24.1 142 20.5  
Unknown  92 7.6 42 6.1  
Grade     0.005 
Well 88 7.3 37 5.4  
Moderate 738 61.3 451 65.2  
Poor/ anaplastic 166 13.8 116 16.8  
Unknown 212 17.6 88 12.7  
Morphology      0.138 
Adenocarcinoma 1,013 84.3 585 84.5  
Mucinous 111 9.2 37 5.3  
Carcinoma, NOS 61 5.1 21 3.0  
Others 30 2.5 25 3.6  
Unknown 8 0.7 3 0.4  
 
4.4.3 Cancer site and treatment characteristics  
Table 11 presents the percent distribution of colon and rectum cancers by treatment 
characteristics (surgery, chemotherapy, radiotherapy, type of surgery, and intent of 
treatment). Differences in the percentage of cancer site by treatment characteristics were 
examined for statistical significance.  
As shown in Table 11, the intent of treatment among CRC cancer patients was mainly 
curative (76.5 percent) and to a lesser degree palliative (23.5 percent). The majority of 
CRC (77.9 percent) patients underwent surgery, the majority of which (82.0 percent) 
underwent elective surgery with only 18.0 percent undergoing emergency surgery. 
Alternatively, 49.3 percent of CRC cancer patients received chemotherapy; while only 17.6 
percent of CRC cases received radiotherapy treatment.   
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Results showed that the percentage of rectum cancer patients (60.7 percent) who had 
chemotherapy treatment to be significantly higher than that for colon cancer (42.8 percent) 
(p-value <0.001).  Conversely, the percentage of rectum cancer patients who received 
radiotherapy treatment (42.2 percent) was significantly higher than that of colon cancer 
patients (3.5percent) (P-value=<0.001). Similarly, the percentage of rectum cancer patients 
who underwent elective surgery (87.7 percent) was found to be significantly higher than 
that of colon cancer patients (78.7 percent) (P-value <0.001).  
Table 11: Percent distribution of colon and rectum cancers by selected 
treatment characteristics, Jordan (2003-2007) 
Variable 
Colon Rectum Colorectal P-
value No. (percent) No. (percent) No. (percent) 
Surgery       0.091 
Yes 924 76.7 552 79.8 1,476 77.9  
No 53 4.4 36 5.2 89 4.7  
Unknown 227 18.9 104 15.0 331 17.5  
Chemotherapy       <0.001 
Yes 515 42.8 420 60.7 935 49.3  
No 192 16.0 85 12.3 277 14.6  
Unknown 497 41.3 187 27.0 684 36.1  
Radiotherapy       <0.001 
Yes 42 3.5 292 42.2 334 17.6  
No 1,162 96.5 400 57.8 1,562 82.4  
 Type of 
surgery*  
     <0.001 
Elective  726 78.7 485 87.7 1,211 82.0  
Emergency  197 21.3 68 12.3 265 18.0  
Intent of 
treatment   
     0.086 
Curative 906 75.3 544 78.7 1,450 76.5  
Palliative 298 24.8 147 21.3 445 23.5  
* Among those who underwent surgery 
 
No significant difference was found between in the percentage distribution of surgery 
treatment and intent of treatment between colon and rectum patients.  
 
4.5 Type of surgery 
Table 12 shows the type of surgical procedure carried out for CRC patients. Among those 
who underwent surgery (1,476), information about type of surgical procedure was 
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available for 1,099 patients (74 percent). The most common surgical procedures were left 
hemicolectomy (22.4 percent) and right hemicolectomy (21.2 percent) followed by lower 
interior resection (LAR) (17.6 percent) and abdomino-perineal resection (APR) (13.2 
percent). Sigmoidectomy was done for 6.3 percent of cases while patients underwent 
partial colectomies, subtotal colectomies/hemicolectomies and total colectomies were 
carried out at a similar rate of 3 percent for each.  
 
Table 12: Percent distribution for type of surgery procedure 
among colorectal cancer patients in Jordan, (2003-2007) 
Surgery procedure Freq. Percent 
Left Hemicolectomy 246 22.38 
Right Hemicolectomy 233 21.2 
Lower Interior Resection 193 17.56 
Abdimino-Perineal Resection 145 13.19 
Sigmoidectomy 69 6.28 
Partial Colectomy, NOS 35 3.18 
Subtotal colectomy/ hemicolectomy 34 3.09 
Total Colectomy 34 3.09 
Surgery, NOS 29 2.64 
Excisional Biopsy 26 2.37 
Hartman Operation 22 2 
Colectomy, NOS 18 1.64 
Others 15 1.36 
Total  1099 100 
 
Surgery and excisional biopsy were done in 2.6 percent and 2.4 percent of cases, 
respectively. Hartman operation accounted for 2 percent of the surgical procedures 
undergone in CRC cases, while colectomy accounted for just 1.6 percent. Other types of 
surgical procedures were reportedly carried out in 1 percent of cases. 
 
4.5.1 Thirty-days postoperative mortality after colorectal cancer surgery 
Among one thousand and four hundred and seventy four (1,476) individuals who were 
diagnosed with colorectal cancer and who subsequently underwent surgery for tumour 
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resection, information about the date of surgery was available for one thousand and three 
hundred and fifty six of them (91.9 percent).  Of those (1,356), 4.8 percent died within 30-
days of resection. 
 
Table 13 shows characteristics of the study population of 30-days postoperative mortality. 
Thirty-day postoperative mortality (the percentage of patients dead within 30 days of 
surgery among those who underwent surgery with an available date of surgery) was 
calculated for sex (male, female), age group in years (≤ 65, > 65), place of residence 
(north, middle, south), topography (colon, rectum), extent of the disease (local, regional, 
distant), operation type (elective, emergency), and treatment site ( public & teaching, and 
private, KHCC and other hospitals). The statistical significance for any differences in 
postoperative mortality among groups was assessed using the chi-square test χ2 (Table 13).   
 
Results showed that postoperative mortality within 30 days of surgery was significantly 
lower among patients aged ≤ 65 years (2.9 percent) than among those over 65 years (7.1 
percent) (p-value < 0.001). Patients with colon cancer had significantly higher 
postoperative mortality (5.3 percent) than those with rectal cancer (2.7 percent) (P-value = 
0.020). Moreover, postoperative mortality was noted to be higher among patients with 
more advanced tumours (1.3percent localized; 2.8 percent for localized and regional, 
compared to 9.3 percent for distant tumours) (p-value<0.001). Thirty-days postoperative 
mortality was significantly higher among those who underwent emergency operations (8.0 
percent) compared to those who underwent elective surgery (3.6 percent) (p-value=0.015).  
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Table 13: Characteristics of study population of thirty- day 
postoperative mortality 
Variables Total 
Died within 30 days of 
surgery  
P-Value  
  Number Percent  
Sex       0.216 
Male 758 37 4.8  
Female 598 21 3.5  
Age       <0.001 
<=65 917 27 2.9  
>65 439 31 7.1  
Place of residence       0.158 
Middle 1,016 39 3.8  
North & South 337 19 5.6  
Topography       0.020 
Colon  831 44 5.3  
Rectum 525 14 2.7  
Extent of disease        <0.001 
Localized & regional  1,067 30   2.8  
Distant 279 26 9.3  
Operation type       0.015 
Elective  1094 39 3.6  
Emergency 259 18 8.0  
Treatment site     0.070 
Public/teaching 755 39 5.2  
Private/KHCC & others  601 19 3.2  
Note: Among (1,476) individuals who were diagnosed with colorectal cancer 
and who subsequently underwent surgery, information about the date of 
surgery was available for 1,356 of them (91.9 percent).  Of those (1,356), 
4.8 percent died within 30-days of resection. 
 
In addition, Thirty-days postoperative mortality was significantly higher among those who 
received treatment in public or teaching hospitals (5.2 percent) compared to those who 
received treatment in private, KHCC, or other hospitals (3.2 percent) (p-value=0.070). As 
expected, postoperative mortality within 30 days of surgery did not differ by sex or by 
place of residence. 
 
4.6 Colorectal cancer and treatment sites  
In order to detect differences of colorectal cancer survival estimates across treatment sites 
in Jordan and explain the variation, the study population was divided into five categories 
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based on the type of treatment site (public, teaching, KHCC, private, and other). Table 14 
displays the percent distribution for the treatment site location (hospital) which represented 
the main source of medical services sought by the patient during the course of cancer 
treatment. Almost one third (32.4 percent) of the cases were treated at public hospital 
facilities; 23.4 percent at King Hussein Cancer Center (KHCC); 18.4 percent at teaching 
hospitals; and 16.8 percent at private health facilities. Only nine percent were treated at 
other sites, which would mainly indicate charitable, non-governmental or out-of-country 
hospitals.  
 
  Table 14: Percent distribution for treatment site of 
colorectal cancer patients in Jordan (2003-2007) 
Site of treatment Frequency  Percent 
Public hospitals 614 32.38 
Teaching hospitals 348 18.35 
KHCC 444 23.42 
Private hospitals 319 16.82 
Others  171 9.02 
Total 1896 100 
 
Table 15 describes the percent distribution of treatment sites (public, teaching, KHCC, 
private and other hospitals) and the sample characteristics in terms of their socio-
demographic (age, sex, place of residence), clinical characteristics (extent of disease, 
topography, grade and morphology), and treatment modalities.  
 
 
 
 
132
Table 15: Percent distribution of treatment sites by selected variables, 
Jordan (2003-2007) 
                Type of  
                Hospital 
 
Variable 
Public 
hospitals 
Teaching 
hospitals  KHCC 
Private 
hospitals  Others 
No. 
(percent) 
No. 
(percent) 
No. 
(percent) 
No. 
(percent) 
No. 
(percent) 
Sex     
Male  323( 52.6) 214( 61.5) 248( 55.9) 164( 51.4)  104( 60.8)
Female  291( 47.4) 134( 38.5) 196( 44.1) 155( 48.6)  67( 39.2)
Age     
< 65y  413( 67.3) 210( 60.3) 333( 75.0) 192( 60.2)  99( 57.9)
>= 65 y  201( 32.7) 138( 39.7) 111( 25.0) 127( 39.8)  72( 42.1)
Place of residence     
Middle  455( 74.4) 162( 46.6) 385( 86.7) 297( 93.9)  131( 78.4)
North  130( 21.2) 177( 50.9) 50( 11.3) 9( 2.9)  24( 14.4)
South  27( 4.4) 9( 2.6) 9( 2.0) 10(3.2)  12( 7.2)
Extent of disease     
Localized  63(10.2) 27  (7.8) 43  (9.7) 62(19.4)  17(9.9)
Regional  388 (63.1) 223(64.1) 267(60.1) 159(49.8)  81(47.4)
Distant metastasis  133(21.7) 91(26.2) 116(26.1) 60(18.8)  32(18.7)
Topography     
Colon  353(57.5) 252(72.4) 238(53.6) 234( 73.4)  127( 74.3)
Rectum  261(42.5) 96(27.6) 206(46.4) 85(26.6)  44(25.7)
Grade     
Well  50(8.1) 25(7.2) 15(3.4) 23(7.2)  12(7.0)
Moderate  406(66.1) 204(58.6) 333(75.0) 167(52.4)  79(46.2)
Poor/ anaplastic  81(13.2) 72(20.7) 49(11.1) 51(16.0)  29(16.9)
Morphology     
Adenocarcinoma  511(83.4) 287(82.5) 389(87.8) 270(84.6)  141(82.5)
Mucinous  52(8.5) 29(8.3) 35( 7.9) 18(5.6)  14(8.2)
Carcinoma, NOS  24(3.9) 24(6.9) 5(1.1) 16(5.0)  13(7.6)
Others  25(4.1) 3(0.86) 13(2.9) 12(3.8)  2(1.2)
Surgery     
Yes  516(84.0) 289(83.1) 363(81.8) 224(70.2)  84(49.1)
No  27(4.4) 17(4.9) 35(7.9) 6(  1.9)  4(2.3)
Chemotherapy     
Yes  405(65.9) 148(42.5) 280(63.1) 69(21.63)  33(19.3)
No  86(14.0) 47(13.5) 75(16.9) 53(16.61)  16(9.4)
Radiotherapy     
Yes  182( 29.6) 18(5.2) 115(25.9) 13(4.1)  6(3.5)
No  432(70.4) 330(94.8) 329(74.1) 306(95.9)  165(96.4)
Type of surgery     
Elective  394(75.9) 231(79.9) 335(91.8) 178(80.9)  73(90.1)
Emergency  125(24.1) 58(20.1) 30(8.2) 44(19.8)  8(9.9)
 
Among all four treatment sites, over half of the patients were men, and almost two third of 
the sample were aged less than 65 years. Less than ten percent of the patients lived in the 
south compared to three-quarters living in the central region of Jordan for public, KHCC 
and private treatment sites. However, fifty percent of the patients receiving treatment at 
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teaching hospitals lived in the northern part of the country. For all sites, at least fifty 
percent of the patients had regional metastasis compared to one quarter or less who had 
CRC distant metastasis at diagnosis.  Across all sites, more than half of the patients had 
colon cancer, with the same percent being classified as moderate grade. Adenocarcinoma 
was the most common form of CRC for all treatment sites as it was found approximately in 
eighty percent of cases, followed by mucinous tumours.  
 
More than two third of the patients at all sites underwent surgery with three quarter of them 
undergoing an elective type of surgery. In addition, about two thirds of patients received 
chemotherapy at public or HKCC hospitals, compared to forty percent at teaching 
hospitals; and reaching only four percent at the private hospitals. Receiving radiotherapy 
was most commonly provided at public hospitals (30 percent) and KHCC (26 percent) with 
less than five percent at all other treatment sites.  
 
4.7 Summary  
This chapter described the sample’s socio-demographic, clinical and treatment 
characteristics of the sample. Males (55.5 percent), age group 60 years and above (50.4 
percent) and central residency (75.4 percent) were prevailing socio-demographic 
characteristics of the total 1,896 study participants. With more cases being diagnosed in 
both 2006 and 2007, the event of death was accounted for by 40.3 percent of all cases with 
more deaths recorded among males (57.9 percent) and those over 60 years of age (54.2 
percent). 
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Topographic data indicated that 63.5 percent (1,204 patients) had colon cancer and 36.5 
percent (692 cases) had rectum cancer. Examination of the clinical characteristics of the 
sample indicated that more than half of the patients (58.9 percent) had regional metastasis, 
22.8 percent had distant metastasis, and 11.2 percent had localized CRC at diagnosis. 
While adenocarcinoma was most commonly found tumours (84.4 percent), mucinous 
tumours were found in 7.8 percent of the patients. In terms of grade, only 6.6 percent was 
classified as well differentiated, while more than half (62.7 percent) were classified as 
moderate and 14.9 percent as poor.  
 
There were significant differences in the percentage distribution of age categories between 
rectum and colon cancer patients, where the percentages of colon cancer patients for the 
older age groups (60-74, and ≥75) were higher (42.6 percent and 11.7 percent respectively) 
than those for rectum cancer patients (36.3 percent and 7.4 percent respectively). In 
addition, the percentages of rectum cancer patients with moderate and poor/anaplastic 
types of cancer were higher than in colon cancer patients.  
 
With the majority of CRC patients (77.9 percent) undergoing surgery, these surgeries were 
found to be mostly elective (82.0 percent). Curative treatment was found to be a more 
common form of treatment for CRC patients (76.5 percent) than palliative (23.5 percent). 
Elective surgery was significantly higher among rectum cancer (87.7 percent) that colon 
cancer patients (78.7 percent). The most common surgical procedures were left 
hemicolectomy (22.4 percent) and right hemicolectomy (21.2 percent) followed by lower 
interior resection (LAR) (17.6 percent) and abdomino-perineal resection (APR) (13.2 
percent). Of those undergoing surgery, 4.8 percent has died within 30-days of resection. 
Moreover, patients aged ≤ 65 years had significantly lower 30 days postoperative mortality 
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(2.9 percent) than those over 65 years (7.1 percent). Thirty days postoperative mortality 
was significantly higher among colon cancer patients (5.3 percent), patients with more 
advanced tumours and those who underwent emergency operations. 
 
Rectum cancer patients were more commonly treated with chemotherapy (60.7 percent) 
than colon cancer patients (42.8 percent). Conversely, rectum cancer patients were found 
to receive radiotherapy treatment (42.2 percent) more than colon cancer patients 
(3.5percent). 
 
In examining the percentage distribution of treatment site, almost one third (32.4 percent) 
were treated at public hospital facilities, 23.4 percent at KHCC, 18.4 percent at teaching 
hospitals; and 16.8 percent at private health facilities. Among all four treatment sites, over 
half of the patients were men, and almost two third were aged less than 65 years. Less than 
ten percent of the patients lived in the south compared to three-quarters living in the central 
region of Jordan for those treated in the public, KHCC and private treatment sites. Across 
all sites, more than half of the patients had colon cancer, with the same percent being 
classified as moderate grade. 
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CHAPTER 5 – INCIDENCE AND SURVIVAL PATTERNS OF COLORECTAL 
CANCER 
 
5.1 Introduction 
This chapter aims at describing the incidence of CRC in the Jordanian population over the 
study period, and to explore age, sex and temporal patterns to allow comparison with other 
populations. The chapter also looks at the observed and relative survival estimates as well 
as survival probability using a variety of approaches and timeframes.  In addition, this 
chapter examines the relationship between patients’ socio-demographic characteristics (i.e. 
sex, age, place of residency and year of diagnosis) and the observed and relative colorectal 
survival estimates. This chapter concludes with a summary and discussion of the main 
results. 
 
5.2 Incidence of colorectal cancer by age and sex  
To better understand the CRC in Jordan, the crude and age–specific incidence rates (ASIR) 
for each year were estimated for both males and females. The overall crude incidence rate 
was estimated using Jordan’s total population in the period of the study corresponding to 
the sum of the populations for each year between 2003 and 2007. World Standardized 
incidence rates (ASR) were used to compare Jordan’s incidence rates to other populations. 
Incidence rate were calculated and analysis undertaken for those patients aged 15-74 who 
were diagnosed with a primary CRC (C18-C20.9) cancer during the study period (2003- 
2007). This resulted in a population of interest of 1,704 CRC patients when doing the 
incidence rates. 
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5.2.1 Crude and adjusted colorectal incidence rates by sex 
Within the group of interest (1,704), 924 of the patients were males (54.2 percent) and 780 
patients were females (45.8 percent). Overall, 1063 (62.4 percent) of cases were colon 
cancer and 641 (37.6 percent) were rectum cancer. Among male cases, 562 (60.8 percent) 
were registered as colon cancer and 362 (39.2 percent) as rectum cancer; while among 
females, 501 (64.2 percent) of cases were registered as colon cancer and 279 (35.8 percent) 
as rectum cancer, [χ2=2.1, P=0.148].  
 
The study reported an annual average of 341 newly diagnosed CRC patients aged from 15 
years through 74 years of age. During the 5-year study period, the overall crude colorectal 
cancer incidence rate for males was 5.6 per 100,000 population and 5.1 per 100,000 
population in females. For colon cancer, the crude incidence rate was 5.4 per 100,000 
population in males and 4.1 per 100,000 population in females. Crude incidence rate for 
rectum cancer was 3.0 per 100,000 population for males and 2.4 per 100,000 population 
for females. 
 
The overall colorectal ASR was 15.5 per 100,000 male population and 12.5 per 100,000 
female populations with a male/female ratio of 1.2:1.  While ASR for colon cancer was 
11.1 and 8.4 per 100,000 for males and females respectively, for rectum cancer, the ASR 
was 6.1 per 100,000 males and 4.9 per 100,000 females respectively (Table 16). 
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Table 16: Number of new cases, Crude Incidence Rates, and Age-
standardized incidence rates per 100,000 population of CRC among 
Jordanian population, 2003-2007 
Year Cancer 
Male Female  
No. 
Cases 
Crude 
Incidence 
*ASR No. 
Cases 
Crude 
Incidence 
*ASR  
2003 Colon 120 5.1 8.3 96 4.1 6.6 
 Rectum 63 2.9 4.8 43 2.2 3.5 
2004 Colon 110 4.7 9.3 87 4.2 7.6 
 Rectum 70 2.6 4.4 60 2.2 3.6 
2005 Colon 101 4.5 8.9 90 4.6 8.0 
 Rectum 72 2.9 5.3 52 2.3 4.0 
2006 Colon 142 5.5 11.0 98 4.7 8.4 
 Rectum 87 3.1 5.7 58 2.5 4.4 
2007 Colon 170 6.4 13.0 130 5.8 11.4 
 rectum 98 3.5 6.7 66 2.8 5.0 
*ASR: World Health Organization Age-standardized incidence  
 
 
5.2.2 Colorectal incidence rates by age and sex 
To allow comparisons with different countries, CRC incidence rates were aggregated into 
5-year age groups (aged 15-74 years). The age-standardized incidence rates and crude 
incidence rates were calculated and examined by sex, age and temporal patterns. 
 
The age specific incidence rates were found to increase with age (Figure 9). Rates were 
slightly higher in females than in males, but this difference was limited to those 55 years or 
younger. In later life, rates in men became more predominant compared to those in 
females. All in all, the results showed a high percentage (13.8 percent) of CRC among the 
young age groups (i.e. less than 40 years of age). Also, almost one third of colorectal 
cancers (31.0 percent) occurred among patients less than 50 years of age; whereas more 
than half (60.3 percent) of the cases were less than 60 years of age.  
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Figure 9: Age-specific incidence rates of colorectal cancers by sex, Jordan (2003-
2007) 
 
The study examined colon and rectum cancers as grouped in Volume IX of CI5, to show 
the different incidence rates of CRC among the different countries in the Eastern 
Mediterranean and other regions. The CRC incidence data in CI5 monograph are 
categorized according to ICD-10 site codes (C18-C20-9), which include cancers of the 
colon and rectum. In Jordan, colon and rectum cancers in both sexes are among the highest 
rates in the region, while it ranked low when compared to European countries (Table 17).  
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Table 17: Age-Standardized Rates (ASR) per 100,000 population of CRC in 
different countries in the Eastern Mediterranean and other Regions 
  Colon Cancer Rectum Cancer (C19-
C20) 
Colorectal Cancer 
(C18-C20) Country  (C18) 
   Male  Female Male Female Male Female 
Jordan 11.1 8.4 5.4 4.1 15.5 12.5 
Algeria, Setif 4.9 5.2 3.2 3.5 8.1 8.7 
Egypt, Gharbiah 3.6 3.4 2.1 1.9 5.6 5.3 
Tunisia, North 6.3 5.5 4.2 3.7 10.5 9.2 
Libya, Benghazi  8.8 9 5 3.3 13.7 12.3 
Bahrain: Bahraini 8.8 7.8 5.7 3.2 14.5 11 
Qatar: Qatari  13.6 9.1 6.6 7.5 20.2 16.7 
Saudi Arabia 6.9 6.3 5.3 4 12.3 10.3 
Kuwait: Kuwaitis 11.2 9.2 5 4.5 16.2 13.7 
Turkey, Izmir 12.5 7.9 8.8 4.8 21.3 12.7 
Israel: Non-Jews 17.1 16.5 10.9 7.1 28 23.6 
India, Mumbai 3.4 2.3 2.9 2 6.3 4.4 
 Korea 21.2 12.4 19.5 10.2 40.6 22.7 
China, Beijing city 10.5 9 8.9 6.5 19.4 15.5 
 Brazil, Goiania 18.9 15.7 11.9 10.6 30.8 26.3 
 Ecuador, Quito 7.3 7.8 4 2.9 11.2 10.6 
 Canada 25.8 19.6 15.9 8.3 41.7 27.9 
 USA, Virginia  23.6 18.8 10.7 6.7 34.3 25.5 
 Austria 23.3 14.3 15.3 7.6 38.6 21.9 
Czech Republic 31.1 17.2 25.9 11.3 57 28.5 
 France, Bas-Rhin 25.4 15.2 17.1 8.4 42.5 23.6 
 Italy, Latina  22.1 14.8 13 7.6 35.1 22.4 
Ireland  25.8 18.4 17.5 8.8 43.3 27.3 
UK, Scotland 24.9 17.6 16 8.2 40.9 25.8 
South Australia 29.2 22.3 18.3 10.1 47.4 32.4 
New Zealand 27.6 25.7 18.2 10.4 45.7 36 
* Source: Cancer Incidence in Five Continents, Vol. X (electronic version) Lyon, IARC. 
http://ci5.iarc.fr last accessed on 2/2/2014. 
 
Table 18 includes the ASR of CRC in Jordan and Nordic countries. Differences between 
age specific rates of patients in Nordic countries and Jordanian patients were observed in 
Jordanian males and females < 65.  These differences were more pronounced for females 
compared to females in Nordic countries in the same age group. Age specific rates among 
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patients in Nordic countries became much larger and more pronounced for individuals 
aged 65 years or older compared to Jordanian patients.  
 
Table 18: A comparison between the colorectal cancer age-specific 
rates per 100,000 by sex in Jordan and Nordic countries* 
Age group 
Males Females 
Jordan  Nordic Countries  Jordan  Nordic Countries  
15_19 0.2 0.3 0.1 0.6 
20_24 0.4 1.0 0.5 1.2 
25_29 1.7 1.3 1.0 1.6 
30_34 2.2 3.6 4.2 3.3 
35_39 6.1 6.3 6.4 6.2 
40_44 8.0 10.8 14.2 12.5 
45_49 13.5 22.5 19.3 23.4 
50_54 26.2 45.0 39.8 42.7 
55_59 37.4 77.5 37.1 65.9 
60_64 63.7 137.0 48.1 106.8 
65_69 58.0 217.7 49.8 156.5 
70_74 84.9 313.3 50.0 213.6 
*Source: Engholm G, Ferlay J, Christensen N, Johannesen TB, Khan S., Køtlum JE, Milter MC, 
Ólafsdóttir E, Pukkala E, Storm HH. NORDCAN: Cancer Incidence, Mortality, Prevalence and 
Survival in the Nordic Countries, Version 6.0 (04.12.2013). Association of the Nordic Cancer 
Registries. Danish Cancer Society. Available from http://www.ancr.nu, accessed on 24/03/2014.  
 
 
5.2.3 Summary and Discussion 
During the 5-year study period, the overall crude colorectal cancer incidence rate for males 
was 5.6 per 100,000 population and 5.1 per 100,000 population in females. This identifies 
Jordan as a low-risk country for CRC compared to developed countries. However, it ranks 
high when compared to neighboring countries for both males and females. In line with 
other studies, this study revealed that the incidence of CRC in the Jordanian population to 
be low compared to developed countries (7;13;58;219). However, this low incidence rate is 
relatively higher than some countries in the region (58;65;220;221). Results from this 
study also revealed, that the CRC incidence rate in Jordan was higher than most Eastern 
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Mediterranean countries (including Algeria, Egypt, Bahrain, Tunisia, and Saudi Arabia), 
and almost similar to rates that were reported in, Qatar, Libya and Kuwait. At the same 
time, the study found colorectal ASR to be lower than those for European countries 
(including UK, Scotland, France, Australia, and New Zealand).  
 
The difference in rates between developing and developed countries can be partially 
attributed to life-style and dietary habits (222;223).  Genetics may also play a role in 
explaining the differences in incidence rates between developed and developing countries 
(224;225). In addition, this study found no significant difference between males and 
females CRC patients. These results are consistent with other international studies (7;58).  
 
The study reported a high percentage of CRC patients (13.8percent) among the younger 
age groups (<40 year). This concurs with other studies from the region, which reported that 
15-35 percent of colorectal cases in the Eastern Mediterranean countries occur among 
young people (226;227). Alternatively, in the developed countries, only 2-8 percent of the 
colorectal cancers occur in young people (228;229). The high proportions of CRC cases 
seen in Jordan among the young population, as other countries from the region, might be 
due to the young age-structure where 80 percent of the Jordanian population are below 50 
years of age (1;22) . On the other hand, comparison of age specific rates of CRC patients in 
Nordic countries (as an example from the European countries) with those of Jordanian 
individuals, showed a higher rates in females Jordanian population who are 54 years of age 
or younger. This difference could be attributed to CRC aetiology in the Eastern 
Mediterranean Region, which may be different from other countries with genetic factors 
playing a role in the development of CRC in young population (230).  
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Another explanation that could explain this difference is the relatively low rates of CRC 
among elderly age groups in Jordan. Moreover, this could also be due to lower recording 
of cases among the elderly. Being ‘affected at an early age’ is a significant group 
characteristic and is an important result that should be taken into account when 
implementing CRC prevention and control strategies. Therefore, further analytical studies 
are needed to better explore these differences, if they truly exist. 
 
According to Jordanian Ministry of Health, the burden of colorectal cancer cases is 
growing; the latest JCR report (2009) has shown the ASR for colorectal cancers among 
males to be 18.2 and for females 16.5 per 100,000 (51). In summary, the increasing in life 
expectancy together with the lifestyle changes in Jordan lead to hypothesize that the 
burden of CRC will continue escalating in the forthcoming years. 
 
5.3 Observed and relative survival estimates 
Kaplan-Meier survival analysis was used to determine the observed survival probability of 
CRC patients. Kaplan-Meier survival analysis allows for measuring the cumulative 
proportion of patients surviving over a period of time and the length of time people remain 
living after being diagnosed with CRC. Kaplan-Meier was used in a univariate analysis to 
identify the potentially important prognostic variables-effect of different predictors on the 
survival rate (e.g. age at diagnosis, sex, stage, site, grade and type of treatment). The 
logrank test was used to compare estimates of the hazard functions of the two groups at 
each observed event time. The logrank test is constructed by computing the observed and 
expected number of events in one of the groups at each observed event time and then 
adding these to obtain an overall summary across all time points where there is an event. 
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Using the Kaplan-Meier technique and logrank tests, the observed 5-year survival 
probability rates were examined for CRC by site, year of diagnosis and socio-
demographics characteristics (e.g. sex, age, place of residence) for Jordanian patients 
diagnosed with CRC between 2003 and 2007. Expected survival was estimated from the 
general population of Jordan, which was extracted from the National life tables of death 
rates by sex, single year of age and calendar year 2000 (22). Relative survival used in this 
study is interpreted as observed survival adjusted for other cases of background mortality 
(expected survival). The relative survival allows for the account of dying from causes other 
than the disease in question (CRC in this study).  
 
Tables A.1, A.2 and A.3 in Appendix A, show the observed and relative survival estimates 
for colorectal, colon and rectum cancers, respectively; as well as the overall survival 
estimates during 2003 through 2007 for male and female patients. To better understand the 
survival pattern, Year 1 was divided into 10 intervals; Year 2 and Year 3 into two 
intervals; Year 4 and Year 5 into one interval each. 
 
Kaplan-Meier survival analysis by cancer site and selected socio-demographic variables 
(i.e. sex, age, region or residence and year of diagnosis) are seen in Figures 12a, 12b, 12c, 
13a, 13b, 13c, 14a, 14b, 14c, 15a, 15b and 15c. The effect of these four socio-demographic 
variables on colorectal cancer, colon cancer and rectum cancer are presented in the 
following sections.  
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5.3.1 Observed and relative colorectal survival probability by cancer site   
Using the Kaplan-Meier technique, the 5-year survival probabilities for CRC patients was 
found to be slightly higher than 50 percent (Figure 10a).  
 
Figure 10a: Observed survival probability for 1,896 Cases of Colorectal 
Cancer in Jordan, (2003-2007) 
 
 
 
When comparing the observed survival probability for rectum cancer and colon cancer, a 
slightly higher probability was found for rectum cancer in the first two years of the disease. 
However, later on gradually the colon cancer became higher than rectum (Figure 10b). 
These differences did not reach significance level (Log-rank test p-value = 0.1474).  
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Figure 10b: Observed survival probability for 1,204 Cases of Colon Cancer 
and 692 Cases of Rectum Cancer in Jordan, (2003-2007) 
  
Log-rank test p-value= 0.1474 
 
Figures 11a, 11b and 11c depict the relative survival statistics at 1-, 3- and 5 -years from 
diagnosis for colorectal cancer (Figure 11a) and by cancer site: colon (Figure 11b) and 
rectum (Figure 11c). 
Figure 11a: Five-year relative survival from colorectal cancer for 1,896 
Cases, Jordan 
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Figure 11b: Five-year relative survival from colon cancer for 1,204 Cases, 
Jordan 
 
Figure 11c: Five- year relative survival from rectum cancer for 692 Cases, 
Jordan 
  
 
Using the Cox analyses to examine the observed survival at 1-, 3- and 5-years from 
diagnosis for all colorectal cancer, and by cancer site: colon or rectum, data demonstrated 
no temporal trend toward improving or worsening survival over the study period. The 
observed survival rates for the overall cases of colorectal cancer were 82.7 percent at year 
1, 67.2 percent at year 3 and 57.7 percent at year 5 of diagnosis. Corresponding relative 
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survival rates were 83.1 percent at year 1, 68.6 percent at year 3 and 61.3 percent at year 5 
of diagnosis (shown in Table 19).  
 
  Table 19: Observed and relative cancer survival estimates by type of 
colorectal cancer, Jordan (2003-2007) 
Variable 
Observed survival 
(percent) 
Relative survival 
(percent) 
1 year 3 years 5 years 1 year 
3 
years 
5 
years 
Colorectal 82.7 67.2 57.7 83.1 68.6 61.3 
Colon 81.9 67.8 59.1 82.3 69.4 63.2 
Rectum 84.3 66.3 55.4 84.7 67.5 58.3 
 
Patients with rectum cancer showed slightly better observed and relative survival rates at 
year 1 of diagnosis than colon cancer, and vice versa at 3- and 5-years of diagnosis. The 
observed survival rates for colon and rectum cancers at year 1 of diagnosis were 81.9 
percent and 84.3 percent, respectively, the corresponding relative survival rates were 82.3 
percent and 84.7 percent, respectively. At 3 years of diagnosis, the observed colon and 
rectum cancer survival rates were 67.8 percent and 66.3 percent, respectively, while at 5 
years of diagnosis these rates were 59.1 percent and 58.3 percent, respectively. The 
corresponding relative survival rates at 3 years of diagnosis were 69.4 percent and 67.5 
percent, while at 5 years of diagnosis they were 63.2 percent and 58.3 percent, for colon 
and rectum cancer respectively (Table 19).  
 
5.3.2 Observed and relative colorectal survival probability by sex  
Figures 12a, 12b and 12c show that males and females have almost similar 5-year survival 
probability for the first two years, which gradually change to slightly higher survival rates 
among females towards the end of the study period in colon cancer and vice versa in 
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rectum cancer. This observed pattern was found insignificant in colorectal cancer (log-rank 
test p-value=0.1698), colon cancer (Log-rank test p-value=0.0919) and rectum cancer 
(Log-rank test p-value=0.8992).  
Figure 12a: Observed survival probability by sex for 1,896 cases of 
colorectal cancer in Jordan 
 
 
Log-rank test p-value = 0.1698 
Figure 12b: Observed survival probability by sex for 1,204cases of colon 
cancer in Jordan 
 
Log-rank test p-value = 0.0919 
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Figure 12c: Observed survival probability by sex for 692 cases of rectum 
cancer in Jordan 
 
Log-rank test p-value = 0.8992
 
No substantial differences were observed in colon and rectum cancer survival estimates in 
the first year intervals for both sexes. Although observed and relative survival estimates 
were higher for females in the three scenarios (i.e. colorectal, colon and rectum), these 
differences were not significant when examined by sex. 
 
Observed and relative survival rates for males and females by site of cancer displayed in 
Table 20, show that females had a slightly better observed survival rates for overall CRC at 
year 1 of diagnosis (83.4 percent) than males (82.2 percent). Similarly,  the observed 
survival rates for CRC at year 3 of diagnosis was higher among females (69.7 percent) than 
among males (65.2 percent); with a similar higher rate at year 5 of diagnosis among 
females (59.9 percent) than males (55.9 percent).  
 
Reported relative survival rates were also better in females; for year 1 of diagnosis: 83.6 
percent and 82.7 percent, for females and males respectively; for year 3 of diagnosis: 70.7 
percent and 67.1 percent, for females and males respectively; and for year 5 of diagnosis: 
62.4 percent and 60.5 percent, for females and males respectively. The same pattern was 
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observed for colon cancer where observed and relative survival rates were higher in 
females at year 1, year 3 and year 5 of diagnosis (OS 83.1 percent, 70 percent and 61.1 
percent), (RS 83.4 percent, 71.4 percent and 64.2 percent) compared to males (OS 80.1 
percent, 65.7 percent and 57.1 percent), (RS 81.4 percent, 67.7 percent, 62.3 percent), as 
illustrated in Table 20.  
     
  Table 20: Observed and relative cancer survival estimates by type of 
colorectal cancer and sex, Jordan (2003-2007) 
Variable 
Observed survival 
(percent) 
Relative survival 
(percent) 
1 year 3 years 5 years 1 year 3 years 5 years 
Colorectal       
Male  82.2 65.2 55.9 82.7 67.1 60.5 
Female 83.4 69.7 59.9 83.6 70.7 62.4 
Colon       
Male  80.1 65.7 57.1 81.4 67.7 62.3 
Female 83.1 70.0 61.1 83.4 71.4 64.2 
Rectum       
Male  84.6 64.5 54.1 84.9 66.0 57.6 
Female 83.9 68.7 57.3 84.1 69.5 59.2 
 
Alternatively, rectum cancer male patients have shown slightly higher observed and 
relative survival rates at year 1 of diagnosis (OS 84.6 percent, RS 84.9 percent) compared 
to females (OS 83.9 percent, RS 84.1 percent). However, rectum cancer female patients 
displayed higher observed and relative survival rate at year 3 (OS 68.7 percent, RS 69.5 
percent) and year 5 (OS 57.3 percent, RS 59.2 percent) of diagnosis, compared to males 
(OS 64.5 percent, RS 66 percent), and (OS 54.1 percent, RS 57.6 percent) (Table 20). 
 
 
152
5.3.3 Observed colorectal survival probability by age  
The observed survival rates noticeably declined for the age group of 75 years of age or 
older (Figures 13a, 13b and 13c) for overall colorectal, colon and rectum cancer scenarios. 
The other age groups were nearly comparable. The observed survival rate mostly 
decreased through all age groups. Early deaths were observed for patients above 75 years 
of age during the first two years. The survival rate for patients among the age group of 15 
through 44 years old and the age group of 60 through 74 years old were quite similar 
during the first three years, after which slightly higher rates were estimated for those aged 
15 through 44 years old. Patients aged 45 through 59 years old had the highest survival 
estimates among all studied age groups.  
 
Figure 13a: Observed survival probability by age for 1,896 cases of 
colorectal cancer in Jordan 
 
Log-rank test p-value < 0.0001
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Figure 13b: Observed survival probability by age for 1,204 cases of colon 
cancer in Jordan 
 
Log-rank test p-value = 0.0008 
Figure 13c: Observed survival probability by age for 692 cases of rectum 
cancer in Jordan 
 
Log-rank test p-value = 0.0400 
 
Examination of the observed and relative survival rates showed a noticeable decline in the 
age group of 75 years and older (Table 21). In general, younger age groups between 15 and 
44 years of age had lower observed and relative survival rates at all years of diagnosis for 
colon and rectum cancer compared to patients’ age groups 45 through 59. The 5-year 
observed and relative survival rates of colorectal cancer were highest in age group 45-59 
years and lowest the 75 years of age and older group.  
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The 5-year observed and relative survival rates for colon cancer were approximately 
similar in age groups 15 through 44 years (OS 58.9 percent, RS 59.4 percent) and 60 
through 74 years (OS 57.1 percent, RS 61.5 percent). The poorest survival rates (OS 45.4 
percent, RS 59.1 percent) were for patients 75 years of age and older.  
 
In cases of rectum cancer, the highest 5-year observed and relative survival rates were for 
the age group 45 through 59 years (58.9 percent and 60.2 percent, respectively), while the 
poorest observed survival (42.9 percent) was for patients 75 years of age and older. 
However, the poorest relative survival rate (55 percent) was for patients aged 15-44.  
 
Table 21: Observed and relative cancer survival estimates by type of 
colorectal cancer and age, Jordan (2003-2007) 
Variable 
Observed survival (percent) Relative survival (percent) 
1 year 3 years 5 years 1 year 3 years 5 years 
Colorectal       
15-44 83.2 66.1 58.9 83.2 66.4 59.4 
45-59 86.4 71.2 61.8 86.6 71.8 63.2 
60-74 83.1 67.3 57.1 83.5 69.1 61.5 
>=75 69.1 55.8 44.7 70.4 61.1 58.8 
Colon       
15-44 83.2 66.2 58.9 82. 3 66.4  60.1 
45-59 86.4 71.3 65.1 86.6 71.8 63.2 
60-74 83.1 67.4 57.1 83.5 69.1 61.5 
>=75 69.3 57.2 45.4 70.7 62.6  59.1 
Rectum       
15-44 84.4 63.6 54.6 85.5 63.9 55.0 
45-59 88.4 72.0 58.9 88.6 72.6 60.2 
60-74 83.6 65.1 55.1 84.0 66.7 59.1 
>=75 68.3 52.2 42.9 69.5 57.1 55.4 
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5.3.4 Observed colorectal survival probability by place of residence  
This study estimated the survival rates for colorectal cancer patients living in three 
different areas of Jordan: middle, north and south. Figures 14a, 14b and 14c show 
significant differences of survival rates in relation to place of residency. While the poorest 
survival was in the south, the highest survival estimates were obtained for patients living in 
the middle part of the country followed by the north, (Log-rank test p-value= 0.0001).  
 
Figure 14a: Observed survival probability by residency for 1,896 cases of 
colorectal cancer in Jordan 
 
Log-rank test p-value = 0.0001 
Figure 14b: Observed survival probability by residency for 1,204 cases of 
colon cancer in Jordan 
 
Log-rank test p-value = 0.0138
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Figure 14c: Observed survival probability by Residency for 692 Cases of 
Rectum Cancer in Jordan 
 
Log-rank test p-value = 0.0045
 
Table 22 displays the observed and relative survival rates for colorectal, colon and rectum 
cancers by place of residency. The 5-year observed survival rates of colorectal, colon and 
rectum cancers for patients living in the central part of Jordan were 60.1 percent, 61.0 
percent and 58.5 percent, respectively. Their corresponding relative survival rates were 
63.9 percent, 65.5 percent and 61.6 percent, respectively. The 5-year observed survival 
rates for colorectal, colon and rectum cancers for patients living in the north of Jordan were 
51.5 percent, 54.1 percent and 47.3 percent, respectively. Their corresponding relative 
survival rates were 54.4 percent, 57.7 percent and 49.4 percent, respectively. The 5-year 
observed survival rates of colorectal, colon and rectum cancers for patients living in the 
south of the country were 44.7 percent, 44.1 percent and 46.8 percent, respectively. Their 
corresponding relative survival rates were 46.6 percent, 44.2 percent and 48.3 percent, 
respectively. 
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Table 22: Observed and relative cancer survival estimates by type of 
colorectal cancer and place of residence, Jordan (2003-2007) 
Variable 
Observed survival 
(percent) 
Relative survival 
(percent) 
1 year 3 years 5 years 1 year 3 years 5 years 
Colorectal       
North 79.4 59.9 51.5 79.8 61.2 54.4 
Middle 83.8 70.0 60.1 84.3 71.5 63.9 
South  77.6 52.2 44.7 77.9 53.0 46.6 
Colon       
North 78.2 62.4 54.1 78.6 63.8 57.7 
Middle 83.1 69.9 61.0 83.5 71.6 65.5 
South  73.8 52.4 44.1 74.2 53.3 44.2 
Rectum       
North 81.3 56.2 47.3 81.7 57.1 49.4 
Middle 85.3 70.1 58.5 85.6 71.5 61.6 
South  84.0 52.0 46.8 84.3 52.6 48.3 
 
5.3.5 Observed colorectal survival probability by year of diagnosis  
Figures 15a, 15b and 15c show colorectal survival rates in relation to the year of diagnosis 
from 2003 through 2007. The figures show no temporal trend toward improving or 
worsening survival over the study period. However, results show that the best 5-year 
survival estimate was found for patients diagnosed in 2004, for all patients and separately 
for both colon and rectum. Alternatively, the poorest result was for patients diagnosed in 
2006, also for combined and separately for both colon and rectum. 
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Figure 15a: Observed survival probability by year of diagnosis for 1,896 
colorectal cancer cases in Jordan 
   
Log-rank test p-value = 0.0012 
 
Figure 15b: Observed survival probability by year of diagnosis for 1,204 
cases of colon cancer in Jordan 
 
Log-rank test p-value =  0.0270 
Figure 15c: Observed survival probability by year of diagnosis for 692 cases 
of rectum cancer in Jordan 
 
Log-rank test p-value  = 0.0506 
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Overall the observed and relative survival estimates were consistently highest during Year 
1 and lowest during Year 5 (Tables A.1, A.2 and A.3 in Appendix A). Table 23 shows the 
observed and relative survival rates for colorectal, colon and rectum cancers by year of 
diagnosis. For colorectal cancer, the 5-year observed and relative survival rates ranged 
from 56.7 percent and 60.7 percent, respectively, for patients diagnosed in 2003, to 61.7 
percent, and 64.3 percent for patients diagnosed at 2007, respectively. The highest 
observed and relative colorectal survival rates (67.1 percent and 70.8 percent respectively) 
were reported in patients diagnosed in 2004.  
 
 
Table 23: Observed and relative cancer survival estimates by type of 
colorectal cancer and year of diagnosis, Jordan (2003-2007) 
Variable 
Observed survival 
(percent) 
Relative survival 
(percent) 
1 year 3 years 5 years 1 year 3 years 5 years 
Colorectal        
2003 83.3 64.9 56.7 83.7 66.4 60.7 
2004 88.1 77.7 67.1 88.5 79.2 70.8 
2005 84.3 61.4 57.9 84.8 69.2 61.9 
2006 77.8 60.7 50.0 78.2 61.8 52.7 
2007 81.3 66.5 61.7 81.7 68.2 64.3 
Colon        
2003 82.9 66.7 58.1 83.4 68.3 62.1 
2004 87.3 77.0 68.2 87.7 78.5 72.2 
2005 82.7 66.3 57.1 83.2 67.9 61.3 
2006 77.1 63.2 52.5 77.3 64.4 55.4 
2007 81.3 66.7 62.9  81.7 68.4 65.8  
Rectum        
2003 84.3 59.1 52.8 84.7 60.3 56.3 
2004 90.7 80.1 63.7 91.1 81.3 66.7 
2005 89.2 71.7 60.2 89.5 73.1 63.6 
2006 80.1 53.9 43.1 80.4 54.8 45.2 
2007 81.5 66.2 58.3  81.8 67.5  60.2 
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Colon cancer patients diagnosed in 2004 had 5-year observed survival rate of 68.2 percent 
and 5-year relative survival rate of 72.2 percent, whereas those diagnosed in 2007 had 5-
year observed survival of 62.9 percent and 5-year relative survival of 65.8 percent. 
Similarly, rectum cancer patients diagnosed in 2004 had the highest 5-year observed 
survival of 63.7 percent and 5-year relative survival of 66.7 percent, whereas those 
diagnosed in 2007 had 5-year observed survival rate of 58.3 percent and 5-year relative 
survival of 60.2 percent. The lowest 5-year observed and relative survival rates for rectum 
cancer were reported among patients diagnosed in 2006 (43.1 percent and 45.2 percent 
respectively). 
 
5.3.6 Observed and Relative survival (%), age standardized to the ICSS weights 
Table 24 shows the survival estimates age-standardised to the ICSS weights. The overall 
age standardized relative survival rate for colorectal cancer at 1 year, 3 years and 5 years 
from diagnosis were 75.9 percent, 63.2 percent and 57.7 percent, respectively.  
 
Table 24: Observed and Relative survival (%), age standardized to the 
ICSS weights for patients (aged 15–99 years) diagnosed with colon and 
rectum cancers during 2003-2007 and followed up to Dec 31, 2010, Jordan  
Cancer site Number 
Observed survival 
(percent) 
Relative survival 
(percent) 
1 year 3 years 
5 
years 1 year 
3 
years 
5 
years 
Colorectal  1 896 75.1 60.3 50.2 75.9 63.2 57.7 
Colon  1204 74.2 60.5 50.1 75.0 63.5 57.4 
Rectum    692 78.2 59.3 50.5 78.9 62.4 58.6 
 
The age standardized observed survival rate for rectum cancer at year 1 of diagnosis was 
78.2 percent compared to 74.2 percent for colon cancer. Observed survival rates for colon 
and rectum cancer at 3 years were close; 60.5 percent and 59.3 percent, respectively. 
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Similarly, the observed survival rates for colon and rectum cancer at 5 years were almost 
the same: 50.1 percent and 50.5 percent, respectively.   
 
The age standardized relative survival rate for rectum cancer was higher than the colon 
survival rate at 1 year: 78.9 percent and 75.0 percent, respectively. Similarly, the age 
standardized relative survival rate for rectum cancer was also higher than the colon 
survival rate at 5 years of diagnosis: 58.6 percent and 57.4 percent, respectively. 
Alternatively, the age standardized relative survival rate for colon cancer at 3 years 
diagnosis was slightly higher than for rectum cancer: 63.5 percent and 62.4 percent, 
respectively.  
 
5.3.7 Summary and Discussion 
This section presented the observed and relative survival estimates and probabilities using 
a variety of approaches and timeframes. The observed and relative colorectal survival 
probabilities were examined in relation to site of cancer, year of diagnosis and patients’ 
socio-demographic characteristics (i.e. sex, age, place of residency). Relative survival rates 
were estimated to infer cancer-specific death rates. 
 
The study revealed that 5-year relative survival rates for colorectal, colon and rectum 
cancer patients to be 61.3 percent and 63.2 and 58.3 percent, respectively. Males and 
females had almost similar 5-year survival probability for the first two years of diagnosis, 
which gradually changed to slightly higher survival rates among females. In the first year 
after diagnosis, females had better observed survival rates for overall colorectal cancer 
than males (Tables in the Appendix).  
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As expected, the observed survival rates mostly decreased through all age groups, with a 
noticeable decline for the age group of 75 years and older. Both the observed and relative 
survival rates declined noticeably for the age group 75 years and above. While the highest 
survival estimates were found among patients living in the central parts of Jordan, the 
poorest was significantly noted in the south. No temporal trend was observed through the 
study period (2003-2007).  
 
The overall observed and relative survival estimates were highest during Year 1 and lowest 
in Year 5, with no significant differences between colon and rectum cancer survival in the 
first year for both sexes. Patients with rectum cancer showed slightly better observed and 
relative survival rates at year 1 of diagnosis than those with colon cancer, with a reverse 
relationship at 3- and 5-years of diagnosis. Results also showed that survival probabilities 
were highest in the central part of Jordan and significantly lower in the south of the 
country.  
 
Colorectal survival rate in Jordan 
The relative 5-year survival rate for colorectal cancer in Jordan found in this study (61 
percent) is comparable with that of other developed countries. The study also revealed that 
the age standardized relative survival rate for the overall cases of colorectal cancer at 5 
years of diagnosis to be 58.1 percent. This rate was slightly higher for rectum cancer (59.2 
percent) when compared to colon cancer (57.8 percent).  
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This study showed a significance variation in survival from colorectal cancer in Jordan 
from other developed and less developed countries (13;18;202;231-235). 
 
The CONCORD study (1990-1994) reported that CRC 5-year RS was higher than 55 
percent in Japan, France, U.S., Canada and Australia, reaching 61.1 percent for males in 
Japan and 61.5 percent for females in France, while it was generally reported to be lower in 
Algeria (22.6 percent) and Poland (male 29.6 percent). In England and Scotland, survival 
rates were found to be 42.3 percent and 44.6 percent, respectively for males, and 44.7 
percent and 47.7 percent, respectively for females (Figure 16) (13).  
 
Figure 16: Five year relative survival (percent), age standardized to the ICSS weight 
with 95 percent CI for adults (aged 15-99 years) diagnosed with colorectal cancer 
during the period 1990-1999 
 
Table 25 displays information from developing countries (1990 to 2001), where the five-
year RS was reported to be higher than 50 percent in Singapore, Turkey and South Korea; 
 
164
and ranged from 28 percent to 44 percent in India, Thailand, Philippines and China; 
whereas it did not exceed 8 percent in Uganda and Gambia (14). 
 
Table 25: 5-year age standardized (0-74 years) colorectal cancer 
relative survival by country according to Cancer survival in Africa, 
Asia, and Central America: a population-based study (1990 to 2001) 
Country 5-year age standardized RS (percent) 
China 44 percent (36 percent-63 percent) 
India 28 percent (6 percent-31 percent) 
Philippines 40 percent 
Singapore 52 percent 
South Korea 60 percent (57 percent-64 percent) 
Thailand 35 percent (31 percent-44 percent) 
Turkey 52 percent 
The Gambia 4 percent 
Uganda 8 percent 
 
In conclusion, the study revealed that the age-standardized relative survival rate for the 
overall colorectal cancer cases at 5 years of diagnosis to be 58.1 percent. It was slightly 
better for rectum, 59.2 percent, compared to 57.8 percent for colon. These observations 
may be associated to differences in clinical characteristics or treatment, which will be 
examined and explored systematically in the next chapter. These results showed good 
survival estimates of CRC compared to developed countries as well as the most developed 
countries in the region and across the Asian continent. Jordan has one of the most modern 
health care infrastructures in the Middle East, a relatively good health expenditure, and 
high percent (79 percent) of health insurance coverage for the Jordanian population. In 
addition, some costly diseases are also insured against according to special regulations 
determined by the Health Insurance bylaw; this includes cancer and its side effects 
(46;47;236). Recently, independent reports and international organizations have begun to 
recognize Jordan’s high level of health care services; the World Bank ranked Jordan as the 
number one health care services provider in the region and among the top five destinations 
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for medical tourism in the world, as well as being the top medical tourism destination in 
the Middle East and North Africa (25;26). Additionally, the King Hussein Cancer Center 
has also been recognized as the only specialized cancer treatment facility in the Middle 
East, and as one of the top cancer treatment facilities in the world (237;238). 
 
Other possible factors could have attributed to the good CRC survival estimates in Jordan 
include early detection programs (102;104), accessibility to hospital care (164;239),  
affordability of health insurance (137;199), availability and affordability of suitable 
treatment and surgical techniques (136;179;240). Estimate of patient survival using the 
complete approach as well as other factors such as death certificate registration could have 
influenced survival estimates in this study. These factors are addressed in Chapter 9. 
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CHAPTER 6 – COLORECTAL CANCER SURVIVAL AND CLINICAL 
MANIFESTATION 
 
6.1 Introduction 
In the previous chapter (5) we established that there are significant demographic and other 
variations in the survival probability of colorectal cancer, and knowing from the evidence 
of the literature review that clinical factors are important determinants in survival, this 
chapter explores the effects of the clinical manifestations (e.g. site, grade, histopathology, 
stage, etc.) and treatment of colorectal cancer on survival estimates. The chapter presents 
and describes the results of colorectal survival analysis in relation to the clinical 
manifestations (grade, morphology or histopathology and extent or of disease or stage) and 
treatment of the tumour (surgery, chemotherapy and radiotherapy). Survival estimates by 
topography or site of cancer were presented and discussed in the previous chapter, and the 
topography variable was selected as a major variable for stratifying results. Furthermore, 
the chapter discusses the results obtained from running Kaplan-Meier technique and 
logrank tests to estimate colorectal survival probabilities in relation to the identified 
clinical and treatment modalities.  
 
Using the life table method, relative survival estimates were computed to account for dying 
from causes other than colorectal cancer during the time of the study. These relative 
survival measures were used to adjust the observed survival rates for selected variables that 
might have an effect on the expected survival. This chapter provides a comparison of 
observed and relative survival proportions surviving at an end of specific time period (1-, 
2- and 5-years).   
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Finally, the chapter discusses the results obtained from running the Cox logistic regression 
model procedure for colorectal survival rates in relation to the socio-demographic (age, 
sex, place of residence), clinical manifestations (topography or site, grade, morphology or 
histopathology and extent of disease or stage) and treatment type of the tumour (surgery, 
chemotherapy and radiotherapy).  
 
6.2 Colorectal cancer and clinical characteristics 
The clinical characteristics examined in this study included grade, morphology and extent 
of disease. Grade was classified into four categories: well differentiated, moderately 
differentiated, poorly differentiated, and undifferentiated anaplastic. Morphology included 
dividing the cancer type into adenocarcinoma, mucinous adenocarcinoma, carcinoma, and 
other morphology; and extent of disease included categorization into three main categories, 
namely: localized, regional and distant metastasis. 
 
6.2.1 Observed and relative colorectal survival probability by grade of tumour 
When survival rates were compared for the different grades of cancer (as shown in Figures 
17a, 17b and 17c), a decrease in survival probability was seen for all grades and all cancer 
categories, with one exception. The exception was that while survival probability 
decreased over time for all grades of rectal cancer, for colon cancer cases of ‘Well’ grade 
the decreased survival probability appeared to level off from year 2 onwards. Moderate and 
well-differentiated colorectal tumours are similar up to 2 years but then diverge with better 
survival for the later. For rectum cancer, survival from moderate was found to be better 
than well-differentiated (for which there are very small numbers by the looks of it). 
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Figure 17a: Observed survival probability by grade of disease for 1,896 of 
colorectal cancer cases in Jordan 
 
P-value of Log Rank test <0.0001 
Figure 17b: Observed survival probability of colon cancer by Grade of 
disease (2003-2007), Jordan 
 
P-value of Log Rank test  = 0.0017 
 
 
 
 
 
 
 
169
Figure 17c: Survival probability of rectum cancer cases cases by Grade 
(2003-2007), Jordan 
 
P-value of Log Rank test <0.0001 
 
Findings shown in Table 26 indicate that 5-year survival rates for colorectal cancer varied 
by cell differentiation. The colorectal cancer patients showed 5-year observed survival 
rates of 68.1 percent for well-differentiated grade, decreasing to 48.4 percent for poor 
differentiated grade. Whereas, relative survival rate was 72.9 percent for well-
differentiated grade decreasing to 51.2 percent for poor differentiated grade. The 5-year 
observed and relative survival rates for colon cancer were 78.9 percent and 84.8 percent 
respectively for well grade, followed by 59.4 percent and 63.7 percent respectively for 
moderate grade, and 53.5 percent and 56.2 percent respectively for poor grade. 
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Table 26: Observed (OS) and relative (RS) colorectal cancer survival by 
grade of tumour, Jordan (2003-2007) 
Extent of 
Disease   Number 
Observed survival 
(percent) 
Relative survival 
(percent) 
1yr 3yr 5yr 1yr 3yr 5yr 
Colorectal               
Well  125 86.3 73.1 68.1 86.8 75.1 72.9 
Moderate  1,189 85.0 70.5 60.0 85.4 71.9 63.7 
Poor/ anaplastic  282 76.8 57.6 48.8 77.2 58.6 51.2 
Colon        
Well  88 89.7 80.3 78.9 90.3 82.5 84.8 
Moderate  738 83.4 69.4 59.4 83.9 71.1 63.7 
Poor/ anaplastic  166 76.6 62.5 53.5 76.9 63.7 56.2 
Rectum               
Well  24 78.4 56.3 44.1 78.9 57.7 46.8 
Moderate  302 87.5 72.2 60.9 87.9 73.5 63.9 
Poor/ anaplastic  82 77.2 50.5 42.2 77.5 51.3 44.2 
 
The 5-year observed and relative survival for rectum cancer were 60.9 percent and 63.9 
percent, respectively, for moderate grade, followed by 44.1 percent and 46.8 percent, 
respectively, for well grade and 42.2 percent and 44.2 percent, respectively for poor grade. 
Survival for well-differentiated colon cancer at 3-years and 5-years of diagnosis was higher 
than that of moderate differentiation grade. In contrast, rectum cancer illustrated different 
observations; survival from rectum cancer was the poorest for well differentiated. The 
observed survival for well-differentiated rectum cancer was 56.3 percent at year 3 and 44.1 
percent at year 5; meanwhile, it was 80.3 percent at year 3 and 82.5 percent at year 5 for 
colon cancer. The relative survival rates for well-differentiated rectum cancer were 56.3 
percent at year 3 and 44.1 percent at year 5, while they were 57.7 percent at year 3 and 
46.8 percent at year 5 for colon cancer.  
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6.2.2 Observed and relative survival probability of colorectal cancer by disease 
morphology  
Figures 18a show that the effect of cancer morphology on the survival rates of colorectal 
patients was observed to be poorest with mucinous tumours, where half of the patients died 
after less than 4 years from diagnosis. When this association was examined by site of 
cancer, Figure 18b shows that survival of colon cancer patients with mucinous carcinoma 
to be significantly lower than that of patients with other morphology types (P-value of log 
rank test = 0.0370), however this relationship was on the borderline of the level of 
significance for rectum cancer(P-value of log rank test = 0.0561) .  
 
Comparatively, survival data analysis showed that adenocarcinoma and NOS carcinoma 
types have almost the same probabilities of survival. Although this association was found 
unchanged when looking at colon cancer (Figure 18b), rectal cancer patients with NOS 
carcinoma type exhibited significantly higher survival probability than patients with 
adenocarcinoma which could be attributed to the small number of cases (Figure 18c). 
Figure18a: Observed survival probability of colorectal cancer cases by 
morphology (2003-2007), Jordan 
 
P-value of Log Rank test =  0.0125
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Figure 18b: Observed survival probability of colon cancer cases by 
morphology (2003-2007), Jordan 
 
P-value of Log Rank test = 0.0370
Figure 18c: Observed survival probability of rectum cancer cases by 
morphology (2003-2007), Jordan 
 
P-value of Log Rank test = 0.0561 
 
Mucinous and serous tumours showed the poorest survival rates among the colorectal 
cancer histological classifications (Table 27). At year 1 of diagnosis, observed and relative 
survival for colorectal cancer were 83.7 percent and 84.2 percent, respectively, for 
adenocarcinoma; and observed and relative survival of 74.8 percent and 75.1 percent, 
respectively, for both mucinous and serous tumours.  
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At year 3, the observed and relative rates were 68.5 percent and 69.9 percent, respectively, 
for adenocarcinoma; 68.3 percent and 70.2 percent, respectively, for NOS and neoplasm; 
and 54.5 percent and 55.4 percent, respectively, for mucinous and serous tumours. With 
regard to 5-year survival, the observed and relative survival rates were 57.9 percent and 
62.6 percent, respectively, for ‘other’ morphologies; and 46.4 percent and 48.4 percent, 
respectively, for mucinous and serous tumours. Considering the patients with colon cancer, 
the 1-year observed and relative survival rates were 82.8 percent and 83.1 percent, 
respectively, for ‘other’ morphologies; 82.9 percent and 83.3 percent, respectively, for 
adenocarcinoma; and 70.8 percent and 71.1 percent, respectively, for mucinous and serous 
tumours. At year 3 from diagnosis, the observed and relative survival rates for colon cancer 
were 79 percent and 80.4 percent, respectively, for ‘other’ morphologies; 55.8 percent and 
56.7 percent, respectively, for mucinous and serous tumours; and 68.7 percent and 70.4 
percent, respectively, for adenocarcinoma.  
 
The results of survival analysis by morphology for rectum cancer illustrated that the 1-year 
observed and relative survival rates were the highest for adenocarcinoma: 85.3 percent and 
85.6 percent, respectively; the lowest were for ‘other’ morphologies: 79.6 percent and 79.9 
percent, respectively. Mucinous and serous reported the poorest survival rates at 3-years 
(52.6 percent and 53.3 percent, respectively) and 5-years from diagnosis (41.4 percent and 
42.8 percent, respectively). At 3- and 5-years from diagnosis, neoplasm and NOS had the 
highest observed survival rates: 74.7 percent and 77.1 percent, respectively, and 63.4 
percent and 70.1 percent, respectively. 
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Table 27: Observed (OS) and relative (RS) colorectal cancer survival by 
morphology, Jordan (2003-2007) 
Morphology  Number 
Observed survival 
(percent) 
Relative survival 
(percent) 
1yr 3yr 5yr 1yr 3yr 5yr 
Colorectal                
Adenocarcinoma  1,598 83.7 68.5 58.6 84.2 69.9 62.4 
Mucinous and 
serous  
148 74.8 54.5 46.4 75.1 55.4 48.4 
Neoplasm, NOS  82 80.65 68.34 60.39 81.07 70.2 65.41 
Others 55 79.6 67.5 57.9 80.0 69.3 62.6 
Colon                
Adenocarcinoma  1,013 82.9 68.7 59.4 83.3 70.4 63.7 
Mucinous and 
serous  
90 70.8 55.8 49.9 71.1 56.7 52.4 
Neoplasm, NOS  61 79.5 65.1 56.1 79.9 66.7 60.1 
Others 38 82.8 79.0 78.5 83.1 80.4 83.2 
Rectum                
Adenocarcinoma  403 85.3 68.1 57.4 85.6 69.3 60.3 
Mucinous and 
serous  33 81.0 52.6 41.4 81.3 53.3 42.8 
Neoplasm, NOS  11 80.0 74.7 63.4 80.5 77.1 70.1 
Others 19 79.6 54.5 44.1 79.9 55.1 45.8 
Note: types of morphology do not round up to 100% because of missing 
information. 
 
6.2.3 Observed and relative colorectal survival probability by extent of disease 
Analysis showed that the survival rates of colorectal cancer patients to be significantly 
associated with the extent of disease (Figures 19a, 19b and 19c). Poor survival rate was 
found for patients with the distant type tumours which seemed to hold plausible when 
examining the association for colon and rectum cancer individually. Although the 
condition was much better when examining the survival rates by localized and regional 
type of tumours, colorectal patients with regional tumours illustrated poorer survival rates 
when compared with the localized the type (P-value < 0.0001). Further examination of 
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colon and rectum cancer survival rates showed that rectal cancer patients with local or 
regional tumours had worse survival rates than patients with colon cancer of such types. 
Figure 19a: Observed survival probability of colorectal cancer cases by 
extent of disease (2003-2007), Jordan 
 
P-value < 0.0001
Figure 19b: Observed survival probability of colon cancer cases by extent of 
disease (2003-2007), Jordan 
 
P-value < 0.0001 
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Figure 19c: Observed survival probability of rectum cancer cases by extent 
of disease (2003-2007), Jordan 
 
P-value < 0.0001 
 
At year 5, observed survival rates of colorectal cancer cases were 84.3 percent in cases of 
localized stage, decreasing to 64.9 percent in cases of regional stage and reaching 23.3 
percent in cases of distant stage. The corresponding relative survival rates were 86.2 
percent, 68.6 percent and 24.8 percent, respectively (Table 28).  
Table 28: Observed (OS) and relative (RS) for colorectal cancer survival 
by extent of disease, Jordan (2003-2007) 
Extent of 
Disease   Number 
Observed survival 
(percent) 
Relative survival 
(percent) 
1yr 3yr 5yr 1yr 3yr 5yr 
Colorectal               
Localized 212 96.2 88.4 84.3 96.8 90.5 86.2 
Regional 1,118 88.7 75.4 64.9 89.1 76.9 68.6 
Distant 432 58.6 33.4 23.3 58.9 34.2 24.8 
Colon        
Localized 133 96.5 91.5 89.6 97.3 94.3 91.3 
Regional 689 89.7 77.7 67.3 90.2 79.4 71.7 
Distant 290 54.7 32.5 22.7 55.0 33.1 23.9 
Rectum               
Localized 68 94.9 83.2 74.9 95.3 85.0 79.4 
Regional 272 87.1 71.9 61.2 87.4 73.2 63.8 
Distant 88 66.7 35.6 24.7 67.0 36.4 26.7 
 
 
177
Survival from localized and regional colon cancer was better than survival from rectum 
cancer in the same stages at 1-, 3- and 5-years of diagnosis. Cases of localized tumours in 
colon cancer showed 5-years observed survival rate of 89.6 percent and relative survival 
rate of 97.3 percent, and regionally spread tumours 67.3 percent and 71.7 percent, 
respectively. The corresponding values of localized and regional rectum cancers were 74.9 
percent and 61.2 percent respectively for the observed survivals, 79.4 percent and 63.8 
percent respectively for the relative survivals. The situation differed with regard to the 
distant tumours: the rectum cancer data produced better survival rates than that of colon 
cancer throughout the first five years after diagnosis. The observed and relative survival 
rates of distant tumours for rectum cancer were 35.6 percent and 36.4 percent, respectively, 
at 3-years of diagnosis; and 24.7 percent and 26.7 percent respectively at 5-years of 
diagnosis. The reciprocal observed and relative survival rates for distant colon cancer at 3-
years were 32.5 percent and 33.1 percent, respectively; and observed and relative survival 
rates for distant colon cancer at 5-years were 22.7 percent, and 23.9 percent, respectively.  
 
6.2.4 Observed and relative colorectal survival probability by extent of disease stratified 
by age and sex 
Table 29 illustrates the colorectal cancer 5-year survival rate by extent of disease stratified 
by age and sex. Results indicated that observed survival became poorer with increasing age 
for both localized and regional tumours. This observation was applicable for both males 
and females.  
 
When combining both sexes across all age groups, the observed 5-year survival rate ranged 
from 84.3 percent to 63.8 percent for localized tumour, and 68.9 percent to 44.3 percent for 
regional tumour. Results of distant tumour for males and females showed highest 5-year 
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observed survival rate for patients in the age group of 45 through 64 years, while observed 
survival of the age group 15 through 44 years was slightly higher than that of the age group 
of 65 years of age or more. For both sexes, the observed 5-year survival rate was 26.1 
percent in the age group 45 through 65 years and decreased to 20.2 percent in age group 65 
years of age or older. 
Table 29: Fiver year relative survival rates of colorectal cancer patients by extent 
of disease, age, sex, and calendar year of diagnosis Jordan (2003–2007) 
Extent of 
disease Age 
Both sexes Males Females 
OS 
percent  
RS  
percent 
OS 
percent  
RS 
percent  
OS 
percent 
RS 
percent  
Localized 15-44 84.31 85.02 82.79 83.6 85.0 85.60 
 45-59 81.02 82.79 78.96 81.01 83.33 84.75 
  60-74 80.35 86.74 78.75 85.90 82.93 88.09 
  ≥75 63.75 81.10 59.40 78.83 67.73 82.61 
  All ages 79.04 84.51 77.04 83.26 81.61 86.10 
Regional 15-44 68.61 69.11 71.38 72.05 66.61 67.00 
 45-59 68.90 70.39 62.17 63.85 75.50 76.79 
  60-74 65.28 70.25 65.71 71.68 64.59 68.09 
  ≥75 44.33 56.39 42.61 56.02 47.70 57.26 
  All ages 65.43 69.02 63.24 67.86 68.02 70.41 
Distant 15-44 19.08 19.25 19.40 19.62 19.05 19.16 
 45-59 30.46 31.19 34.89 35.92 26.29 26.71 
  60-74 17.70 19.14 19.72 21.60 14.47 15.27 
  ≥75 21.87 28.95 22.72 31.04 18.18 21.19 
  All ages 22.49 23.98 24.12 26.17 20.17 20.86 
All  15-44 57.64 58.08 55.46 55.90 57.17 57.61 
 45-59 60.55 61.88 59.39 60.71 60.24 61.56 
  60-74 56.79 61.18 55.26 59.59 55.38 59.61 
  ≥75 40.89 52.35 38.38 49.49 41.21 52.56 
 
 
6.3 Colorectal survival estimates and treatment 
The treatment characteristics examined in this study included intent of treatment, surgery, 
chemotherapy and radiotherapy. Colorectal cancer survival probabilities for the treatment-
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related variables (surgery, chemotherapy, and radiotherapy) were computed using Kaplan-
Meier technique and logrank tests. These probabilities were examined in relation to tumour 
site.  
 
6.3.1 Surgery treatment  
6.3.1.1  Thirty-days postoperative mortality after colorectal cancer surgery 
Table 30 displays the results of multivariable analyses done to examine the adjusted odds 
of death within 30 days of surgery. The adjusted odds ratios for CRC thirty-day 
postoperative mortality for sex, age, place of residence, extent of disease, topography, 
operation type, and treatment site were calculated using the logistic regression modelling 
procedure. Irrespective to the level of significance of the sex variable, we entered it into 
the multivariable model to confirm that it remain non-significant determinant of thirty-days 
postoperative mortality after adjustment for other confounding factors.  For other variables, 
significant predictors (p-value ≤ 0.2) were included in the adjusted model. 
 
The odds of dying were significantly higher among colorectal cancer patients older than 65 
years who underwent surgery (OR 2.3, 95percent CI: 1.3-4.1). In addition, CRC patients 
with distant tumors who underwent surgery had higher odds of dying than those with 
local/regional tumors (OR 3.6, 95 percent CI: 2.0-6.2); and those operated upon as an 
emergency had higher odds compared with those operated upon electively (OR 2.3, 
95percent CI: 1.2-4.1). Sex, place of residence, topography, and treatment site were 
insignificant predictors.  
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Table 30: Multivariable analyses for odds of dying within 30 
days of surgery for colorectal cancer patients 
Variables 
multivariable analyses 
OR 
(95percent 
CI) 
P-value  
Sex    0.482 
Male  1 -  
Female  .81 0.45-1.4  
Age   0.003 
<=65 1 -  
>65 2.3 1.3-4.1  
Place of residence    0.400 
Middle  1   
North & South  1.3 0.70-2.4  
Topography   0.141 
Colon  1 -  
Rectum .62 0.33-1.2  
Extent   <0.001 
Localized / regional  1 -  
Distant 3.6 2.0-6.2  
Operation type   0.008 
Elective  1 -  
Emergency 2.3 1.2-4.1  
Treatment site    0.257 
Public/teaching  1 -  
Private/KHCC & others  .70 0.38-1.3  
 
6.3.1.2 Survival probability of colorectal cancer by surgery   
Figure 20a shows that the observed survival probability was significantly higher for 
colorectal cancer patients who underwent surgery than for those patients who did not 
undergo surgery. This scenario was similarly observed for both colon and rectum (p-value 
< 0.001; Figures 20b and 20c, respectively).  
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Figure 20a: Observed survival probability of colorectal cancer cases by 
undergoing surgery (2003-2007), Jordan 
 
P-value< 0.0001
Figure20b: Observed survival probability of colon cancer cases by 
undergoing surgery (2003-2007), Jordan 
 
P-value < 0.0001 
Figure 20c: Observed survival probability of rectal cancer cases by 
undergoing surgery (2003-2007), Jordan 
 
P-value < 0.0001 
 
182
6.3.1.3 Relative survival rates of colorectal cancer undergoing surgery 
Table 31 illustrates relative survival (RS) for patients of colorectal, colon and rectum 
cancer in terms of undergoing surgery. For this effect three models were constructed, one 
for each type of cancer. To better understand changes in RS between the first and fifth year 
the period between zero timing and the end of the first year was divided into ten intervals. 
The periods between the start of the second year and the end of the second year as well as 
the start of the third year and the end of the third year were divided into two intervals for 
each. The periods between the start of the fourth year and the end of the fourth year, as 
well as the start of the fifth year and the end of the fifth year, were divided into single 
intervals for each (as seen in Table 31).   
 
The colorectal model showed that RS declined all the way from 96.2 percent to 62.6 
percent for patients who underwent surgery and from 86.5 percent to 23.5 percent for 
patients who did not undergo surgery; the difference between the two groups was observed 
clearly during all time periods. The colon cancer model showed that RS declined from 95.4 
percent to 64.7 percent for patients who underwent surgery; at the same time RS dropped 
from 81.3 percent to 24.1 percent for patients who did not undergo surgery. The difference 
between both groups in this model was clearly observed over all time periods as well.  
 
The rectal cancer model illustrated that RS declined from 98.4 percent to 56.8 percent for 
patients who underwent surgery and from 96.7 percent to 21.0 percent for patients who did 
not undergo surgery. The difference between both groups was minimal until the end of the 
eighth time period of the first year; later the RS for patients who underwent surgery was 
clearly higher compared to those patients who did not undergo surgery. RS for those 
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patients who underwent surgery was always higher than those for patients who did not 
undergo surgery (Table 31).  
 
Table 31: Five year relative survival rates for colorectal, colon and rectum 
cancer patients by surgery, 2003–2007 
Time 
Colorectal Colon Rectum 
Surgery  No surgery Surgery 
No 
surgery Surgery 
No 
surgery 
Start End RS percent 
RS 
percent 
RS 
percent 
RS 
percent 
RS 
percent 
RS 
percent 
0 0.1 96.2 86.5 95.3 81.2 98.4 96.7 
0.1 0.2 94.7 82 93.5 74.3 97.9 96.8 
0.2 0.3 93.3 75.2 92.2 67.5 96.3 90.1 
0.3 0.4 91.6 69.5 90.7 58.8 94.2 90.2 
0.4 0.5 90.1 67.5 89.2 57.1 92.6 86.9 
0.5 0.6 88.8 67.3 88.2 55.4 91.9 87.0 
0.6 0.7 87.9 66.2 87.4 50.3 89.5 83.7 
0.7 0.8 86.9 61.7 86.3 48.6 88.7 83.7 
0.8 0.9 85.4 60.5 85.1 46.9 86.6 80.4 
0.9 1 84.6 58.3 84.3 43.4 85.5 67.1 
1 1.5 79.6 51.5 79.6 38.3 79.1 50.6 
1.5 2 75.6 42.5 76.3 33.2 73.6 47.4 
2 2.5 72.5 38.1 73.3 29.9 70.3 37.5 
2.5 3 70.3 32.5 71.5 30.1 67.1 34.4 
3 4 66.1 31.6 67.4 23.4 62.1 24.2 
4 5 62.6 23.5 64.6 24.1 56.8 20.9 
 
 
 
6.3.1.4 Survival probability of colorectal cancer by type of surgery   
Figures 21a, 21b and 21c show the overall colorectal survival probability as well as 
individually for colon and rectum cancers by surgery type. The figures show that no 
significant pattern among patients who had elective surgery compared to those who 
underwent emergency surgery for both colon and rectum.  
 
 
 
184
Figure 21a: Observed survival probability of colorectal cancer cases by 
surgery type (2003-2007), Jordan 
 
P-value 0.0601 
Figure 21b: Observed survival probability of colon cancer cases by surgery 
type (2003-2007), Jordan 
 
P-value 0.1738 
Figure 21c: Observed survival probability of rectum cancer cases by 
surgery type (2003-2007), Jordan 
 
P-value 0.0830 
 
185
6.3.2 Survival probability of colorectal cancer by chemotherapy  
Figures 22a, 22b and 22c show the survival probabilities of colorectal cancer by 
chemotherapy treatment during 2003 through 2007 in Jordan. The figures show that 
patients who received chemotherapy treatment had better survival for almost the first four 
years; later, though, patients who didn’t receive chemotherapy treatment had better 
survival. However, this relationship did not reach significant levels either for colon or for 
rectum cancer. Moreover, the shapes of these Kaplan–Meier curves were found dissimilar; 
the non-chemo have a steep initial death rates which plateaus but the chemo group deaths 
are more constant over time.  This could be because patients who died within the first few 
months were not offered or given chemotherapy.  
Figure 22a: Observed survival probability of colorectal cancer cases by 
chemotherapy treatment (2003-2007), Jordan 
 
P-value 0.7981
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Figure 22b: Observed survival probability of colon cancer cases by 
chemotherapy treatment (2003-2007), Jordan 
 
P-value 0.0595 
Figure 22c: Observed survival probability of rectum cancer cases by 
chemotherapy treatment (2003-2007), Jordan 
 
P-value 0.0650 
 
6.3.3 Survival probability of colorectal cancer by Radiotherapy  
Figures 23a, 23b and 23c show the survival probabilities of colorectal cancer by 
chemotherapy treatment during 2003 through 2007 in Jordan. Figures show that patients 
who received radiotherapy treatment had better survival for almost the first year; later, 
patients who did not receive radiotherapy treatment had better survival. This relationship 
reached significant levels for rectum cancer but not for colon cancer.   
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Figure 23a: Observed survival probability of colorectal cancer cases by 
radiotherapy treatment (2003-2007), Jordan 
 
P-value 0.0041
Figure 23b: Observed survival probability of colon cancer cases by 
radiotherapy treatment (2003-2007), Jordan 
 
P-value 0.0074 
Figure 23c: Observed survival probability of rectum cancer cases by 
radiotherapy treatment (2003-2007), Jordan 
 
P-value 0.1232 
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6.4 General Predictive Model for Colorectal Cancer 
Table 32 shows the hazard ratios for CRC calculated using the Cox logistic regression 
model. Three predictive survival models were examined and presented based on 
topography (overall CRC, colon, and rectum). Using the Cox logistic regression model 
procedure, hazard ratios for CRC survival were first estimated as crude, and then adjusted 
for sex, age, place of residence, year of diagnosis, extent of disease, grade, morphology, 
and topography.  Irrespective to the level of significance of sex and age in univariate 
models, we entered them into the multivariable model.  For other variables, only 
significant predictors (P-value ≤ 0.2) were included in each adjusted model. 
 
Age was found to be a significant predictor for survival of colon cancer; colon cancer 
patients aged 75 years and above had 2.2 times higher risk of death than those aged 44 
years or less (HR=2.2, 95% CI: 1.5-3.1). Residing in the central region of the country was 
a significant predictor for survival of rectum cancer, where patients residing in the central 
region had a 27 percent lower risk of death compared with those residing in the North 
(HR=0.73, 95% CI: 0.56-0.95).  
 
Extent of disease was found to be a significant survival predictor for both colon and rectum 
cancers. Colon and rectum cancer patients with regional metastasis had three times and one 
and the half times higher risk of death than those with localized disease respectively 
(Colon: HR=3.3, 95% CI: 2.0-5.6); (Rectum: HR=1.6, 95% CI: 1.1-2.5). Moreover, colon 
patients with distant metastasis had fourteen times higher risk of death and rectum cancer 
patients portrayed four and the half times higher risk of death than those with localized 
disease (Colon: HR=14.0, 95% CI: 8.0-23.8); (Rectum: HR=1.6, 95% CI: 2.8-7.5). Colon 
patients with poor or anaplastic grade had almost twice the risk of death than those with 
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well grade (HR=1.9, 95% CI: 1.1-3.2). On the other hand, patients diagnosed with 
mucinous rectum cancer had 1.4 times higher risk of death than those with adenocarcinoma 
(HR=1.4, 95% CI: 1.1-2.1). Sex and year of diagnosis were not significant survival 
predictors across the three models (CRC, colon and rectum). The HR CRC adjusted model 
showed no statistically significant survival difference between colon and rectum. 
 
In summary, this study revealed that age, place of residency, extent of disease, topography 
and morphology to be significant predictors for colorectal cancer survival estimates. 
However, sex, grade and year of diagnosis were insignificant predictors.  
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Table 32:  Cox hazard proportions for colorectal, colon and rectum cancers, Jordan (2003-2007)  
Variable 
Colorectal cancer Colon cancer Rectum cancer 
Unadjusted HR 
(95percent CI) 
Adjusted HR 
(95percent CI) 
Unadjusted HR 
(95percent CI) 
Adjusted HR 
(95percent CI) 
Unadjusted HR 
(95percent CI) 
Adjusted HR 
(95percent CI) 
Sex       
Male 1 1 1 1 1 1 
Female 0.90 (0.78-1.1) 1.0 (.90-1.2) 0.85 (0.71-1.1) 1.0 (0.86- 1.3) 0.98 (0.78-1.2) 1.1 (0.89-1.4) 
Age       
15-44 1 1 1 1 1 1
45-59 0.88 (0.71-1.10) 0.89 (0.71-1.1) 0.95 (0.71-1.2) 0.95 (0.70-1.3) 0.81 (0.59-1.1) 0.83 (0.60- 1.2) 
60-74 1.03 (0.84-1.27) 1.2 (0.94-1.4) 1.1 (0.83-1.5) 1.2 (0.93-1.6) 0.99 (0.73-1.3) 1.1 (0.80-1.5) 
≥75 1.6 (1.2-2.03) * 1.8 (1.4-2.3)* 1.7 (1.2-2.4)* 2.2 (1.5-3.1)* 1.5 (0.95- 2.3) 1.3 (0.85-2.1) 
Place of residence       
North 1 1 1 1 1 1 
Middle 0.81 (0.63-0.88)* 0.77 (0.65-0.92)* 0.80(0.64-0.99)* 0.82 (0.65-1.1) 0.67 (0.52-0.86)* 0.73 (0.56-0.95)* 
South 1.2 (0.83-1.7) 1.1 (0.65-1.5) 1.3 (0.83-2.1) 1.1 (0.66-1.7) 1.0 (0.57-1.8) 0.98 (0.54-1.8) 
Year of diagnosis 1.1 (0.98-1.3) 1.0 (0.98-1.1) 1.0 (0.98-1.1) 0.99 (.93-1.1) 1.1 (0.98-1.2) 1.1 (0.98-1.2) 
Extent of disease       
Localized 1 1 1 1 1 1 
Regional 2.4 (1.7-3.4) * 2.4 (1.7-3.4)* 3.2 (1.9-5.5)* 3.3 (2.0-5.6)* 1.8 (1.1-2.8)* 1.6 (1.1-2.5)* 
Distant metastasis 8.8 (6.2-12.5) * 8.6 (6.1-12.4)* 13.5 (8.0-22.9)* 14.0 (8.2-23.8)* 5.0 (3.1-8.1)* 4.6 (2.8-7.5)* 
Grade       
Well 1 1 1 1 1 1 
Moderate 1.3 (0.93-1.8) 1.1 (0.78-1.5) 1.9 ( 1.2-3.1)* 1.5 (0.92-2.4) 0.64 (0.40-1.1) 0.65 (0.40-1.1) 
Poor/ anaplastic 1.9 (1.3-2.6)* 1.3 (0.90-1.9) 2.4 (1.4-4.0)* 1.9 (1.1-3.2)* 1.1 (0.69-1.9) 1.0 (0.60-1.7) 
Morphology       
Adenocarcinoma 1 1 1 1 1 1 
Mucinous 1.5 (1.2-1.9)* 1.3 (1.1-1.7)* 1.4 (1.1-1.9)* 1.2 (0.89-1.7) 1.5 (1.2-2.2)* 1.4 (1.1-2.1)* 
Carcinoma, NOS 0.97 (0.68-1.4) 0.70 (0.48-1.1) 1.1 (0.71-1.6) 0.82 (0 .52-1.3) 0.76 (0.35-1.6) 0.51 (0.23-1.1) 
Others 0.89 (0.56-1.4) 0.98 (0.61-1.6) 0.49 (0.22- 1.1) 0.65 (0.28-1.5) 1.4 (0.82-2.5) 1.3 (0.72-2.3) 
Topography       
Colon 1 1     
Rectum 1.1 (0.96-1.3) 1.1 (0.98-1.3)     
* Statistically significant  
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6.5 Summary and Discussion 
This chapter examined and discussed colorectal survival probabilities and their relationship 
to clinical characteristics (i.e. morphology, extent of disease, topography and grade) and 
treatment characteristics (surgery, chemotherapy, and radiotherapy). In addition, these 
probabilities were explored in relation to patients’ socio-demographic characteristics. 
Moreover, this chapter also examined and discussed 30-days postoperative mortality.  
 
Using the Cox logistic regression model procedure, this study revealed that age, place of 
residency, extent of disease, morphology and typography are significant predictors for 
colorectal cancer survival estimates. However, sex, grade and year of diagnosis were 
insignificant predictors.  
 
The existing information from JCR was complete for the variables of age, sex, and place of 
residency. However, data on some variables was incomplete. This study supplemented JCR 
with additional information in order to improve the quality of cancer registry data and its 
completeness. For example, 25% of distance stage, 14% of morphology and 17% of 
disease grade data were completed as a result of additional collection. All information 
related to treatment (surgery, chemotherapy and radiotherapy) came from actively 
collecting new data. However, this study did not bring any improvements to the quality and 
completeness of the data on other information such as level of education, occupation, 
health insurance, smoking status, or marital status. It is important to note that patient 
outcome information was not collected by JCR, and that information on vital status for the 
study population was added to the JCR by this study.  
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Colorectal survival rates and age 
This study, in line with other studies, showed poor survival with advancing age 
(138;140;145;190;247). This could be attributed to poor general health and the difficulties 
in prescribing cancer treatment (such as surgery) and possibly an association with more 
advanced disease stages (248).  A study showed that survival for patients younger than 65 
years improved over time compared with older patients. This improvement was attributed 
to the increase in the use of adjuvant treatment in younger patients as well as tolerance to 
surgery (148). The effect of adjuvant therapy on improving cancer–related survival rates 
was also reported for patients younger than 50 years with rectum cancer. Furthermore, less 
co-morbidity and emergency operations compared with older patients were identified as 
possible factors (143). Analysing the data obtained from Ontario cancer registry, the 
relative odds of early death at 1 year increased by 85 percent in age range 65-69 years 
compared with age range 40-49 years (145). Hazard ratios of death at 1 year for white and 
black patients; registered in the national cancer data base; was increased by 37 percent and 
38 percent respectively in age range 61-64 compared with age 18-49 years (190). In 
Jordan, the high prevalence of non-communicable diseases (especially hypertension and 
diabetes) could be contributing to the poor health of the elderly population (3;4;125). 
 
A worse prognosis of disease in young patients was reported by many researchers (139-
143). Although the differences did not reach significant levels, this study revealed that 
younger age groups between 15 and 44 years generally had lower survival rates at all years 
of diagnosis for colon and rectum compared to patients’ age groups 45-59 and 60-74. This 
was in line with studies (138;150).  Study from China showed that the difference in 
survival rates among patients aged 40 years and younger, and older patients aged more 
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than 40 years was insignificant in a study conducted on 230 colorectal cancer patients 
(140). 
 
Colorectal cancer survival rates and place of residence 
Variations in estimates of cancer survival between geographic locations are well 
documented in the literature (46;159;164;199;236;249-253). This study reported that 
patients living in the central part of Jordan had the highest 5-year observed survival rate for 
colorectal, colon and rectum cancers (at 60.1 percent, 61 percent and 58.5 percent, 
respectively) compared to the northern and southern regions. In Jordan, the central region 
has better health indicators compared to other region (22;46;236). Preventive programs 
such as screening were mostly established in the central region, leaving other regions 
lagging behind in this area. It is worth mentioning that patients from the south and north 
regions prefer coming to the central region to get their treatment. Kaplan-Meier shows that 
survival rates in the first year are almost the same among the three regions. Later though, 
discrepancies among the regions were observed, with the north and south regions showing 
a steady decrease, particularly the southern region (46;236). This finding might be 
attributable to poorer quality of health services in these regions. The association between 
CRC survival rates and place of residence remained statically significant after controlling 
for the effect of potential confounding variables.  
 
This study revealed that patients from peripheral regions were more likely to die from CRC 
than those residing in the central region. Access to treatment services has been shown to 
influence cancer outcome; and high quality and timely treatment can lower the probability 
of early death among patients (46;159;164;199;236;250). Further research to study the 
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influence of spatial (location and distance) and non-spatial determinants (socio-economic 
and cultural factors) on survival differences is highly recommended.  
  
Colorectal cancer survival rates and extent of disease 
Stage of tumour at diagnosis is the most important predictor of survival. Patients' survival 
from CRC was estimated for the different stages of tumour recorded at the time of 
diagnosis. This study showed that more than half of the patients (59 percent) were 
presented with regional metastasis; 22.8 percent with distant metastasis, and only 11.2 
percent with a localized CRC at diagnosis. This is an important result that should be taken 
into account in implementing CRC prevention and control strategies. In line with other 
studies, these findings indicate that survival rates become shorter as the cancer spread 
beyond the origin site. Thus the highest survival rate was found for patients with localized 
tumour and the lowest for the distant tumour stage (11;12;73;137;144;171;174;175). 
Supported by the literature, this result was found independent of patient's race (73;137), 
treatment type (174) and tumour site (175). 
 
The study revealed that at year 5, relative survival rates of CRC cases with localized, 
regional and distant forms were 86.2 percent, 68.6 percent and 24.8 percent, respectively. 
The 5-year survival of colorectal cancer patients were 100 percent for Stage I, 68 percent 
for Stage II, 44 percent for Stage III and 2 percent for Stage IV (176). Others found that the 
5-year survival of colorectal cancer patients were 89 percent for Dukes’ stage A, 75 
percent for Dukes’ stage B, 49 percent for Dukes’ stage C and 12 percent for Dukes’ stage 
D (176). The differences between our results compared to other studies could be attributing 
to medical therapy, surgery type and screening programs and early diagnosis (130;254-
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256).  Moreover, this study revealed that a high percentage of CRC patients (13.8percent) 
were in the young age group (<40 year). CRC in the young patients appears to be more 
aggressive, to present with later stage, and to have poorer pathologic findings (142;146).  
 
Moreover, this study shows that the survival rates for localized and regional colon cancer 
were better than those for rectum cancer in the same stages at 1-, 3- and 5-years of 
diagnosis. Alternatively, the rectum cancer data produced better survival rates than that of 
colon cancer throughout the first five years following diagnosis, which could be attributed 
to the extent of tumour invasion into the colon serosa and other adjacent tissues as this 
produces poorer survival rates of colorectal cancer patients (178). 
 
Mucinous adenocarcinoma 
Mucinous adenocarcinoma is a type of epithelial tumours that is classified by the WHO as 
tumours where the lesion is more than fifty percent composed of mucin (63). In this study, 
mucinous tumour was found to be uncommon, 7.8 percent of all CRC cases. This result 
was comparable to estimates reported by other population studies around the world, for 
example Iran (8.6 percent) (257),  China (7 percent) (257-259). This study also revealed 
that CRC mucinous adenocarcinomas to be predominantly higher among older patients (> 
50 years) which contradicts findings of other researchers (16;257-261). Alternatively, the 
study finding showing equal presence of mucinous adenocarcinoma among male and 
female patients, was similar to some studies (231), but conflicting with others which 
reported predominance among male patients (257;261;262). In addition, the study found 
mucinous adenocarcinomas to be more commonly present in the colon, which is in line 
with findings of several researchers (257-260;262;263). 
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As one of the poorly differentiated CRC tumours, mucinous adenocarcinoma has poor 
prognosis because of being usually presented at a later stage. Although still controversial, 
patients with CRC mucinous adenocarcinomas are reported to have poorer outcome when 
compared to those with non-mucinous adenocarcinoma (259;260;264). Results of this 
study support this notion, where the poorest survival rates among the CRC patients was 
observed among patients with mucinous tumours, (half of the patients died after less than 4 
years from diagnosis). In addition, the five-year relative survival rate for mucinous 
adenocarcinoma of 46.4 percent was almost comparable to other studies (41.3 percent) 
(257), with a lower rate found among mucinous adenocarcinoma of the rectum (42.8 
percent) than among the colon (52.4 percent); which might be due to specific biological 
behaviour of the tumour. Moreover, the study outcome of having mucinous tumors of the 
rectum associated with a higher risk of death than mucinous tumors of the colon is similar 
to findings of other studies (264).  
 
The study also concluded that diagnosis with mucinous carcinoma was a predictive 
variable when calculating the hazard ratio using the cox logistic regression model, where 
patients with mucinous colorectal cancer had 1.5 times higher risk of death than those with 
adenocarcinoma (HR=1.5, 95percent CI: 1.2-1.9). This result might be attributed to the 
later staging of the mucinous adenocarcinomas, where the majority of the mucinous 
cancers in this study were found to be of a moderate grade (61.6 percent) and with a 
regional extent (64.86 percent), thus making mucinous type a significant predictor 
(16;265). 
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In conclusion, mucinous adenocarcinoma is an important factor to consider when treating 
CRC patients. Several studies concluded that mucinous histology to be an independent 
prognostic factor for poor prognosis of patients (16;257;259;266). Although many aspects 
of the mucinous histological type are still controversial, this study suggests that patients 
presented with an advanced grade of colorectal mucinous adenocarcinoma are at a higher 
risk of dying, thus requiring special attention when prescribing the treatment regimen. 
 
Colorectal cancer survival rates and Treatment  
Although information on treatment in our study is relatively incomplete, study findings 
revealed that RS for those CRC patients who underwent surgery to be consistently higher 
than that of patients who did not have surgery. This pattern was observed for colon and 
rectum models alike. The difference between both groups in this model was clearly 
observed over all time periods as well. Moreover, those who underwent emergency surgery 
had a higher risk of death than those who underwent an elective one. In addition, those 
who did not get chemotherapy treatment had a higher risk compared to those who did. On 
the other hand, study results indicated that patients who received radiotherapy had lower 
risk of death during the first year from diagnosis compared to those who received no such 
treatment, and that this relationship reversed subsequently.   
 
Appropriate surgery is recognized as the most important aspect of CRC treatment and as a 
necessary curative treatment modality for CRC (18;77). However, the inclusion of other 
modalities in the treatment of CRC, like chemotherapy and radiotherapy, can reduce the 
probability of disease recurrence (18;108). Albeit having surgery as the backbone for CRC 
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management, the use of adjuvant chemotherapy and radiotherapy to improve survival of 
CRC patients has been on the rise (18;77;111;113;114;267). In Jordan, chemotherapy and 
radiotherapy treatment have been well developed specifically at the tertiary healthcare 
facilities. Moreover, preoperative and postoperative chemotherapy treatment became more 
common treatment for colorectal patients with advanced stages.  
 
Regarding to our result concerning radiotherapy treatment, we believe that such a result is 
an artefact because those who died early were not offered radiotherapy. In addition, 
radiotherapy is rarely included as part of colon cancer treatment, and is a common 
treatment modality for rectum cancer patients. Radiotherapy tends to be given after surgery 
in colon cancer; hence a survivor bias occurs in the observed outcomes. However, 
radiotherapy is given pre-operatively in rectal cancers, the effect of which appears much 
later.  
 
It is worth noting that this study lacked the inclusion of specific information on 
chemotherapy and radiotherapy treatment regimens, such as length of treatment, and 
absence of information about complications during or after primary surgery. Such 
information is not collected by JCR and was not available on patients’ medical records.  
 
The study hazard ratios were calculated using the Cox logistic regression model. Two 
models were examined and presented based on treatment (Model 1 without treatment and 
model 2 with treatment as a predictor). The rationale behind running the cox regression 
model without the treatment variable lies in that treatment variables are considered 
confounders because they are associated with better survival, and that the probability of 
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receiving treatment is dependent on the survival time (i.e. patients have to live longer in 
order to be able to receive treatment). In addition, the reason for receiving treatment can 
play an important role in confounding its effect on the survival rate, thus masking the 
effect of other important predictors. Based on this argument, this study considers Model 1 
as the main predictive model for calculating the hazard ratios when adjusting for important 
variables that are associated with colorectal cancer survival.   
 
Thirty-day postoperative mortality  
Addressing 30-days postoperative mortality can enrich the attempt to understand CRC 
survival and its associated factors or predictors.  This study provides information related to 
the risk of surgical treatment which should enable informed decision-making by clinicians. 
The study indicated that during the study period, 4.8 percent of patients who underwent 
surgery had died within 30 days of surgery. When examining the factors that might have 
influenced the 30-days postoperative mortality, data indicated higher mortality among 
patients who were elderly (over 65 years of age), those with distant tumours and those who 
were operated upon as an emergency.  
 
When compared to other studies, the overall 4.8percent 30-days postoperative mortality 
seen in this study was found to be lower than that of a population-based study done in the 
United Kingdom (6.7 percent) and of another nationwide cohort study conducted within 
the entire Danish population (8.8percent) (268;269). Both the UK and Denmark studies 
supported the results of this study in that the elderly and those having an emergency type 
of operation were found to have higher mortality within 30 days postoperatively. 
Differences in the 30-day postoperative mortality rates between colon and rectum cancer 
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seen in this study, contradicted the results of the population-based studies done in the UK 
and Denmark which reported higher postoperative mortality after 30 days from colon 
cancer surgery than after rectal cancer surgery. Higher postoperative mortality during the 
first 30 day from surgery, for patients with distant tumours found in this study, was 
confirmed by results from the UK study. 
 
The increase in the incidence of CRC in this study and the noticeable decline in the relative 
survival rate among the elderly population, raise a question of whether these results are 
related to greater risk of dying from surgical treatment; especially when considering the 
significantly higher 30-days postoperative mortality rate among this group. Even though 
elderly people might be presented with comorbidities and a generally weaker health status, 
this notion should not pose as a reason for precluding them from surgery. In this arena, a 
study done in the Netherlands to support the decision of surgical treatment in octogenarian 
and nonagenarian patients with cancer reported 30 day postoperative CRC mortality rates 
to increase from 8percent in patients aged 80-84 years, to 13percent in patients aged 85-89 
years and to 20 percent in those over 90 years; thus concluding that surgery resection can 
be performed at an acceptable risk in the elderly with CRC (270). 
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CHAPTER 7 – COLORECTAL CANCER SURVIVAL AND TREATMENT SITES 
 
7.1 Introduction 
There is no evidence that attempts to assess the performance of the health care system in 
Jordan in relation to survival outcome for long treatment cases such as cancer. Despite the 
documented wide health coverage in Jordan, there remains a need to assess differences in 
the responsiveness and function of major health providers in association with treatment 
outcomes for serious and long-term illnesses such as cancer. While public health insurance 
(civil and RMS) is a crucial source of coverage for the majority of Jordanians, the KHCC 
and teaching hospital provide a safety net for many cancer patients across Jordan. 
  
One of the objectives of this study was to examine the usage of treatment sites in 
association with survival probability of colorectal cancer patients by developing Hazard 
Ratios using the Cox Proportional Hazard Model. The study used a national population 
sample obtained from the JCR, which included all Jordanian patients diagnosed with first 
invasive primary colorectal cancer during the period 01 January 2003 through 31 
December 2007. Data on the treatment site was collected by identifying the main source of 
medical services sought by the patient during the course of cancer treatment. Treatment 
sites were mainly categorized according to payment regimens, which is the main factor that 
is usually considered when describing the health care system in Jordan. 
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7.2 Survival probability of colorectal cancer by treatment site  
The Kaplan-Meier method was used to determine the observed cumulative survival 
probability over time by calculating the proportion surviving after being diagnosed with 
colorectal cancer. Five year survival probabilities for colorectal, colon and rectum cancer 
were developed to compare the overall survival probability across the different treatment 
site categories.  
 
Figures 24a, 24b and 24c show that there is a clear grouping between private; KHCC and 
others; and teaching and public. Patients who got treatment at private hospitals had better 
survival outcomes when compared to all the other treatment sites, followed by patients 
who got treatment at KHCC. However patients who received treatment at public or 
teaching hospitals had the lowest survival probability. Further stratification of data by 
cancer location showed that this relationship retained a statistically significant level for 
colon (Log-Rank test, P-value < 0.001) and for rectum (Log-Rank test, P-value < 0.001) 
cancer alike (Figure 24b and 24c).  
Figure 24a: Observed survival probability of colorectal cancer cases by 
treatment site (2003-2007), Jordan 
 
P-value < 0.0001
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Figure 24b: Observed survival probability of colon cancer cases by 
treatment site (2003-2007), Jordan 
 
P-value < 0.0001
Figure 24c: Observed survival probability of rectum cancer cases by 
treatment site (2003-2007), Jordan 
 
P-value < 0.0001 
 
 
7.3 Hazard ratio for colorectal cancer survival and treatment site 
Hazard ratios for colorectal survival by treatment site were calculated using the Cox 
proportional hazard model to adjust for age, extent of disease, place of residence, surgery, 
chemotherapy, radiotherapy and intent of treatment. Results showed that getting treatment 
at KHCC or getting the treatment at one of the private sector hospitals to be significant 
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independent predictors of survival in colorectal cancer. Correspondingly, patients who 
received treatment at KHCC (HR=0.63, 96percent CI: 0.52-0.76) or at private sector 
hospitals (HR=0.40, 96percent CI: 0.31-0.52) had a 37 percent and 60 percent lower risk of 
death compared with those who received the treatment at public sector hospitals (Table 
33). 
 
Table 33: Hazard ratios in colorectal cancer in treatment 
sites adjusted by Cox proportional hazard model 
Site 
Hazard 
ratio 
[95 percent CI) 
Upper limit  Lower limit 
Public 1.00     
Teaching 0.82 .69 1.1 
KHCC 0.63 0.52 0.76 
Private 0.40 0.31 0.52 
Others 0.57 0.42 0.78 
*The model adjusted for age, sex, place of residence, extent of disease, 
grade, and morphology. 
 
Table 34 shows results of cox proportional hazard models for each treatment site 
separately displaying unadjusted and adjusted hazard ratio for CRC patients by each 
treatment site.  The overall unadjusted HRs for the selected variables showed that age, 
place of residence, extent of disease, morphology, and grade as significant predictors to 
CRC survival. However, sex and topography variables did not reach the level of 
significance.    
 
For further exploration of the CRC cancer survival according to treatment sites, Cox 
Proportional Hazard modalities of the effect of selected characteristics on treatment sites 
were examined. In addition to age and sex as constant variables for each adjusted model, 
only significant predictors were included in each adjusted treatment site models (p-value ≤ 
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0.2). The unadjusted HRs indicated that extent of disease were only strong significant 
predictors for CRC survival in all four adjusted treatment sites models. Morphology was a 
significant predictor for public, teaching, and KHCC hospitals but not the private ones. 
Moreover, age was a significant predictor for both public and teaching models only; 
indicating that CRC patients aged 65 year or older were 1.4 and 2 times more likely to die 
at these type of hospitals compared to those aged 65 year or less at each of the hospitals( 
HR=1.4, P-value ≤ 0.001); ( HR=2.0, P-value ≤ 0.001) respectively.  
For the adjusted HR model of private sector treatment site place of residency was a 
statistically significant predictor for CRC, where CRC patient who resided in the southern 
part of the country were 2.5 more likely to die compared to those who reside in the middle 
part of the country (HR=2.5, p-value = 0.012). However; sex and topography were 
insignificant predictors for all four models.  
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Table 34: Cox Proportional Hazard Models for death after colorectal cancer according to the effect of selected characteristics on treatment sites, 
Jordan (2003-2007) 
Variable 
Overall 
Unadjusted HR  
(95percent CI) 
Public hospitals Teaching hospitals KHCC Private hospitals
Unadjusted HR
(P‐value) 
Adjusted HR
(P‐value) 
Unadjusted HR
(P‐value) 
Adjusted HR 
(P‐value) 
Unadjusted HR
(P‐value) 
Adjusted HR
(P‐value) 
Unadjusted HR
(P‐value) 
Adjusted HR 
( P‐value) 
Sex     
Male  1  1  1 1 1 1 1 1 1
Female  0.91(0.79‐1.1)  0.97 (0.809) 1.0 ( 0.780) 0.78 (0.129) 0.92 (0.625)  0.95 (0.774) 1.1 (0.473) 0.93 (0.783) 0.98 ( 0.954) 
Age     
< 65y  1  1  1 1 1 1 1 1 1
>= 65 y  1.3(1.1‐1.5)  1.1 (0.706) 1.4 ( 0.001) 1 .7 (0.001) 2.0 (0.001)  1.3 (0.120) 1.4 (0.080) 0.95 (0.840) 1.2 (0.491)
Place of residence      
Middle   1  1  1 1 1 1 1 1
North/South  1.1(1.0‐1.4)  1.0 (0.756) 1.1 ( 0.176) 1.0 (0.860) 1.3 (0.163) 1.3 (0.195) 3.1 (0.001) 2.5 (0.012)
Extent of disease      
Localized   1  1  1 1 1 1 1 1 1
Regional   2.2 (1.5‐3.1)  1.6 (0.044) 2.2 (0.001) 3.2 (0.022) 3.1 (0.031)  2.6 (0.039) 2.7 (0.030) 4.9 (0.008) 5.6 (0.005)
Distant metastasis   8.4 (5.9‐11.9)  6.1 (0.001) 8.1 (0.001) 11.3 (0.001) 12.7 (0.001)  12.3 (0.001) 13.1 (0.001) 19.4 (0.001) 17.7 (0.001)
Topography      
Colon   1  1  1 1 1 1
Rectum  1.1 (0.92‐1.2)  1.2 (0.097) 1.1 (0.261) 1.2 (0.288) 0.94 (0.689) 0.86 ( 0.616)
Grade     
Well  1  1  1 1 1 1 1 1
Moderate  1.3 (.93‐1.8)  1.4 (0.194) 1.1 (0.561) 1.4 (0.386) 1.2 (0.685)  0.66 (0.296) 2.6 (0.186) 1.9 (0.375)
Poor/ anaplastic  1.9 (1.4‐2.8)  1.9 (0.020) 1.4 (0.095) 1.7 (0.162) 1.3 (0.443)  1.4 (0.391) 4.1 (0.057) 2.6 (0.206)
Morphology      
Adenocarcinoma  1  1  1 1 1 1 1 1
Mucinous  1.4 ( 1.1‐ 1.8)  1.4 (0.096) 1.4 ( 0.013) 1.2 (0.579) 1.3 (0.386)  1.7 (0.030) 1.8 (0.025) 1.5 (0.304)
NOS/others  0.93(0.70‐ 1.2)  0.79 (0.359) 0.77 (0.096) 0.62 (0.003) 0.32 (0.002)  1.3 (0.450) 2.1 (0.045) 0.91 (0.838)
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7.4 Summary and Discussion 
This chapter discussed the findings in relation to treatment site usage, survival probability 
by treatment site and hazard ratios (using the Cox model) associated with treatment sites. 
The study revealed that in terms of treatment sites (i.e. hospitals), 32.4 percent of cases 
were treated at public health facilities; 23.42 percent were treated at KHCC; 18.4 percent 
were treated at teaching hospitals; and 16.82 percent were treated at private health 
facilities. After adjusting for age, extent of disease, place of residence, surgery, 
chemotherapy, radiotherapy and intent of treatment, the Cox proportional hazard model 
showed that getting treatment at KHCC or at one of the private sector hospitals was a 
significant independent predictor of survival in colorectal cancer. Patients who received 
CRC treatment at KHCC or at private sector hospitals had a lower risk of death compared 
with those who received the treatment at public sector hospitals.  
 
In conclusion, survival in public hospitals is less than half that in private hospitals in 
Jordan after adjustment for several main casemix variables.  The public health impacts of 
such differences are very large and the explanations therefore need to be understood. 
 
Health care system 
Jordan’s health care system is a complex amalgam of three major sectors: public, private 
and donors. Patients receive treatment according to their type of health insurance, noting 
that about 79 percent of the population in Jordan is covered by formal civil health 
insurance. Moreover, MOH is the largest health insurer (34 percent) followed by RMS (26 
percent), private firms (9 percent), and university hospitals (1.3 percent) (49). Individuals 
certified as poor, the disabled, children below the age of six years and blood donors, 
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pregnant women and elderly above 60 are also formally treated in the public health sector 
(MOH and RMS). However, private hospitals and non-profit centres cover individuals who 
are able to pay the cost of treatment out of pocket or who have private insurance. 
Colorectal survival is very much dependent on socioeconomic status and differences 
between treatment sites might reflect this as a result of selection bias (62). Moreover, there 
is a belief that hospitals could be more efficiently operated and quality of patient care 
enhanced if autonomy was granted to them (236). In addition, Amman, as the capital, 
attracts the majority of investments, including healthcare; thus, most of the private 
hospitals are mainly located in Amman. 
 
What can be observed is that hospitals (like KHCC) that focus specifically on cancer 
treatment combined with an institutional goal of continuous improvement to quality of 
healthcare might be able to achieve better performance results than public hospitals. 
Results of this study present evidence and hence an opportunity for the public health sector 
to invest in aspects of health-care management, quality and infrastructure in an attempt to 
impact the outcome of cancer. 
 
Jordan was ranked by the World Bank to be the number one health care service provider in 
the region and among the top five in the world, as well as being the top medical tourism 
destination in the Middle East and North Africa  (26). In 2007, total health expenditures – 
both public and private was estimated at 1.016 million JD, or 177.5 JD per capita (253 US 
dollars). This is equivalent to 9.05 percent of GDP which is comparable to figures of some 
developing countries and considered among the highest in the Middle East and North 
Africa (MENA) region. The government share in the financing of health expenditures has 
increased from 43 percent in 1998 to 57 percent in 2008 (46;236).  
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Curative care, in Jordan like many other developing countries, takes up a 
disproportionately large share of public spending on health. During the period 1998-2007, 
the share of curative care increased. Expenditure on curative care was about 79 to 82 
percent of the total state health expenditure, while the proportion spent on primary health 
care was less than 20 percent (23;25;46). Overall spending has increased in nominal terms 
over the past six years and has grown slightly more rapidly than GDP. Nevertheless, 
Jordan's health care spending, whether measured in per capita U.S. dollar terms or as a 
share of GDP, is high compared to other countries of the MENA region and compared to 
other middle-income countries (2). 
 
About 79 percent of the population in Jordan is covered by formal health insurance. In 
addition to its general public health functions, the MOH is responsible for administering 
the CHIP that covers civil servants and their dependents. Individuals certified as poor, the 
disabled, children below the age of six years, and blood donors, pregnant women and the 
elderly (above 60 years of age) are also formally covered under the CHIP. In addition, 
some costly diseases, including cancer and its side effects, are also insured according to 
special regulations determined by the Health Insurance bylaw (46;49) . All of these 
aforementioned factors have contributed to the good survival estimates of colorectal cancer 
in Jordan.  
 
A major influence on quality in healthcare performance (particularly in recent years) has 
been the goal of maintaining Jordan’s competitiveness as a destination in the international 
medical tourism industry. This has had a spillover effect on healthcare performance 
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characteristics, especially in the private sector hospitals that seek to compete 
internationally based on ‘price advantage’ while offering equivalent medical standards and 
patient support services that could be expected in North America and Europe. 
 
After adjusting for age, extent of disease, place of residence, surgery, chemotherapy, 
radiotherapy and intent of treatment, the Cox proportional hazard model showed that 
getting treatment at KHCC or at one of the private sector hospitals was a significant 
independent predictor of survival in colorectal cancer. Patients who received treatment at 
KHCC or at private sector hospitals had a lower risk of death compared with those who 
received the treatment at public sector hospitals.  
 
Aspects of health-care 
Although without a comprehensive assessment of the underlying factors that might be 
related to the disparities in survival of colorectal cancer among types of treatment sites, it 
is possible to set forth explanations or assumptions for the results based on best available 
information. Therefore, the following interpretations are presented to support the variations 
in CRC survival in association with treatment sites presented in this study. 
 
Health-care Management 
In a study that aimed at exploring the different aspects of short and long term CRC survival 
in Denmark, delay for rectum cancer treatment, and emergency post-operative 
complications were reported as strong independent risk factors for death (271). Although 
specific information related to treatment regimens and facility features, provider delay ≥ 60 
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days, hospital delays ≥ 30 days or ≥ 60 days cannot be addressed in the present study, 
some elements related to health-care management can be noted as possible factors that 
might generally influence the outcome of long-term illnesses.  
 
Consequently, private hospitals and KHCC utilize treatment protocols that conform with 
international standards; the public hospitals do not (necessarily) utilize international 
standards. In addition, treatment at KHCC and private hospitals is based on a team 
approach.  For example, KHCC utilizes a team of health providers that is comprised of 
“board certified oncologists, surgeons, radiologists, radiation oncologists, pathologists, 
nurses, and ancillary service providers that work together to treat and follow up every case 
from start to finish” (237).   
 
Not only have the private hospitals and KHCC looked to North American and European 
treatment standards, they have hired medical staff (including not only doctors, but nurses 
and other support staff) with qualifications from western countries (i.e. specifically North 
America and Europe). Moreover, the role of continuing professional education for 
physicians and other staff has also played a strong role in improved performance in the 
private sector and KHCC with access to training that provides the staff with the most up-
to-date methods of treatment.   
 
Recently the private hospitals in Jordan adopted a new team approach in cancer care 
management by establishing multimodality clinics in which a treatment plan is identified 
for each cancer patient where a group of no fewer than three specialists are engaged. Each 
clinic includes a medical oncologist, a surgical oncologist and a radiation oncologist, in 
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addition to other specialized physicians needed for particular treatments. Recognizing that 
prevention is the best medicine, lately three awareness clinics were established: the Diet 
Clinic, the Lifestyle Clinic and the Stop-Smoking Clinic. In addition, screening clinics 
have been established for different types of cancer (colorectal, breast, cervical, prostate, 
testicular, and skin). Moreover, these private hospitals offer psychological counselling, 
patient support, education of families of cancer patients, and after-therapy care in addition 
to the specific cancer treatment.  
 
A culture of Quality 
Quality of care allows different countries to compare performance of their health care 
system (196;272). The literature provides evidence on the relation of quality of care and 
the relative survival of cancer. For example inequalities in access to and receipt of quality 
health care were reported as possible associates to disparities in cancer survival between 
African and White Americans (273).  
 
In Jordan, a strong culture of quality prevails in the healthcare sector with a greater 
emphasis and attention on quality aspects in the private sector. For example, 11 hospitals 
have been accredited by the Joint Commission International (JCI); 12 hospitals have been 
accredited by the Health Care Accreditation Council (HCAC) in cooperation with ISQua; 
five of these hospitals have both accreditations.  In addition, there is a national award for 
quality (the King Abdullah II Award for Excellence) for which both private and public 
hospitals can compete; one of the private hospitals has won the award two years in a row.   
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The influence of accreditation and the possibilities for twinning also enhance the 
performance of an institution. While twinned projects are usually formed between a facility 
in a lesser developed country and one in a more developed region (such as North America 
or Europe), KHCC provides an example of how that dynamic can be reversed: In January 
2011, KHCC “entered a partnership and twinning deal with the Hassan II University 
Hospital in Fes, Morocco, to increase the level of care offered to patients…the 
agreement…involves staff training, capacity building and experience sharing, specifically 
in the segment of quality assurance and hospital accreditation. The Hassan II Hospital is 
initiating the process of securing accreditation as a general hospital from the Joint 
Commission International” (272).  
 
Investment in infrastructure 
Differences in levels of institutional investment contribute to improved performance in the 
private sector compared with the public, as well.  For example: Private hospitals have 
greater availability for appointments and surgeries as they carry an overall lower patient 
load than in the public hospitals. There is less frequent patient follow up in public hospitals 
with longer intervals between appointments; there is also less availability of all diagnostic 
equipment (such as CT scan and MRI) in public hospitals, making patient follow up more 
difficult.  
 
Even such basic requirements as well-maintained patient records systems may be affected 
by whether or not an institution has had the resources to invest in computerization. 
Financial considerations influence the ability of an institution to provide proper 
recordkeeping, but standards of quality and performance contribute, as well. The private 
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hospitals that are accredited have committed themselves to maintaining specific standards 
of process performance that have been proven to be more efficient and robust in a variety 
of treatment sites across the world; simply following those commitments leads to better 
quality of care, as well. 
 
In 2007, KHCC became the first hospital outside the U.S. to be JCI-accredited as a cancer 
centre. During the intervening years, KHCC has introduced more and varied auxillary 
services while continuing to strive for improved process performance. Some examples: 
Thirty-plus professionals providing psychosocial services for inpatients, outpatients, family 
members and healthcare staff; pain management centre for adults based on pain nurse-
anaesthesia supervised concept; a paediatric pain management team that includes a 
paediatric haematologist/oncologist, a general paediatrician and a nurse coordinator; a 
variety of support groups based on various cancer types and follow-up needs; and spiritual 
care for both Moslems and Christians. In addition, KHCC assists Jordanian patients to 
petition the Royal Court for financial assistance when patients do not have insurance or for 
services not covered by insurance. While none of these examples is likely to independently 
influence survival rates, taken altogether they show that private sector hospitals are more 
likely to comprehensively care for cancer patients. 
 
Optimizing insurance coverage 
Although issues related to health insurance coverage are not clinical issues, they are 
important dimensions that need to be considered because they might affect cancer survival 
rates (197;199;201). Consequently, a plausible question that is worth considering when 
exploring the survival discrepancies between the different treatment sites is whether 
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patients are getting maximum potential services from their CHIP and the Health Insurance 
bylaw. In addition, assessing coverage gaps in the CHIP that is provided to the majority of 
the Jordanian population and the type of health provision provided to the elderly and to 
those patients living in more rural areas (particularly in the south of Jordan) are essential 
aspects to note.   
 
Eminently, KHCC offers a variety of payment/financing assistance including, as a last 
resort, advocating on the patient’s behalf for assistance from the Royal Court.  This 
suggests that some Jordanian patients might not have health insurance or that the CHIP 
doesn’t fully cover all areas of care.  In most cases, patients who have no insurance are 
treated at KHCC within a specific programme that assists them in getting financial 
assistance to cover their treatment. 
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CHAPTER 8 – COLORECTAL CANCER SURVIVAL AND DIABETES MELLITUS  
 
8.1 Introduction 
Recently, the International Diabetes Federation (IDF) estimated as many as 183 million 
people worldwide, or half of those who have diabetes, to be unaware of their condition 
(274). In ‘middle income’ MENA countries, the percentage of undiagnosed diabetics 
increases to 61.6 percent of the total number of diabetes cases (274). In the last two 
decades, diagnosed cases of diabetes mellitus in Jordan increased by three folds; from 6.8 
percent in 1996 to 19.5 percent in 2007. Moreover, published figures denote an estimated 
12 percent of Jordan’s population to have impaired fasting glucose (3;125). In addition, 
crude population projection estimates suggest that approximately one to three million 
individuals in Jordan will have diabetes by 2050 depending on changes in disease 
prevalence and the growth of the population (45). 
 
One of the aims of this study was to explore the effect of diabetes mellitus (one of the most 
prevalent comorbidities in Jordan) on colorectal cancer survival among Jordanians. This 
chapter examines the survival probability for colorectal cancer among patients with history 
of diabetes and the different correlates affecting this association.  
 
 
 
 
 217 
8.2 Survival probability of colorectal cancer by diabetes mellitus 
As an important comorbidity, information collected from the medical records of each 
patient on the history status of diabetes was carried out in order to study its relationship 
with colorectal cancer survival. The study population was divided into two groups based 
on the history status of diabetes (diabetic and non-diabetic).  
 
The Kaplan-Meier method was used to determine the observed cumulative survival 
probability over time by calculating the proportion surviving after being diagnosed with 
colorectal cancer. Five year prognostic probabilities for colorectal, colon and rectum 
cancer were developed to compare the survival relationships between patients with 
diabetes and no diabetes. According to hospital medical records, 306 CRC patients were 
detected as diagnosed diabetic patients, which consisted of 16.2 percent of the study 
population.  
 
Table 35 summarizes the baseline characteristics of colon patients categorized according to 
presence of diabetes. Only colon cancer cases are presented because based on the logrank 
test the relationship between colon cancer and diabetes was found significant, and thus 
worth further exploration. Compared to patients without pre-existing diabetes, patients 
with diabetes were significantly older. Significant differences were reported for extent of 
disease and predictors of undergoing surgery between the two groups. However, there were 
no significant differences with regard to sex, morphology, histology grade, chemotherapy 
and radiotherapy.  
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Table 35: Baseline characteristics of patients with colon cancer 
according to diabetic status Jordan, (2003-2007)  
Variable 
Diabetes 
(percent)  
(n= 306) 
No diabetes 
(percent)  
(n= 593) 
P-value  
Sex     
Male  159 (51.9) 239 (56.5) 0.157 
Female  147 (49.3) 184 (43.5)  
Age     
15-44 9 (4.1) 131 (30.9) 0.000 
45-59 72 (32.29) 122 (28.8)  
60-74 109 (48.8) 142 (33.7)  
≥75 33 (14.80)  28 (6.6)  
Extent of disease      
Localized  30 (14.2) 31 (7.7) 0.036 
Regional  133 (62.7) 269 (66.4)  
Distant  49 (23.1) 105 (25.9)  
Morphology     
Adenocarcinoma  188 (85.1) 344 (81.9) 0.249 
Mucinous and serous  14 (6.3) 42 (10.0)  
Neoplasm, NOS  14 (6.3) 19 (4.5)  
Others 6(2.3) 15  (3.6)  
Grade     
Well  13  (6.8) 30 (8.1) 0.304 
Moderate  149 (78.4) 269 (72.5)  
Poor/ anaplastic  28 (14.7) 72 (19.4)  
Surgery     
Yes  158 (70.9) 345 (81.6) 0.002 
No  65 (29.2) 78 (18.4)  
Chemotherapy     
Yes  91 (85.1) 246 (91.4) 0.066 
No  16 (14.9) 23 (8.6)  
Radiotherapy     
Yes  17 (7.6) 44 (10.4) 0.251 
No  206 (92.4) 379 (89.6)  
 
Using Kaplan-Meier survival analysis, the relation between colorectal cancer survival 
estimates and diabetes mellitus patients was explored using the Log-Rank test (Figure 
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25a). It was found that the mean survival for colorectal cancer patients with diabetes 
mellitus was significantly lower than that for patients without diabetes (Log-Rank test, 
p=0.0359). By further stratification, it was found that this relation was statistically 
significant for colon (Log-Rank test, P-value 0.0262) as seen in Figure 25b, but not for 
rectum (Log-Rank test, P-value 0.6337) cancer as shown in Figure 25c. 
 
Figure 25a: Observed survival probability of colorectal cancer cases by diabetes 
mellitus status, (2003-2007), Jordan 
 
(P-value 0.0359) 
Figure 25b: Observed survival probability of colon cancer cases by diabetes 
mellitus status, (2003-2007), Jordan 
 
(P-value 0.0262) 
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Figure 25c: Observed survival probability of rectum cancer cases by diabetes 
mellitus status, (2003-2007), Jordan 
 
(P-value 0.6337) 
 
When examining the extent of the disease, diabetic patients with a regional extent of the 
disease were found to have a significantly lower survival time than non-diabetics (Log-
Rank test, P-value 0.0093) (Figure 26b). No significant differences in survival time were 
found in relation to diabetes when examining localized (Figure 26a) and metastatic extent 
of the disease (Figure 26c). 
 
Figure 26a: Observed survival probability of colon cancer cases by localized extent 
of the disease, (2003-2007) Jordan 
 
(P-value 0.1511) 
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Figure 26b: Observed survival probability of colon cancer cases by regional extent 
of the disease (2003-2007), Jordan 
 
(P-value 0.0093) 
Figure 26c: Observed survival probability of colon cancer cases by metastasis 
extent of the disease (2003-2007), Jordan 
 
(P-value 0.5598) 
 
8.3 Hazard Ratio for colorectal cancer survival and diabetes mellitus 
The status of diabetes was examined in relation to the correlates of age, sex, clinical 
characteristics (e.g. morphology, grade, and extent of disease) and tumour treatment. 
Hazard ratios were calculated using the Cox Logistic regression model for diabetes, sex, 
age, year of diagnosis, extent of disease, morphology, grade, surgery, chemotherapy, and 
radiotherapy. These ratios were first estimated as crude using a univariate analysis to 
identify the potentially important prognostic variables-effect of different predictors on 
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survival rate (e.g. age, sex, stage, site, grade and type of treatment), followed by a 
multivariate analysis to identify the prognostic factors for predicting observed survival for 
colorectal cancer in relation to diabetes. Only significant variables from the univariate 
analysis were included in the multivariate analysis. Table 36 summarizes the univariate 
and multivariate analysis of prognostic factors predicting observed survival.  
 
Diabetes mellitus was identified as a predictor associated with lower observed survival in 
multivariate analysis, where diabetic patients were one and one-half times more likely to 
be at risk of death compared to non-diabetic patients.  Age group 75 years or older, 
regional and distant metastasis of disease were shown to be independent prognostic factors 
for observed survival in multivariate analysis.  
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Table 36: Prognostic factors for observed survival in patients with colon 
cancer and diabetes mellitus (n=899) according to univariate and 
multivariate analysis 
Variable Univariate analysis Multivariate analysis 
 HR 95perc P- HR 95perc P-
Diabetes Mellitus        
No  1  0.0285 1   
Yes  1.3 1.1-1.6  1.5 1.1-1.9 0.011* 
Sex    --------- --------- ---------
Male  1  0.8857 --------- --------- ---------
Female  1.1 .81- 1.3  --------- --------- ---------
Age        
15-44 1  0.0424 1   
45-59 .94 .67-1.3  .92 .63- 1.3 0.688 
60-74 .91 .66- 1.3  .82 .57-1.2 0.328 
≥75 1.6 1.1-2.3  2.1 1.3-3.4 0.002* 
Year of diagnosis  1.03 .94-1.1 0.5662 --------- --------- ---------
Extent of disease     0.0000    
Localized  1   1   
Regional  1.9 1.1-3.5  2.2 1.2-4.2 0.017* 
Distant  8.9 4.9-  11.3 5.7- 0.000* 
Morphology     --------- --------- ---------
Adenocarcinoma  1  0.3264 --------- --------- ---------
Mucinous / serous/ 1.2  .86-1.5  --------- --------- ---------
Grade    0.0062    
Well  1   1   
Moderate  1.8 1.1-3.4  1.6 .88-3.0 0.116 
Poor/ anaplastic  2.5 1.3-4.9  1.4 .76-2.8 0.239 
Surgery        
No 2.1 1.6-2.7 0.0000 .77 .55-1.2 0.122 
Yes   1   1   
Chemotherapy        
No 1.5 .88-1.5 0.0982    
 Yes 1      
Radiotherapy    0.8893    
No  .97 .67- 1.4     
Yes 1      
NOTE: only significant variables in univariate analysis were entered into the 
multivariate analysis 
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8.4 Summary and Discussion 
The relationship between survival from colorectal cancer and diabetes mellitus was 
examined by analysing the data on 306 diabetic patients out of the total study population of 
899. Analysis was done with respect to age, sex, clinical characteristics (e.g. morphology, 
grade, and extent of disease) and tumour treatment. Prognostic probabilities were 
compared with various patient characteristics and clinical characteristics as well.  
 
Diabetes mellitus was identified as a predictor associated with lower observed survival 
time for colon cancer in multivariate analysis, where diabetic patients were one and one-
half times more likely to be at risk of death compared to non-diabetic patients. In addition 
to diabetes, being 75 years of age or older and/or having regional and distant metastasis of 
disease were shown in multivariate analysis to be independent prognostic factors for 
observed survival. 
 
The study results for Jordan were not very different from those of other countries (187-
189; 191; 192; 194).  However, due to the anticipated increase of the diabetic population 
over the next few decades, the need to examine the association between diabetes and CRC 
survival in light of other predictors poses as a priority area that needs to be addressed in the 
future. 
 
The positive association observed in this study was consistent with similar studies done in 
other countries (116-119; 122). However, there is insufficient evidence to largely support 
the association between diabetes and colon cancer survival probability in Jordan. 
Additional follow up and larger scale studies need to be implemented in Jordan in order to 
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depict the association of diabetes with the prognostic probability of colon cancer. Such 
studies present a priority in light of the escalating prevalence of diabetes in Jordan. 
 
It is expected that Jordan’s undiagnosed diabetic population is as numerous as the 
diagnosed group. In other words, for each new case of colorectal cancer, there is a strong 
possibility that the patient already has diabetes. Detection and treatment protocols urgently 
need to be adjusted for this potential reality. 
 
Although the literature strongly supports the association between diabetes and an increased 
risk of colorectal cancer (116-119; 122; 187-189; 191; 192; 194), such evidence remains 
non-existent in the Eastern Mediterranean Region, including in Jordan. Therefore, this 
study comes as one of the first attempts to explore the relationship between diabetes and 
the prognostic survival of colorectal cancer in Jordan, where results showed a lower 5-year 
survival probability for colorectal cancer patients who have diabetes than for non-diabetics 
(Log-Rank test, p=0.0359).  
 
These findings are consistent with results of a study done in China where diabetic patients 
were found to have significantly lower 5-year survival rate when compared to the non-
diabetics (275). Similarly, several meta-analysis reports support the notion that diabetes is 
positively associated with increased colorectal cancer outcome and mortality (116-
118;121;123;276-278). The findings are also uniform with the results of a recent large 
population-based controlled cohort study done in Taiwan on a total of 37,001 diabetic 
patients and 148,004 controls, where diabetes was reported to increase the risk of 
colorectal cancer (279).  
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A focus on colon cancer 
Even though studies investigating the association of diabetes and the outcome of colon 
cancer are not available in Jordan, global evidence on the prognostic survival (outcome) of 
colon cancer in association with diabetes remains controversial, especially when 
examining the relationship between diabetes and the outcome in relation to the extent of 
disease and other important independent predictors.  
 
Results of the stratified analysis for colorectal cancer data and diabetes in this study 
revealed a statistically significant association between diabetes and prognostic survival of 
colon cancer (Log-Rank test, p=0.0262) compared to non-diabetics. Cox multivariate 
regression analysis showed that diabetic patients with colon cancer have one and one-half 
times the likelihood of mortality than non-diabetic patients. These findings suggested a 
decreased 5-year survival risk among diabetic patients with colon cancer (HR=1.5, 95% 
CI: 1.1-1.9) in Jordan, which were found to be consistent with results of a studies done in 
Taiwan and China, which  reported a negative prognostic impact of diabetes on the overall 
survival in patients with colon cancer (120;122).  
 
Age and extent of disease as main predictors to colon cancer 
The present results are also in agreement with the findings of a large prospective multi-
ethnic cohort study done in Los Angeles County on a five racial/ethnic populations 
(European, American, African American, Native Hawaiians, Japanese Americans and 
Latinos). The study reported diabetes as a significant factor associated with colorectal 
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cancer in all ethnic groups except among Native Hawaiians and African Americans with a 
significantly increased risk for colon cancer compared to a non-significant overall positive 
association for rectum cancer (280). 
 
The results of this study are also supported by results of a cohort study of 256,036 diabetic 
patients done in Taiwan to study the age and sex-specific mortality rates in diabetic 
patients and their mortality rate ratios compared to the general population. The study 
reported a significantly higher risk of mortality from colon cancer for the diabetic patients 
compared to the general population, with the magnitude increasing with the decrease of 
age (281). Results of the multivariate Cox Regression for this study found that the risk of 
predicting survival among diabetic patients to be higher among patients who were 75 years 
or older (HR=2.1, 96% CI = 1.3-3.4), and/or having regional (HR=2.2, 96% CI = 1.2-4.2) 
or distant (HR=11.3, 96% CI = 5.7-22.3) metastasis of the disease. Among the few studies 
that were found to investigate similar associations was a retrospective multi-ethnic cohort 
study which reported significant increases in the risk of both regional and distant cancer 
with no differences between males and females (280).  
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CHAPTER 9 – SUMMARY AND RECOMMENDATION 
 
This section includes is the major hub of this study because it explores study implications 
for practice as well as recommendations for further research in the area of colorectal 
cancer. Recommendations presented in this chapter are mainly built around the results of 
this study.  
 
9.1 Study overview  
CRC is a common form of cancer that is receiving great interest especially when it comes 
to identifying its associated risk factors. The literature provides supporting evidence for the 
need to concentrate on treatment and early recognition of CRC in order to improve its 
overall survival. Improved population coverage by preventive programmes, such as 
organized screening programmes, can result in a decrease or even stabilization in CRC 
incidence rate. This study provides evidence that can benefit CRC mortality in Jordan, 
while taking into consideration other variables of interests, such as socio-demographic, 
clinical and treatment characteristics and diabetes mellitus as an important comorbidity. 
 
This study is a population-based survival study of colorectal cancer in Jordan. The study 
population consisted of 1,896 patients diagnosed during the period 2003 through 2007. The 
study aimed to: 1) produce estimates of observed and relative survivals for Jordanian CRC 
patients; 2) compare colorectal cancer survival among Jordanian patients with other 
comparable countries; and 3) explain possible differences. The study investigated the 
possible effects of socio-demographic patient status, the clinical manifestations and 
treatment of the tumour on survival of CRC in Jordan.  
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The study was carried out at the national level by investigating data from the JCR, Jordan 
CRB, hospitals and laboratories - both governmental and non-governmental sectors in 
Jordan. The sample consisted of all Jordanian CRC patients (aged 15 years and above) who 
were diagnosed with invasive primary CRC (C18-C20.9) during the period of 01 January 
2003 through 31 December 2007 and registered in the JCR with verified histopathology 
report. To the best of the investigator’s knowledge, this study represents the first attempt to 
examine and study colorectal cancer survival data of the Jordanian population. 
 
9.2 Addressing the research questions 
The study focused on six research questions introduced in Section 1.4.1 as the following: 
RQ1: What are the observed and relative 5-year survival rates of colorectal cancer among 
Jordanian patients diagnosed in 2003-2007?  
RQ2: Do survival rates from colorectal cancer differ between Jordan and other 
comparable countries, and if so, how can this be explained? 
RQ3: Do socio-demographic characteristics (e.g. age, sex, and place of residency) affect 
the survival rate of colorectal cancer in Jordan? 
RQ4: Do the patient clinical manifestations (site, histopathology, grade, stage) and 
treatment of the tumour affect the survival rate of colorectal cancer in Jordan? 
RQ5: Are there differences of colorectal cancer survival estimates across treatment sites 
within Jordan and how could they be explained?   
RQ6: Does diabetes mellitus affect the survival of colorectal cancer among Jordanian 
patients?  
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Answers to the research questions are presented and discussed in the summary of the main 
findings under chapters 4 through 9 of this document. 
 
9.3 Summary of the main findings  
The study consisted of a total of 1,896 study participants with 62.4 percent of colon cancer 
and 37.6 percent of rectum cancer cases. While half of the sample (50.5 percent) was aged 
60 years and above, 55.5 percent were males and 75.9 percent was living in the central 
region of Jordan. By the end of the five year study period, 40.3 percent of the study 
participants had died with more deaths occurring among the male population 442 (57.9 
percent). 
 
Incidence rates were calculated using data from newly diagnosed CRC patients aged 15 
years through 74 years (1,704 cases). The 5-year overall crude CRC incidence rate was 5.6 
per 100,000 males and 5.1 per 100,000 females. Further examination of the crude 
incidence rates revealed higher colon and rectum cancer incidence rates among males 
(colon cancer: 5.4 per 100,000 males and 4.1 per 100,000 females, rectum cancer: 3.0 per 
100.1000 males and 2.4 per 100,000 females). The overall colorectal ASR was higher 
among males with a male/female ratio of 1.2:1 (15.5 per 100,000 males and 12.5 per 
100,000 females).  
 
The 5-year observed and relative survival rates of colorectal cancer were 57.7 percent, and 
61.3 percent respectively. The 5-year observed survival rates for colon and rectum cancers 
were 59.1 percent and 55.4 percent respectively, the corresponding relative survival rates 
were 63.2 percent and 58.3 percent respectively. The age-standardized relative survival 
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rate for the overall cases of colorectal cancer at 5 years of diagnosis was 58.1 percent. It 
was slightly better for rectum (59.2 percent) compared with (57.8 percent) colon.  
 
This study revealed that age, place of residence, extent of disease, and morphology had 
significant effects on the colorectal cancer survival estimates: the oldest age group had 
worse survival estimates compared with the younger age groups; the highest survival 
estimates were obtained for patients living in the middle of the country compared with 
those living in the north and the south; and poorer survival rates are associated with distant 
and regional tumours compared with localized tumours. 
 
Survival was significantly higher for patients who underwent surgery than for those 
patients who did not. Although not of significant value, patients who received 
chemotherapy treatment had better survival for almost the first four years; later, though, 
patients who didn’t receive chemotherapy treatment had better survival. Similarly, colon 
cancer patients who received chemotherapy treatment had better survival rates for nearly 
four years afterward; but beyond that time, those patients who didn’t receive chemotherapy 
treatment had a slightly better survival.  Alternatively, rectum cancer patients who received 
chemotherapy had better survival rates for the first two years; but after that time those 
patients who didn’t receive chemotherapy had higher survival rates.  
 
In terms of treatment sites (hospitals), results showed that 32.4 percent of cases were 
treated at public health facilities, 23.4 percent at King Hussein Cancer Center (KHCC), 
18.4 percent at the teaching hospitals, 16.8 percent at the private health facilities, and only 
9.1 percent at other sites. The results of Cox proportional hazards ratios, after adjusting for 
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age, sex, place of residence, extent of disease, topography, morphology, and grade have 
shown that patients who received treatment in private hospitals as well as in the King 
Hussein Cancer Center, had better survival rates compared with those who received their 
treatment in the public sector. 
 
Finally, this study revealed a significant relationship between diabetes mellitus and colon 
cancer survival; diabetic patients with colon cancer were less likely to survive compared to 
non-diabetic patients with colon cancer. However, no significant association was observed 
regarding diabetic patients with rectum cancer. On the other hand, this study did not report 
significant relationships between CRC and sex, topography, grade and radiotherapy 
treatment. 
 
9.4 Strengths and limitations 
As with any other research, this study comes with strengths and limitations that need to be 
set forth in order to provide an advantage to other investigators.  
 
9.4.1 Strengths and challenges 
The following list of strengths is presented to optimize the study results and project the 
main advantages believed to prompt prominence to benefiting from the survival analysis of 
colorectal cancer undertaken in this study.  
 
– Study significance: Results of this study hold important significance because it is the 
first colorectal cancer survival study done to estimate survival rates among colorectal 
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cancer patients in Jordan and compare these estimates with similar ones in other 
populations. The study instrument was designed to gather information on socio-
demographic characteristics, clinical and histo-pathological information, treatment, co-
morbidities and information about patients’ vital status. Therefore the study holds 
prominence because it allowed for examining the relationship between colorectal 
cancer survival estimates and various potential predictors. 
 
– Study methodology: The study was carried out at the national level using a relatively 
large sample (1,896) that allowed examination of subgroups among the Jordanian 
population. In addition to using the routine JCR population-based data base, active 
strategies were utilized for collecting more clinical information on treatment, and 
diabetes mellitus as an example of co-morbidity and the site of receiving health care 
services, thus enabling review of hospital records and pathological laboratory reports at 
the national level. Furthermore, the five year study period is relatively a suitable follow 
up period that allowed for the detection of any plausible survival trends in the 
population of interest. 
 
– Statistical analysis: In this study, advanced statistical principles were employed along 
with advanced methods and applications of cancer survival using population-based 
data. The investigator took into account several statistical methodological issues in 
order to minimize bias and allow for comparisons when interpreting survival functions. 
More explicitly, the investigator used different statistical methods, such as calculating 
relative survival rates, age standardized survival rates and Cox ratios in order to control 
for variables that might have had an effect on the survival rates. This allowed for the 
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control of confounding variables thus allowing for causal inference to ascertain that the 
observed differences in survival were of a real causal effect rather than due to 
differences in the nature of the groups that were being compared. Moreover, special 
precautions were taken into account when interpreting survival data by referring to the 
particular statistical method that was used. 
 
– Case ascertainment: Using the JCR data base for case ascertainment/recruitment 
allowed for a nearly comprehensive inclusion of patients diagnosed with colorectal 
cancer during the five year study period in Jordan. Furthermore, verified by 
histopathology reports, the JCR was used to ascertain cases that had colon or rectum 
cancer as the primary diagnosis of cancer. Matching the national ID number of 
recruited cases to vital records mortality information at the Civil Registration Bureau 
data base enabled accurate and complete ascertaining of death information due to the 
reliability and completeness of vital recording at the Bureau.  In addition, actively 
collecting information from medical records and pathological laboratory reports at 
hospitals was an appropriate  strategy utilized to compensate for missing clinical 
information at the JCR (such as the site, stage and grade of the cancer). In many 
hospitals the data related to patient treatment was available and medical records were 
found to be good resources to complete the missing information gap at the JCR.   
 
9.4.2 Limitations 
The following list of limitations is presented in order to outline confinements and 
constraints for other researchers who are keen at undertaking similar studies. The list 
includes bias that might have influenced the estimates, and hence the validity of 
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comparisons among groups. These limitations are by no means exhaustive and are 
presented in order of importance. 
– Complete Approach for estimating survival: In this study, the estimate of patient 
survival was made using the complete approach. This approach allows for inclusion of 
all patients in the study period (2003-2007).  Besides including patients diagnosed 
more than five years ago the approach also allows for including recently diagnosed 
patients, even though they were not followed for five years. Although the complete 
approach is more up-to date than the cohort approach estimates, it remains subject to 
influence by survival estimates of patients who were diagnosed in the preceding years. 
In particular, it usually underestimates the relative survival ratio (213;214;241). 
 
– Record keeping: Jordan, as many other developing countries, still suffers from 
inadequate clinical follow-up systems in hospitals and an absence of computerized 
patient records’ systems. Most of the hospitals do not apply ICD coding; data is not 
standardized and most of the time hospitals do not provide timely patient discharge 
summaries. For example, during the data collection phase, it was noted that the 
hospitals and pathology laboratories collect the stage of the colorectal cancer 
information using Duke’s or TNM systems; however the JCR uses the SEER Summary 
Staging approach. In addition, most of the hospitals do not have written policies and 
procedures for medical records upkeep, and do not conduct periodic quality reviews for 
accuracy and completeness of information. Even though, reviewing individual medical 
records was very beneficial to figure out the type of treatment the patient received as 
well as to fill the gap of missing information from the JCR, the quality of recording and 
maintaining updated information was found to be inadequate. Moreover, using 
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routinely collected data such as that of the JCR introduces an error effect especially 
when data quality monitoring measures are lacking.  
 
– Death certificate registration: The proportion with microscopic verification, autopsy 
diagnosis, or of those dying within one month of diagnosis could be factors that 
influence the survival estimates, thus affecting the external validity of regional and 
international comparisons (242). This study addressed some points regarding quality of 
data as important limitations. For example, the total number of CRC cases reported to 
the JCR during the study period was 1,896 of which 99.1 percent was microscopically 
verified, which is considered a good indicator of quality (58;243). By restricting the 
sample and excluding patients with no histology, survival will be higher than if all 
patients were included, however, due to the very small proportion of patients with no 
histopathology reports (<1%) this type of bias is unlikely to have had a significant 
effect on the results. In addition, more than one-third (37 percent) of the colorectal 
cases were coded as “Colon, NOS”.  While this issue affects the specificity of the data, 
it does not affect the overall incidence of CRC (65). However, non-usage of additional 
sources of information e.g. death certificates limits the completeness of data at the JCR. 
In 2003, the Jordan Ministry of Health updated its death certificate according to 
international standards. The improving of quality of death certificate and increasing the 
coverage and utilization of medical death certificates allows mortality statistics to be 
used with greater confidence for causes of death. However even mandatory death 
certification requires basic additional information to enable verification of the causes of 
death statistics with other sources. Recently, the JCR started using death certificates as 
a reliable source of information.   
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– Incomplete ascertainment of cases (incidence) and incomplete ascertainment of death 
in registered cancer patients are factors that may cause bias in comparative survival 
estimates (244). In this study Cancer registration in Jordan only started in 1996 and, as 
with any newly established registry, there were some difficulties in ascertaining all 
cases and gathering all the required information as well as in coding and validation 
procedures. Completeness and reliability are important components to assess the 
quality of cancer registries (245;246). External assessors assessed completeness and 
reliability of the JCR data in 1998 where registrations at the JCR were determined to be 
88 percent complete. Such a completeness rate is considered good for a newly establish 
registry (57). Moreover, In Jordan, the reporting of incident cancer cases is obligatory 
by law, and it is obligatory to get treatment, thus incomplete ascertainment of incidence 
cases (incidence) is probably to be relatively limited. Regarding to ascertainment of 
death in registered cancer patients, we actively followed up with CRB to ascertain the 
vital status of the patients. CRB, a part of the Ministry of Interior in Jordan, has very 
advanced civil registration system. As a result, such type of bias may still exist in this 
study, but with a minor effect on our survival estimates.  
 
– Completeness of data: The validity and strength of the incidence data affects the 
survival inferences in the study. Hypothetically, JCR should have on record, 
documentation of all diagnosed colorectal cancer cases in Jordan. However, because 
the JCR is  a fairly new entity (established in 1996), and as with any newly established 
registry, there are predominant difficulties in ascertaining all cases and gathering all the 
required information as well as in coding and validation procedures.  Although the JCR 
collects data on CRC from all related health facilities (i.e. Ministry of Health, the 
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Royal Medical Services, universities and private as well as public-sector pathology 
laboratories) using active and passive methods of case finding, so far the registry 
collects only the basic information of the patients (i.e. four digit name, sex, age, ID, 
nationality, stage, morphology, topography, behaviour, site of treatment and place of 
residency). However, other information such as level of education, occupation, health 
insurance, smoking status, treatment, marital status and patient outcome are not 
collected.  
 
Moreover, the researcher was able to collect information only about diabetes mellitus, 
because absence of information related to other comorbidities was incomplete. In 
addition, information about other comorbidity risk factors e.g. smoking, obesity, 
hypertension, and physical inactivity and other factors were not collected by JCR and it 
was not available in patients’ medical records. These comorbidities factors are 
associated with poorer survival (187;189;191;192;282), and lack of information about 
them poses as a limitation to the study. 
The association between colorectal cancer and diabetes remains of a complex nature 
when considering the variety of variables and predictors that might affect such an 
association. Other comorbidities such as hypertension and cardiovascular disease are 
among such leading variables. In addition, factors affecting the progress and control of 
diabetes might be important predictors that need to be controlled when examining the 
association of diabetes with cancer survival. Not including some of these factors in this 
study should be noted as a study limitation, especially given that some of these factors 
are mentioned in the literature, such as: quality of diabetic care, type of diabetic 
treatment, duration of diabetes.  
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Other comorbidities, such as cholesterol, hypertension or cardiovascular diseases, 
might also significantly affect the mortality from colorectal cancer 
(161;162;171;172;186-192). In addition, behavioural risk factors affecting diabetes and 
cancer, such as smoking and obesity, ought to be considered when examining the 
association under study. In summary, this study did not control all causes that might be 
associated with mortality, for which we offer a recommendation to undertake a more 
comprehensive study in the future to help ascertain the association between diabetes 
and prognostic probability of CRC. 
 
– A multifaceted research problem: CRC is a multifaceted health problem with a wide 
range of risk factors that ought to be considered when determining the hazard risk. 
Such an assumption maximizes the need to combine information that can possibly add 
value to the current focus of the study, such as: behaviour, lifestyle, social support and 
other pertinent risk factors. In addition, examining the association of treatment site and 
survival of colorectal cancer does not come free of limitations. The most important 
limitation lies in the information collected on the different treatment sites from the 
patients’ perspective. Responsiveness of the health care system in terms of patient 
satisfaction, trust and acceptance of treatment are important elements that were not 
addressed in this study. In addition, including health-care management aspects and 
focusing on health insurance of patients are major areas that could have added value to 
the results. 
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– Survival differences: Although the study used the log rank test and the cox proportional 
hazard regression analysis to examine factors that affect survival differences, several 
factors can affect these differences especially if they are related to issues beyond the 
control of the study design. For example, adjusting for the rate of disease progression 
of cancer in this study was limited by the type of study design because the progression 
depends on the length of time of the preclinical phase, usually referred to as length 
bias. Similarly, the lead time bias which is the effect of early detection of cancer on 
survival could have influenced the association between treatment and survival and 
should have therefore been controlled for when examining the association between 
cancer survival and type of treatment. Subsequently, including the stage of disease and 
year of diagnosis as predictors in this study was insufficient to control for such bias. 
Colorectal cancer survival is determined by socio-economic status and the socio-
economic selection biases of different hospitals (e.g. those that only accept patients 
who can pay directly or who are privately insured) may explain the observed 
differences in outcomes between hospitals.   
 
9.5 Recommendations 
As the first colorectal cancer survival study in Jordan, this study brings interesting and 
important findings that should serve as a call for action to policymakers and program 
planners in Jordan. The main findings worth noting include: 1) high incidence of colorectal 
cancer in younger patients, 2) poorer survival in younger patients, 3) very large variations 
in survival between hospitals and 4) large effect of diabetes mellitus on survival – which, 
given the high prevalence of 19 percent, has very large implications for public health. 
Therefore, these results provide a foundation of evidence and an essential element for 
raising public awareness, advocacy and improving health care service delivery. Continued 
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monitoring and evaluation of the colorectal survival estimates is a vital component to 
developing future targeted and effective programs and policies in Jordan.  In addition, 
expanding the establishment of the estimates of survival among Jordanian patients with 
other types of cancers in Jordan is highly recommended.  
 
Due to the scarcity of colorectal cancer survival estimates from the Eastern Mediterranean 
countries, and the availability of only a few studies in less developed countries, this study 
can serve as a model for the region to assist other countries to ascertain national colorectal 
cancer survival estimates as well as survival estimates for other types of cancers.  
 
Results of this study prompted a set of recommendations to assist national efforts in 
preventing and controlling colorectal cancer. Attempts were made to extend 
recommendations that are applicable to countries of similar nature to Jordan. The 
recommendations presented herewith were grouped alongside core areas that are necessary 
for advancing national strategies and actions in the combat against the burden of colorectal 
cancer. 
 
9.5.1 Strengthen health service provision 
Mandate early detection programs especially in the older adult population. The study, 
in line with other studies, showed poor survival with advancing age; people aged 75 years 
and above had approximately a two-times higher risk of death than those aged 44 years or 
less. This could be attributed to poor general health for CRC patients and the difficulties in 
prescribing cancer treatment (such as surgery) and possibly an association with more 
advanced disease stages. Specifically for Jordan, the high prevalence of non-communicable 
diseases like hypertension, cardiovascular diseases and diabetes could be contributing to 
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the poor health of the elderly population. Health care professionals should be encouraged 
to pay special attention and focus on older patients.  
 
On the other hand, screening programmes are considered to be the cornerstone of 
prevention for colorectal cancer. However, due to the limited available financial resources 
allocated to health care, caution should be exercised toward other considerations in the 
control of the low risk of CRC in Jordan as a country with low financial resources 
compared with the developed countries.  In addition, this study revealed that 14 percent of 
the CRC among patients aged 40 years or less. In the event of implementing screening 
activities, age at diagnosis of CRC should be taken into consideration. In light of this 
finding, this study recommends further investigation to investigate CRC among the middle 
aged Jordanian population in order to attest the need to introduce screening at a younger 
age whenever possible.  
 
Develop appropriate protocols and clinical practice guidelines for the management of 
colorectal cancer. This study revealed that there is statistically significant difference in 
CRC survival estimates in relation to treatment sites, where patients who received CRC 
treatment at private sector hospitals and King Hussein Cancer Center had lower risk of 
dying compared to those who received treatment at public sector hospitals. This result calls 
for an urgent action to adopt measures that can resolve any discrepancies in the survival 
estimates across various local treatment sites. Treatment protocols should be unified and 
developed to conform with international standards and the multidisciplinary Team 
Approach to Healthcare. These treatment protocols and strategies should be applied 
uniformly to allow for the provision of effective and efficient care to CRC patients across 
Jordan.  
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In addition, bringing qualified staff to the public sector health facilities should be taken 
into consideration as well as the provision of continuing professional education to 
physicians and other staff. The study also recommends evaluating the affordability and 
accessibility of diagnostic equipment and procedures at public hospitals and making 
essential upgrades for improving the quality of care. In addition, the study recommends 
pursuing accreditation of public service hospitals as an opportunity for improving the 
quality of services, with a proposition to consider twinning of cancer services across 
hospitals in order to enhance performance across Jordan. Therefore, the study recommends 
introducing managed clinical networks as an approach for reducing the variation in 
survival between the different hospitals as a worthwhile suggestion to be considered. 
 
Develop and endorse national guidelines for effective colorectal cancer management 
in diabetic patients. The researcher believes that this is the first study from the region to 
examine the relationship of colorectal cancer and diabetes. Furthermore, based on the in 
depth literature review, the researcher did not find any peer reviewed articles that address 
the relationship between CRC and diabetes mellitus in Jordan nor in any other countries 
where diabetes is known to be highly prevalent. The high prevalence of diabetes mellitus 
in Jordan and the significant relationship between colon cancer survival estimates and 
diabetes mellitus that was detected in this study, call for intensifying efforts to promote 
measures that can improve and advance the management of diabetes in CRC patients. 
Therefore, program planners should consider developing and adopting guidelines for 
effective management of diabetes in the presence of CRC cancer. The study stresses the 
need to intensify public health efforts in preventing and controlling diabetes. This together 
with conducting further research to investigate the increased mortality among diabetic 
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CRC patients are worthwhile recommendations to be considered by health planners and 
policy makers.   
 
Due to the limited local financial resources and the tremendous impact of cancer on public 
health in light of the escalating health care cost, strategies for prevention and control are 
becoming increasingly more important. Consequently, raising awareness of CRC risk 
factors, symptoms and early warning signs in the general population could help reduce 
incidence, ensure earlier detection and thus improve survival rates. Adopting a policy for 
introducing community programs to raise public awareness regarding the early warning 
signs of CRC as a primary prevention strategy is highly recommend. Therefore, the study 
recommends for policymakers and researchers the need to explore more fully the viability 
of establishing a CRC screening programme and to adapt the CRC national screening 
guidelines according the country’s needs.  
 
9.5.2 Assure provision of health care by expanding services 
Expand cancer treatment sites beyond the central region of Jordan. The survival rates 
in the central region of the country were found to be higher than those in the north and 
south. Patients who resided in the central region of Jordan had a 27 percent lower risk of 
death compared with those who resided in the north. This could be attributed to the 
concentrated development plans targeting the centre of the country since the establishment 
of Jordan. Infrastructure and healthcare have significantly improved in this region 
compared to those services offered in the north and south.  However, one of the 
contributing factors that should be considered is the widespread existence of the private 
sector hospitals and treatment sites in the central region as well as the centralized 
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government structure in Jordan. Accessibility, affordability and quality of health services 
across the regions of Jordan should be addressed. Furthermore, socio-demographic 
potential predictors of the colorectal cancer survival estimates should be also examined. 
Finally, the on-going development of health services implemented in the northern and 
southern regions of the country should be monitored to identify gaps and areas of 
improvement. Further research to study the influence of spatial (location and distance) and 
non-spatial determinants (socio-economic and cultural factors) on survival differences is 
highly recommended. 
 
9.5.3 Improve monitoring by promoting policy and research 
Conduct studies to examine the role of lifestyle habits in colorectal cancer. Jordan is 
experiencing demographic and epidemiological transitions where the life expectancy is 
increasing and infectious diseases are declining and chronic diseases, such as cancer, are 
becoming more predominant. Sedentary lifestyle, high fat diet, obesity, physical inactivity 
and smoking are becoming common in Jordan.  Therefore, it seems reasonable to 
hypothesize that the incidence of colorectal cancers in Jordan is likely to increase steeply 
in the next coming years in light of the expected increase in these modifiable risk factors. 
In addition, this study showed that the overall Age Standardized Rate for CRC to be 15.5 
per 100 000 males and 12.5 per 100 000 females, which is considered low compared to 
developed countries but yet similar to CRC incidence rates in other countries in the region.  
However, colon cancer in the Jordanian population is one of the highest in comparison to 
the various regional countries for both sexes; while at the same time, rectum cancer was 
one of the highest among females. These variations could be attributed to differences in 
food and lifestyle habits within the region. Therefore, this study recommends undertaking 
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epidemiological analytical studies to further investigate the role of different lifestyle 
attributes on colorectal cancer survival. In addition, the study recommends conducting 
further studies to better understand the differences in incidence among different 
neighboring countries in the Eastern Mediterranean region. 
 
Conduct studies to explore the age and sex differences in colorectal cancer. This study 
was found to be in line with other studies from the region where a large proportion (13.8 
percent) of diagnosed colorectal cancers cases occurred in patients who were aged 40 years 
and less. However, in the developed countries, only 2 to 8 percent of the colorectal cancers 
occur in young people. Although this might be due to the high percentage of young 
population in Jordan, it can also suggest a lower recording of cases among the elderly. 
Moreover, age specific rates among patients in Jordan for individuals aged 65 years or less 
were found to be more pronounced when compared to developed countries. Nevertheless, 
being ‘affected at an early age’ is a significant group characteristic and is an important 
result that should be taken into account in implementing CRC prevention and control 
strategies. As a result there is an urgent need to better understand the local CRC burden by 
conducting further studies to explore the age differences and causality for high occurrence 
of colorectal cancer among the young age groups (i.e. less than 40 years of age). Such 
studies can provide an explanation as to why the disease occurs at such early ages in 
Jordan.  
 
Implement research studies to investigate the relationship between diabetes and 
colorectal cancer. Although the relationship between colorectal survival and diabetes 
mellitus is still not well established in the literature, this study provided an added value to 
the available works in this field. Nevertheless, further clinical studies are needed to 
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investigate whether diabetes mellitus influences the outcome of CRC as well as investigate 
the possible association between CRC survival and the level of diabetes control. Although 
this study mainly detected a relationship between cancer survival and diabetes in patients 
with a regional extent of colorectal cancer, undertaking clinical studies to ascertain the 
underlying mechanism(s) that affect cancer survival in diabetic patients is needed. Further 
investigation of the role of co-morbidities and their risk factors, such as obesity, on CRC 
survival can play an important role in identifying prevention and treatment strategies.  
 
Promote decision-finding evidence in public health policy leaders. The findings from 
this study indicated that survival rates were reduced as the cancer spread beyond its site of 
origin; the highest survival rate was found for patients with localized tumour stage and the 
lowest for those with distant tumour stage. In addition, the study results showed that more 
than half of the patients had regional metastasis at the time of diagnosis, 22.8 percent had 
distant metastasis and only 11.2 percent had localized CRC at diagnosis.  
 
Having overall good survival estimates of CRC with such advanced stage descriptions at 
the time of diagnosis could be attributed to the advanced curative care in Jordan. Curative 
care takes up a disproportionately large share of public spending on health (about 79 to 82 
percent of the total state health expenditure, while the proportion spent on primary health 
care is below 20 percent).   
 
Moreover, the study showed that treatment was better in some sectors (i.e. geographic, as 
well as public versus private), than in others.  This raises questions that have implications 
for policy considerations: Why is there a difference in geographic survival rates? Can 
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something be done to improve the situation? While it might not be economically attractive 
for private hospitals to build new centres in the south of the country, is there any ‘scaled 
back’ version that could significantly impact survival rates?  For example, JCI literature 
describes cancer-specific accredited treatment centres (such as KHCC).  In the U.S., Mayo 
Clinic not only operates inpatient cancer hospitals in the state of Minnesota, but also 
provides several day-patient satellites in less-densely populated areas of the state.  Could 
this model be successfully applied in Jordan by KHCCH?  Or, might it be feasible to 
establish some form of twinning between private hospitals from Amman with public 
treatment centres in other parts of the country?  What might the likely impact on CRC 
survival rates be? All these questions should steer decision-finding evidence to assist 
policy makers and program planners in providing optimal and essential CRC care.  
 
In this study we estimated the survival estimated based on the available Jordanian data. 
Information about the socio-economic factors was available neither in medical records nor 
in JCR. This leaves questions about the nature and extent of variations in survival 
according to personal characteristics reflecting socio-economic status. It may be that 
additional data on income and health-related behaviours could be gathered routinely to 
help understand these influences. Issues such as this should be taken into consideration for 
future in-depth research to provide greater insights into determinants of outcomes. 
 
In conclusion, there are potential policy issues that can enhance efforts for better 
prevention and management of colorectal cancer in Jordan, albeit the evidence provided in 
this study which discloses a better than expected colorectal survival rates. It is 
recommended that policy makers and health researchers investigate more fully the reasons 
behind the phenomenon of regional differences, and, in particular, to examine the 
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associated factors of use of health services in the southern region. It is also recommended 
that policy makers implement strategies for primary and secondary prevention since such 
strategies are becoming increasingly important for Jordan. 
 
9.5.4 Improve and strengthen data quality measures 
Improve completeness and quality of Jordan Cancer Registry. As mentioned earlier, 
the national JCR was established in 1996 in collaboration with NCI-USA and the MECC. 
External assessors evaluated completeness and reliability of the JCR data in 1998 and 
registrations at the JCR were determined to be 88 percent complete. Such a completeness 
rate is considered good for a newly established registry. However, when collecting 
information from JCR, there were some difficulties in ascertaining all cases and gathering 
all the required information as well as in coding and validation procedures, which in turn 
call for employing further data quality control measures.  
 
JCR collects data on CRC from all related health facilities; i.e. Ministry of Health, the 
Royal Medical Services, universities and private as well as public-sector pathology 
laboratories; and uses active and passive methods of case finding, thus far the registry only 
collects the basic information of the patients (e.g. four digit name, sex, age, ID, nationality, 
stage, morphology, topography, behaviour, site of treatment and place of residency), 
However, other useful information (such as level of education, marital status, occupational 
status, health insurance, smoking status, treatment and patient outcome) are not collected. 
The study recommends increasing the awareness of JCR staff of the importance of quality 
and benefits of the registry and increasing the active data collection registry. Nowadays the 
cancer registry role has developed beyond providing cancer counts and incidence. 
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Therefore, the study recommends that JCR consider scaling up its role to include 
following-up with cancer patients in order to monitor the quality of cancer services they 
receive. 
 
Establish linkages and networking to improve information sharing. Currently there is 
no direct electronic network between the JCR and the CRB. Thus, it is recommended to 
establish such a link to support completeness, accuracy and timeliness of the vital status of 
cancer patients.  
 
Jordan still suffers from absence/inadequate computerized patient records’ systems, 
particularly in public health hospitals. However, KHCC and many of the private hospitals 
do have such computerized systems. It is recommended that JCR enhance the quality of its 
data by collaborating with the already-computerized hospitals in establishing a directly 
linked electronic network.  
 
Improve patient medical records and establish quality improvement systems. In this 
study the medical records were an important source of data.  Reviewing the medical 
records was very beneficial to better understand the type of treatment administered as well 
as to attempt to fill the gaps in information missing from JCR. However, Jordan, as in 
many other developing countries, still suffers from inadequate clinical follow-up systems 
in hospitals and an absence of computerized patient records’ systems. Medical records with 
missing data are very common. Most of the hospitals do not have written policies and 
procedures for medical records upkeep. Moreover, few of the hospitals conduct periodic 
quality reviews for accuracy and completeness of information. Cancer registries should 
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foster awareness of the importance and uses of the valuable data that they collect. 
Clinicians and pathologists should recognize their potential contribution in improving the 
quality of cancer registry data. Well-maintained patient records’ systems should be 
implemented irrespective to whether or not an institution has its own resources to invest in 
computerization; where institutional funds are lacking, the government should assist.  
Providing proper recordkeeping, standards of quality and performance should be 
implemented as well. All of these steps lead toward continuous improvement in the quality 
of services provided.  
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APPENDIX 2: OBSERVED AND RELATIVE SURVIVAL RATES BY SEX AND 
YEAR OF DIAGNOSIS 
Table A.1: Observed (OS) and relative survival (RS) estimates for patients diagnosed 
with colorectal cancer during 2003-2007, Jordan 
Year 
Male Female Overall 
No. OS percent 
RS 
percent No. 
OS 
percent 
RS 
percent No. 
OS 
percent 
RS 
percent 
0.0- 0.1 1 053 95.9 95.9 843 96.9 96.9 1 896 96.3 96.4 
0.1-0.2 1 001 94.1 94.1 814 94.8 94.9 1 815 94.4 94.5 
0.2- 0.3 976 92.2 92.4 788 93.4 93.5 1 764 92.8 92.9 
0.3- 0.4 953 90.1 90.3 772 91.8 91.9 1 725 90.9 91.1 
0.4- 0.5 925 88.7 89.0 756 89.4 89.5 1 681 89.0 89.2 
05- 0.6 907 87.3 87.6 734 87.7 87.8 1 641 87.5 87.7 
0.6- 0.7 889 85.9 86.3 714 86.7 86.8 1 603 86.3 86.5 
0.7- 0.8 872 85.3 85.6 705 85.6 85.8 1 577 85.4 85.7 
0.8- 0.9 862 83.5 83.9 693 84.2 84.4 1 555 83.8 84.2 
0.9- 1.0 840 82.2 82.6 681 83.3 83.6 1 521 82.7 83.1 
1.0- 1.5 825 76.4 77.1 671 78.3 78.7 1 496 77.3 77.9 
1.5- 2.0 761 71.9 73.1 620 74.5 75.1 1 381 73.1 73.9 
2.0- 2.5 713 67.9 69.3 587 71.5 72.2 1 300 69.5 70.6 
2.5- 3.0  668 65.2 66.9 557 69.7 70.6 1 225 67.2 68.6 
3.0- 4.0 641 60.1 62.9 542 64.7 66.3 1 183 62.1 64.5 
4.0- 5.0 541 55.9 60.1 372 59.8 62.3   823 57.7 61.3 
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Table A.2: Observed (OS) and relative survival (RS) estimates for patients 
diagnosed with colon cancer during 2003-2007, Jordan 
Year 
Male Female Overall 
No. OS percent 
RS 
percent No. 
OS 
percent 
RS 
percent No. 
OS 
percent 
RS 
percent 
0.0- 0.1 658 94.8 95.3 643 96.1 96.1 1 420 95.6 95.7 
0.1-0.2 617 92.3 93.1 615 93.6 93.7 1 348 93.3 93.4 
0.2- 0.3 597 90.5 91.3 592 92.2 92.3 1 304 91.6 91.8 
0.3- 0.4 581 88.3 89.2 581 90.7 90.8 1 275 89.8 89.9 
0.4- 0.5 563 86.9 87.7 570 88.3 88.5 1 243 87.9 88.1 
05- 0.6 552 86.1 86.3 553 87.1 87.2 1 212 86.5 86.7 
0.6- 0.7 539 84.9 85.3 539 85.9 86.1 1 183 85.4 85.7 
0.7- 0.8 532 84.3 84.7 532 84.6 84.8 1 165 84.4 84.8 
0.8- 0.9 524 82.4 82.8 521 83.8 84.0 1 146 83.0 83.4 
0.9- 1.0 509 81.4 81.9 515 83.0 83.3 1 124 82.1 82.5 
1.0- 1.5 500 76.4 77.2 510 78.1 78.5 1 110 77.2 77.8 
1.5- 2.0 464 72.0 73.1 471 75.1 75.7 1 029 73.4 74.2 
2.0- 2.5 438 68.0 69.5 452 71.9 72.7 977 69.8 70.9 
2.5- 3.0  410 66.1 68.0 429 69.9 70.9 920 67.8 69.3 
3.0- 4.0 399 63.8 63.7 416 69.9 67.4 893 62.9 65.4 
4.0- 5.0 282 56.9 61.8 290 65.7 63.7 626 58.8 62.7 
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Table A.3: Observed (OS) and relative survival (RS) estimates for patients diagnosed 
with rectum cancer during 2003-2007, Jordan 
Year 
Male Female Overall 
No. OS percent 
RS 
percent No. 
OS 
percent 
RS 
percent No. 
OS 
percent 
RS 
percent 
0.0- 0.1 276 97.8 97.9 200 99.5 99.5 476 98.5 98.6 
0.1-0.2 268 97.1 97.2 199 99.0 99.0 467 97.9 97.9 
0.2- 0.3 264 95.3 95.4 196 97.5 97.5 460 96.2 96.3 
0.3- 0.4 259 93.4 93.6 191 95.4 95.5 450 94.3 94.4 
0.4- 0.5 252 92.3 92.5 186 92.9 92.9 438 92.5 92.7 
05- 0.6 248 91.2 91.5 181 89.8 89.9 429 90.6 90.8 
0.6- 0.7 245 88.9 89.3 175 89.3 89.4 420 89.1 89.3 
0.7- 0.8 239 88.2 88.6 173 88.8 88.9 412 88.4 88.7 
0.8- 0.9 237 86.7 87.1 172 85.7 85.8 409 86.3 86.6 
0.9- 1.0 231 84.5 84.9 166 84.6 84.8 397 84.5 84.9 
1.0- 1.5 225 76.6 77.2 161 79.3 79.7 386 77.7 78.2 
1.5- 2.0 203 71.9 72.9 149 72.9 73.3 352 72.4 73.1 
2.0- 2.5 188 67.8 69.1 135 70.2 70.8 323 68.8 69.8 
2.5- 3.0  177 62.8 64.3 128 69.1 69.9 305 65.4 66.6 
3.0- 4.0 164 58.5 60.8 126 61.5 62.8 290 59.7 61.7 
4.0- 5.0 115 53.2 56.8 82 55.8 57.8 197 54.3 57.2 
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ANNEX 1: DATA COLLECTION QUESTIONNAIRE 
Colorectal cancer survival in Jordan (2003-2007) 
Information collection instrument 
 
 
Number of case: ------------ 
 
1. Cancer registry  
 
 
National ID: 
 
 
Name:       -----------------------------------------------------------------                                                
 
Sex         Male        Female  
 
 
 Age   
 
   
  
4- Address: Governorate: ---------------------------------- 
                     
District:----------------------------------------       
 
Date of diagnosis: DD/MM/YYYY 
 
Site of the tumor (Topography) according to ICD (O3):  
 
 
------------------------------------ 
 
 
Morphology ICD (O3): ------------------------------------------------- 
 
 
Staging:  
TNM classification: 1- Stage I      2- Stage II    3-stage III     4- stage IV         
5- unknown 
 
Dukes Classification: 1- Stage A    2- Stage B    3-Stage C      4- Stage D         
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 5- unknown 
 
Summary stage: 0  1 2 3 4 5 6 7 9  
 
Extent of disease      1- Local         2 - Regional        3 -  Distant metastasis 
 
Grade and differentiation: 1. Well    2. Moderate    3. Poor    4.anaplastic    
  5.Unknown  
 
Treatment:      1. Palliative treatment          2. Curative treatment:  
 
If curative specify:       1.surgey         2.chemotherapy            3.radiotherapy  
 
 
Vital status : 1- A live      2-dead        3-unknown 
 
 
Date of last visit:  DD/MM/YYYY 
 
 
Time passed (months) from date of diagnosis to date of last visit:------------ 
 
Cause of death:   1- Cancer    2- Other causes (specify):----------------------- 
 
2. Medical records:  
 
Hospital name: ………………………………………… 
 
Patient’s record serial number:……………………………….. 
 
Patient’s doctor name: …………………………… 
 
Smoking status    Yes    No 
 
Occupation:………………………………………. 
 
Level of education :------------------------------------------------------------------ 
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Family history :   1- yes       2- no      which relative 
 
Any benign tumors (adenomatous polyp) 
 
Last contact date: DD/MM/YYYY 
 
Co-morbidity: 1. diabetes  ………………..for   …………years 
2.Hypertension   3.cholesterol 4.obesity   
  
Case summary: --------------------------------------------------------------------------- 
 
 
 
 
 
Admission history: -main symptom (presenting) ------------------------------------ 
 
---------------------------------------------------------------------------------------------- 
 
Emergency or elective…………………………… 
 
Endoscopy done    1- yes     Date : dd/mm/yyyy      2- no               
 
Main source of medical services:  
1. MOH  2.University   3.Military  4.UNRWA  5. Private  
6. Other (specify)……………………………………… 
 
Health insurance status:  
Having health insurance:   Yes   No  
Type of health insurance: …………………………………….. 
Treatment:  
1.surgey 2.chemotherapy 3.radiotherapy (you can circle more than one) 
 280 
Surgery:  
Date of surgery: DD/MM/YYYY 
Type of surgery: emergency   elective  
Surgery procedure:  
Date of starting chemotherapy: DD/MM/YYYY 
Frequency:-----------------------------  
Duration:------------------------------  
Radiotherapy: 
Date of starting radiotherapy: DD/MM/YYYY 
Frequency:-------------------------------  
Duration:----------------------------------  
 
 
3. Histopathology report:  
 
Laboratory name:  
Record serial number:  
Referral side:  
Case summary: …………………………………………………. 
Tumor size at histological examination      1 -  (<2 cm)         2 -  ( ≥2 cm)  Lymph nodes 
   1- None           2-one          3 – (2-3)         4- ( >3)  
 
 Receptors status (carcinoembryonic antigen (CEA) and CA 19-9 
    1- Positive    2- Negative          3 – Unknown 
 
Time passed (months) from the date of diagnosis and the last visit:  DD/MM/YYYY 
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ANNEX 2: PERMISSIONS AND ETHICAL APPROVALS  
 
Dear Mr Al-Nsour 
 
Project Title: Colorectal cancer survival in Jordan (2003-2007).                      
Project No:  FM 00310 
 
The College Ethics Committee has reviewed your application and has agreed that there is 
no objection on ethical grounds to the proposed study.  They are happy therefore to 
approve the project, subject to the following conditions  
The research should be carried out only on the sites, and/or with the groups defined in the 
application.  
Any proposed changes in the protocol should be submitted for reassessment, except 
when it is necessary to change the protocol to eliminate hazard to the subjects or where 
the change involves only the administrative aspects of the project.  The Ethics Committee 
should be informed of any such changes. 
 If the study does not start within three years of the date of this letter, the project should 
be resubmitted. 
 You should submit a short end of study report to the Ethics Committee within 3 months 
of completion. 
 
Yours sincerely 
 
 
 
Professor William Martin 
College Ethics Officer  
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150 cours Albert Thomas 
69372 Lyon cedex 08, France  
 
 
 
 
IARC Ethics Committee (IEC) Tel.: +33 4 72 73 85 43  
Fax: +33 4 72 73 85 64 E-mail: iec@iarc.fr http://ethics.iarc.fr/ 
 
 
 
Ref.: IEC 12-07                            28th March 2012 
 
 
You submitted the following project for review by the IARC Ethics 
Committee (IEC): 
Project No. 12-07 
 
Colorectal cancer survival in Jordan 2003-2007 
 
 
Dr M. Nsour  
Cancer Information Section (CIN)  
IARC 
 
 
 
28th March 2012 
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UNIVERSITY OF GLASGOW 
 
FACULTY OF MEDICINE ETHICS COMMITTEE FOR NON CLINICAL  
RESEARCH INVOLVING HUMAN SUBJECTS 
 
 
APPLICATION FORM FOR ETHICAL APPROVAL 
 
 
NOTES: 
 
THIS APPLICATION FORM SHOULD BE TYPED NOT HAND WRITTEN. 
 
ALL QUESTIONS MUST BE ANSWERED.  
“NOT APPLICABLE” IS A SATISFACTORY ANSWER WHERE APPROPRIATE. 
 
 
FACULTY PROJECT CODE: 
 
 
Project Title  
Colorectal cancer survival in Jordan (2003-2007).                      
 
Date of submission: 17 August 2010.   
 
Name of all person(s) submitting research proposal: Mohannad Al Nsour  
 
Position(s) held:               PhD student  
Department/Group/Institute/Centre:  
University of Glasgow. College of Medical, Veterinary and Life Sciences. Public 
Health and Health Policy.  
International Agency for Research on cancer (IARC). Cancer Information Section 
 
 
Address for correspondence relating to this submission 
Mohannad Al- Nsour  
P.O.BOX:963709.  
Postal code: 11196, Amman, Jordan.  
Mobile: +962 (0) 777763519. 
E-mail: mohannadnsour973@yahoo.com    
 
Name of Principal Researcher (if different from above e.g., Student’s Supervisor)  
 
Position held :  
Undergraduate student project   Yes/No 
Postgraduate student project    Yes/No 
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 If yes, please state degree being undertaken: PhD  
1. Describe the purposes of the research proposed.  Please include 
the background and scientific justification for the research.  Why is 
this an area of importance? 
 
Jordan, as other Eastern Mediterranean countries, still suffers from scarcity of 
local research that investigate the incidence, survival, prevalence and the other 
different aspects of cancer in these countries. Recently, Jordan, in cooperation 
with World Health organization (WHO), launched the National Health 
Research Priorities (2009-2012).  Colorectal cancer was at the top of these 
priorities.  
In Jordan, colorectal cancer is the second leading incidence rate in both males 
(after lung cancer) and females (after breast cancer) where it affected 
(12.1percent), and (8.9percent) respectively. Furthermore, colorectal cancer is 
considered the second prevalent cause of death among cancer deaths.  
Few survival studies were conducted in developing countries. In Jordan, to 
best of our knowledge no information is available about the survival statistics 
of colorectal cancer. Survival statistics are means of quantifying the 
effectiveness of early detection strategies and treatment regimes at the 
population level [15, 24]. They are useful as comparative measures between 
different populations. Information about the survival rates will help us take 
further preventive and control measures in order to improve the quality of 
cancer care they receive. Survival data is an important tool to evaluate the 
effectiveness and efficiency of cancer health services.   
 
 
2. Describe the design of the study and methods to be used.  
Include sample size and the calculation used to determine this.  
Statistical advice should be obtained if in doubt. 
 
The design for this project will be a descriptive study using data from the 
Jordan cancer registry (JCR). All Jordanian colorectal patients who were 
diagnosed with Colorectal cancer during the period 2003 (January 1st- 2007 
(December 31st) and registered in Jordan cancer registry will be enrolled in 
this project. No sample size will be drowning. Colorectal cancer information 
patients will be officially collected from the Jordan cancer registry. 
Identifying the vital status of the patients will be ascertained from Civil 
registration Bureau through unique National Identification number (ID) of the 
patients. ID number will be used for verifying the duplication. Active 
strategies for completing the missing information will be followed: Reviewing 
medical records of the hospitals and reviewing the pathological laboratory 
reports to obtain the missing information related to the site, stage, and grade of 
the cancer. Patients not traced after these efforts, they will be considered as a 
lost of follow cases. No home visits or phone calls to the patients.  
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3. Describe the research procedures as they affect the research subject and 
any other parties involved. 
It should be clear exactly what will happen to the research participant, how 
many times and in what order. 
 
 
Not applicable.  
 
 
 
 
 
 
 
4. How will potential participants in the study be (i) identified, (ii) 
approached and (iii) recruited?   
Give details for cases and controls separately if appropriate: 
 
The subjects of this study will the Jordanian population, aged 15 years and over, who 
were diagnosed with a primary colon (International Classification of Diseases-10 C-18) or 
rectum (ICD-10 C19 and C20) cancer during the period 2003 (January 1st- 2007 
(December 31st) and registered in Jordan cancer registry verified by histopathology 
report. Non-Jordanian nationalities, any case with no histological report and prevalent 
and/or recurrent cases will be excluded from the study.  
 
 
 
5. What are the ethical considerations involved in this proposal?  (You may 
wish for example to comment on issues to do with consent, confidentiality, 
risk to subjects, etc.) 
 
Data will be handled in compliance with the Data Protection Act 1988; information will 
be treated with utmost confidentially: At the analysis stage, computer generated numbers 
replace subjects. Identifying information and the results published with no reference to 
names of studied subjects. Results obtained from data collection and analysis stayed 
confidential and not used for purposes other than those mentioned in the proposal.  
 
 
 
6. Outline the reasons why the possible benefits, to be gained from the 
project, justify any risks or discomforts involved.  
There is no direct contact with patients. No any risks or discomforts can be caused.  
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7. Who are the investigators (including assistants) who will conduct the 
research?  What are their qualifications and experience? This research will be 
contacted by me (Mohannad Al-Nsour). Iam a holder Bachelor of Medicine, Bachelor of 
Surgery (MB, BSc.), MSc. In Epidemiology, and Board in Community 
Medicine/Epidemiology. Currently Iam PhD fellow at International Agency for research 
on cancer & Glasgow university (Joint program). Iam working in this project under 
supervision of : Dr.David Forman, International Agency for Research on Cancer  (IARC). 
Head, Descriptive Epidemiology   Production Group.  
Dr. David S Morrison,  University of Glasgow. Director, West of Scotland Cancer 
Surveillance Unit.  
 
 
 
 
8. Are arrangements for the provision of clinical facilities to handle 
emergencies necessary?  If so, briefly describe the arrangements made.  
 
Not Applicable. There is no direct contact with study subjects 
 
 
9. In cases where subjects will be identified from information held by another 
party (for example, a doctor or hospital), describe how you intend to get this 
information.  Include, where appropriate, which Multi Centre Research Ethics 
Committee or Local Research Ethics Committee will be applied to.   
 
Official approval of Jordan cancer registry to utilize available colorectal cancer data was 
obtained. Official approval from the ethical committee at the Jordan ministry of health was 
obtained. Furthermore, official approvals from different sectors will be obtained according 
to the project needs. 
 
 
 
10. Specify whether subjects will include students or others in a dependent 
relationship.   
 
Not Applicable. There is no direct contact with study subjects 
 
 
11. Specify whether the research will include children or people with mental 
illness, disability or handicap.  If so, please explain the necessity of involving 
these individuals as research subjects, and include documentation of the 
suitability of those researchers who will be in contact with children (eg 
Disclosure Scotland). 
No children or people with mental illness, disability or handicap will be including in thee 
project.  
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12. Will payment or any other incentive, such as a gift or free services, be 
made to any research subject?  If so, please specify and state the level of 
payment to be made and/or the source of the funds/gift/free service to be 
used. Please explain the justification for offering an incentive. 
 
 There is no any type of incentive will be made to any research subject 
 
 
     
13. Please give details  of how consent is to bee obtained. A copy of the 
proposed consent form, along with a separate information sheet, written in 
simple, non-technical language MUST ACCOMPANY THIS PROPOSAL FORM. 
 
A special form (appendix 1) was developed to collect the requested information. This 
information includes: 1. Socio-demographic data: ID number, name, sex, age, date of birth, 
address, (Governorate), main source of medical services, having health insurance,  the type 
 of health insurance, and date of diagnosis. 2. Clinical data: site, grade, stage, and 
morphology. 3. Type of treatment collected from medical records form main hospitals and 
pathological laboratories. 4. Vital status data: if the patient alive or dead. The starting point 
is the date of diagnosis of the patients, which was reported in files from 2003-2007.  No 
any other forms will be used during project implementation.   
 
 
 
 
14. Comment on any cultural, social or gender-based characteristics of the 
subject, which have affected the design of the project or may affect its 
conduct. 
 
Not applicable.  
 
 
15.  Please state who will have access to the data and what measures will     
be adopted to maintain the confidentiality of the research subject and to 
comply with data protection requirements e.g. will the data be anonymised, 
how will it be stored, how will access be restricted, and for how long will it be 
retained? 
 
Information will be treated with utmost confidentially: At the analysis stage, computer 
generated numbers replace subjects. Identifying information and the results published with 
no reference to names of studied subjects. Results obtained from data collection and 
analysis stayed confidential and not used for purposes other than those mentioned in the 
proposal. 
           
16. Will the intended group of research subjects, to your knowledge, be 
involved in other research?  If so, please justify. 
 
Not applicable.  
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17. Proposed starting date : 01/05/2009.  
 
      Expected completion date: 01/05/2012.      
 
 
 
 
 
18. Please state location(s) where the project will be carried out. 
 
 
Jordan cancer registry, government and private hospitals, and Pathology laboratories, and 
Civil Registration Bureau.   
 
 
 
 
19. Please state briefly any precautions being taken to protect the health and 
safety of researchers and others associated with the project (as distinct from 
the research subjects) e.g. where blood samples are being taken 
 
Not applicable.  
 
 
 
20. Please state all relevant sources of funding or support for this study  
 
There is no fund for the Project.  
 
 
 
21 a). Are there any conflicts of interest related to this project for any 
member of the research team? This includes, but is not restricted to, financial 
or commercial interests in the findings. If so, please explain these in detail 
and justify the role of the research team. For each member of the research 
team please complete a declaration of conflicts of interest below. 
 
No conflict of interest. 
 
Researcher: 
Name: _________________________________________conflict of interest Yes / No 
If yes, please detail below 
Researcher: 
Name: __________________________________________conflict of interest Yes / 
No 
If yes, please detail below 
Researcher: 
Name: __________________________________________conflict of interest Yes / 
No 
If yes, please detail below 
Researcher: 
Name: __________________________________________conflict of interest Yes / 
No 
If yes, please detail below 
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21 b). If there are any conflicts of interest, please describe these in detail 
and justify conducting the proposed study. 
 
None.  
 
 
 
22. How do you intend to disseminate the findings of this research? 
 
 
I intend to disseminate the findings of this research through presentations, publications, 
and sharing my results with technical persons and policy makers who are working in 
cancer field in Jordan.    
 
 
 
 
 
 
 
I confirm that have read the University of Glasgow’s Data Protection Policy  
[http://www.gla.ac.uk/services/dpfoioffice/policiesandprocedures/dpa-policy/]    
 
       Please check initial box     
 
 
 
Signed __Mohannad Al-Nsour     Date: 17 August 2010  
(Proposer of research) 
 
 
 
For student projects 
 
I confirm that I have read and contributed to this submission and believe that 
the methods proposed and ethical issues discussed are appropriate. 
 
I confirm that the student will have the time and resources to complete this 
project.  
 
 
Signed __Mohannad Al-Nsour _______________    Date _17 August 2010 
(Supervisor of student) 
 
 
 
 
Send completed signed form to 
 
Sarah Torbet  
Medical Faculty Office  
Wolfson Medical School Building  
University Avenue  
Glasgow  
√ 
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G12 8QQ  
Tel:  0141 330 5921  
Fax:  0141 330 5440 
 
Please also send electronic versions of completed form and all other paperwork to  
s.torbet@clinmed.gla.ac.uk 
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W O R L D    H E A L T H 
 O R G A N I Z A T I O N 
 
ORGANISATION  MONDIALE 
DE  LA  SANTE 
CENTRE  INTERNATIONAL  DE  RECHERCHE  SUR  LE  CANCER 
INTERNATIONAL  AGENCY  FOR  RESEARCH  ON  CANCER 
 
IARC ETHICS QUESTIONNAIRE 
 
 
This form should be completed by the Principal Investigator for all applications.  Please 
answer all questions carefully.  If you consider some of these are not relevant to your 
study, answer N/A.  The IRB/ERC will decide. 
 
 
1.  Title of Research: 
 
Full title  
 
 
 
 
 
 
Acronym  
 
 
Type of project (please circle): 
i. Studies based on grouped data (pooled and previously collected material)   
ii. Descriptive epidemiological studies (record linkage and population surveys)  
iii. Analytical epidemiological studies (case-control and cohort) 
iv. Randomized population studies 
v. Other 
 
If other, give details: 
 
 
    
 
 
 
Please indicate whether project funded on external funds:     Yes       No  
 
 
OR on the regular budget. Please provide Project Abstract Sheet reference:  
 
 
2.  IARC Principal Investigator: 
 
 Title:         First Name/Initials:                Last Name:   
 
  
IARC Cluster/Group/Team:  
 
Colorectal cancer survival in Jordan 
2003-2007 
Student Mohannad  AlNsour
 
Cancer Information Section
X
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3. Proposed study dates and duration: 
 
 Start date:      End date:  
 
 
Duration: Years:                 Months:    
 
 
 
4. What is the principal research question / objectives? (Must be in language 
comprehensible to a lay person – up to 250 words) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
01/05/2009 01/05/2012 
Three -
Research questions:  
1. What are the Observed and relative 5 years Survival rate of colorectal cancer in 
Jordan in patients diagnosed in 2003-2007? 
2. Does survival from colorectal cancer differ between Jordan and other 
comparable countries, and if so, can these be explained by differences in patient 
factors, disease characteristics, or treatment?”.  
3. Are there survival differences between treatment cites within Jordan and how 
might they be explained?”. 
 
Objectives:  
1. To produce estimates of observed survivals 1, 3, and 5 years for colorectal 
cancer Jordanian patients.  
2. To report the influence on survival rates of patient’s age, and the morphology, 
anatomical sub-site of the tumour, age at diagnosis, and type of treatment). 
Moreover, to determine the net effect of each of these different variables on the 
risk of survival rates of colorectal cancer patients. 
3. To produce estimates of 5 years relative survivals for colorectal cancer 
Jordanian patients with their corresponding age-standard relative survivals.  
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5. What is the rationale and justification for the research? (Must be in language 
comprehensible to a lay person – up to 250 words) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Provide practical details of the research to be conducted. It should be clear what 
happens to each research participant, how many times and in what order (up to 250 
words) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Survival statistics are means of quantifying the effectiveness of early detection 
strategies and treatment regimes at the population level. They are useful as comparative 
measures between different populations. It is these comparisons that help us to identify 
possible reasons for the differences and suggest targets for improvement and a means 
of monitoring progress toward them. Nowadays cancer registry role has developed 
beyond providing cancer counts and incidence; cancer registry is plying a major role in 
monitoring and evaluation of screening programs, and following-up of cancer patients 
to examine the quality of cancer services they receive.  
In Jordan, there are two main referral centres provide treatment for patients with cancer; AL-
Basheer hospital which belongs to ministry of health and King Hussein Cancer Center. The 
name of the center to honor the late King Hussein, who died of cancer, implied full Royal 
support for this project. These two centres are located in Amman the capital city of Jordan and 
they receive cancer patients from different governorates in the country. Furthermore, the two 
major histology laboratories are located in these two centres. All Jordanian colorectal cancer 
patients who diagnosed in 2003 (January 1st) – 2007 (December 31st) will be included in the 
study.  
1. Colorectal cancer information patients will be officially collected from the Jordan 
cancer registry.   
2. Identifying the vital status of the patients will be ascertained from Civil registration 
Bureau through unique National Identification number (ID) of the patients. ID number 
will be used for verifying the duplication.  
3. Active strategies for completing the missing information will be followed :  
 Reviewing medical records of the hospitals.  
 Reviewing the pathological laboratory reports to obtain the missing information 
related to the site, stage, and grade of the cancer.  
4. Patients not traced after these efforts, they will be considered as a lost of follow cases. 
No home visits or phone calls to the patients. 
 
Written permissions to the Ministry of Health, King Hussein Cancer Center, Royal Medical 
Services Hospitals, private hospitals and labaratories, civil registration Beuro (Ministry of 
interior), and department of Health Statistics will be requested. Furthermore, a copy of the 
proposal should also be submitted.  
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7. Please list all partner institutions where the research will take place and indicate 
their tasks. Give details of the main investigator in each centre. For new partners, 
please provide their website address: 
 
Name and address of institution Main investigator 
 
 
Ministry of Health  
 
 
 
 
 
Mohannad Al Nsour  
 
King Hussein Cancer Centre 
 
 
 
 
Mohannad Al Nsour  
 
 
8. Has local ethics approval been requested from all the partner institutions listed in 
question 7? If yes, what was the outcome? (Attach copies) If no, please indicate if it 
will be requested and if not, explain why. 
 
  
 
 
 
 
 
9. Will the research participants receive any clinical intervention or procedure 
including taking samples of human biological material over and above that which 
would normally be considered a part of routine clinical care? 
 
                                      YES        NO      
  
 
 
Additional intervention Average number per patient 
 
 
Average time taken 
(mins/hrs/days) 
Details of additional 
intervention or procedure, 
who will undertake it and 
what training they have 
received 
Routine care Research 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Add more details on a separate sheet if necessary. 
 
 
 
 
 X
Yes. Local ethics approvals have been requested from all the partner institutions listed in question 7. 
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10. Will research participants be subject to any non-clinical research-related 
interventions or procedures (for example, administration of questionnaires)? 
 
                                      YES        NO    
  
 
Additional intervention Average number per patient 
 
 
Average time taken 
(mins/hrs/days) 
Details of additional 
intervention or procedure, 
who will undertake it and 
what training they have 
received 
Research 
 
 
 
   
 
Add more details on a separate sheet if necessary. 
 
 
 
 
 
11. Will interviews discuss any topics or issues that might be sensitive, embarrassing or 
upsetting?  
                                      YES         NO    
 
If yes, give details of procedures in place to deal with these issues: 
 
  
 
 
 
 
 
 
 
 
 
12. What are the potential adverse effects, risks or hazards for research participants 
either from giving or withholding medications, medical devices, ionizing radiation or 
from other interventions including non-clinical: 
                                     
 
 
 
 
 
 
 
13. What is the potential for pain, discomfort, distress, inconvenience or changes to 
lifestyle for research participants: 
 
      
 
 
 
 
 
 
 X
 X
 
            None                                 
                        
None 
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14. What is the potential for benefit for research participants and the community as a 
whole? 
 
 
 
 
 
 
 
 
15. What is the potential for adverse effects, risks, discomfort, distress or 
inconvenience to the researchers, technicians and nurses involved? 
 
  
 
 
 
 
16. How will potential research participants in the study be (i) identified, (ii) 
approached and (iii) recruited? What are the principal inclusion and exclusion criteria? 
 
Give details for controls separately if appropriate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17. Will any research participants be recruited who are involved in existing research or 
have recently been involved in any research prior to recruitment? 
 
                         YES          NO             NOT KNOWN   
 
 
 
Information about the survival rates will help us take further preventive and control 
measures in order to improve the quality of cancer care they receive. Survival data is an 
important tool to evaluate the effectiveness and efficiency of cancer health services.  
None 
All Jordanian colorectal cancer patients who diagnosed in 2003 (January 1st) – 2007 
(December 31st) will be included in the study. No sample size will be drowning. The 
outcome of interest is colorectal cancer cases is either alive or dead or unknown. 
Inclusion criteria: All Jordanian colorectal patients (aged 15 years and above) who 
were diagnosed with invasive primary Colorectal cancer (C18-C20.9) during the period 
2003 (January 1st- 2007 (December 31st) and registered in Jordan cancer registry 
verified by histopathology report.  
Exclusion criteria: Non-Jordanian nationalities, any case with no histological report 
and prevalent and/or recurrent cases will be excluded from the study 
X 
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Give details and justify their inclusion: 
 
 
 
 
 
 
 
18. Has any responsibility for the research been delegated to a subcontractor? 
 
                                    YES       NO  
  
Give details including name of research contract organization/site management organization and 
summary of delegated responsibility 
 
 
 
 
 
 
 
19. Will informed consent be obtained from research participants? 
 
                                  YES          NO    
 
 
Give details of how it will be done and who will do it. Also provide the information sheet: 
 
 
 
 
 
 
 
20. Describe and justify the inclusion of vulnerable groups: children, the elderly, those 
unable to consent because of mental incapacity. 
 
 
 
 
 
 
 
 
21. Will a signed record of consent be obtained? 
 
                                      YES        NO    
 
If answer is YES, please provide copies. If answer is NO, please justify: 
 
 
 
 
 
 
 
 
 
 X
 
 X
 
Not applicable 
X
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22. How long will the participants have to decide whether to take part in the research? 
 
 
 
 
 
 
 
23. What arrangements have been made for participants who might not adequately 
understand verbal or written information in the local language? (e.g. translation, use of 
interpreters, etc.) 
 
  
 
 
 
 
 
24. Will individual research participants receive any payments for taking part in this 
research? 
 
                                    YES      NO    
 
 Indicate how much and on what basis this has been decided: 
 
  
 
 
 
 
 
 
 
25. Will individual research participants receive reimbursement of expenses or any 
other incentives or benefits for taking part in this research? 
 
                                    YES      NO     
 
 Indicate how much and on what basis this has been decided: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Not applicable.  
Not applicable.  
 X
 
 
 X
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26. What arrangements have been made to provide indemnity and/or compensation in 
the event of a claim by, or on behalf of, participants for non-negligent harm? 
 
 
 
 
  
 
 
 
 
27. How is it intended the results of the study will be reported and disseminated? 
 
 |_X_| Peer reviewed scientific journals 
 |X__| Internal report 
 |_X_| Conference presentation 
 |_X_| Other publication 
 |_X_| Submission to regulatory authorities 
 |__| Access to raw data and right to publish freely by all investigators in study or by  
   Independent Steering Committee on behalf of all investigators 
 |__| Written feedback to research participants 
 |__| Presentation to participants or relevant community groups 
 |__| Other/None 
 
  
 
 
If other/none of the above, give details and justify: 
 
  
 
 
 
 
 
28. Will the research involve any of the following activities at any stage (including 
identification of potential research participants)?  
 
                                  YES      NO     
 
If yes, tick as appropriate: 
 
|__| Examination of medical records by those who would not normally have access 
|__| Electronic transfer by magnetic or optical media, e-mail or computer networks 
|__| Sharing of data with other organizations 
|__| Export of data 
|__| Use of personal addresses, postcodes, faxes, e-mails or telephone numbers 
|__| Publication of direct quotations from respondents 
|__| Publication of data that might allow identification of individuals 
|__| Use of audio/visual recording devices 
|__| Storage of personal data which allows identification on any of the following: 
   
 |__| Manual files including X-rays 
 |__| Local study centre 
 |__| IARC computer 
 
 
 
 
 
X
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 Further details: 
 
 
 
 
 
 
 
 
 
 
29. What measures will be put in place to ensure confidentiality of personal data? Give 
details of whether any encryption or other anonymisation procedures will be used, and 
at what stage: 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
30. Where will the analysis of the data from the study take place and by whom will it 
be undertaken? 
 
 
 
   
 
 
 
 
 
 
 
 
31. Who will have control of, and act as the custodian for, the data generated by the 
study? 
 
 
 
 
 
 
 
 
 
 
 
 
Data will be handled in compliance with the Data Protection Act 1988. Information 
will be treated with utmost confidentially: At the analysis stage, computer generated 
numbers replace subjects. Identifying information and the results published with no 
reference to names of studied subjects. Results obtained from data collection and 
analysis stayed confidential and not used for purposes other than those mentioned in 
the proposal.  
The data analysis will take part at IARC setting. Section of information.  The analysis 
will contacted by the main researcher under supervision of Dr.Forman head, section of 
cancer information and Dr.Morrison, Glasgow University.   
The analysis will contacted by the main researcher under supervision of Dr.Foreman 
head, section of cancer information and Dr.Morrison, Glasgow University.   
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32. Who will have access to the data generated by the study? 
 
 
 
 
 
 
 
33. For how long will the data be stored?        Years  Months  
 
 Give details of where they will be stored, who will have access, and of the custodial 
arrangements for the data: 
 
 
 
 
 
 
 
 
 
34. Explain measures for specimen storage, transport and processing.  
 
Include details of (i) where will the specimens be stored and for how long, (ii) who will have access 
to these samples, (iii) will identification of individuals be feasible. 
 
 
 
 
 
 
 
35. How has the scientific quality of the research been assessed? (Tick as appropriate) 
 
 |__| Independent external review 
 |__| Review within a multi-centre research group 
 |_X_| Internal review (e.g. involving colleagues, academic supervisor) 
 |__| None external to the investigator 
 |__| Other, e.g. methodological guidelines 
 
 If other, give details 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
The main researcher.  
5  
Data files will be maintained on a single password protected computer. The main 
researcher will control access to the computer.  
 
Not applicable.  
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If you are not in possession of any referees’ or other scientific critique reports relevant to your 
proposed study, justify and describe the review process and outcome. If review has been 
undertaken but not seen by the researcher, give the details of the body which has undertaken the 
review: 
 
  
 
 
 
 
 
A copy of any referees’ comments or other scientific critique reports relevant to the proposed 
research must be enclosed with the application form. 
 
 
36. What arrangements are in place for monitoring and auditing the conduct of the 
research? 
 
 
 
 
 
 
 
 
37. Has funding for the research been secured?          YES       NO    
 
Give details of funding organization(s), amount secured and duration of funding: 
 
 
Organisation 
 
 
Address  
 
 
Postcode  
IARC contact 
 
 
Telephone  
e-mail  
Fax  
Amount €  
Duration (months)  
 
Organisation 
 
 
Address  
 
 
Postcode  
IARC contact 
 
 
Telephone  
e-mail  
Fax  
Amount €  
Duration (months)  
 
 
 X
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38. Will individual researchers, other than IARC staff, receive any personal payment 
over and above normal salary for undertaking this research? 
 
                                     YES      NO 
 
 Indicate how much and on what basis this has been decided: 
 
 
 
 
 
 
 
 
39. Will the host organisation or the researcher’s department(s) or institution(s) 
receive any payment or benefits in excess of the costs of undertaking the research? 
 
                                      YES     NO    
 
 Give details: 
  
  
 
 
 
 
 
 
 
 
 
40. What do you consider to be the main ethical issues or problems which may arise 
with the proposed study, and what steps will be taken to address these? 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 X
 
1. Official approval of Jordan cancer registry to utilize available colorectal 
cancer data. Furthermore, official approval from the ethical committee at the 
Jordan ministry of health, King Hussein Cancer Center, Royal medical 
services, Department of Health statistics, and some of the private sector 
hospitals are needed to be obtained in advance.  
2. Data will be handled in compliance with the Data Protection Act 1988  
 Information will be treated with utmost confidentially: At the analysis 
stage, computer generated numbers replace subjects.  
 Identifying information and the results published with no reference to 
names of studied subjects.  
 Results obtained from data collection and analysis stayed confidential 
and not used for purposes other than those mentioned in the proposal.  
 x
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Please attach: 
 The participant information sheet 
 The consent form  
 The questionnaire 
 
 The protocol  
 Any advertising material 
 Any other relevant documents 
(as appropriate) 
 
 
 
Date 01/08/2010 
 
Signature of Principal Investigator :  Mohannad Al-Nsour  
 
Signature of Group Head ………………………………………………………………………….. 
 
Signature of Cluster Coordinator ……………………………………………………………….. 
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Confidentiality Form 
 
 
I the undersigned: …………………………………………………………… 
Agree not to disclose any information related to cancer patients that are registered at the 
Jordan Cancer Registry. 
 
 
I hereby sign, holding all responsibility to the above. 
 
 
Full Name: --------------------------------------------- 
 
Signature: --------------------------------------------- 
 
Certified by Non_Communicable Disease Directorate 
 
Certified by the Jordan Cancer Registry 
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Ministry of Health – NCDD 
                                 Jordan Cancer Registry 
Amman-Ph.962 6 5662067 
Request for Data from the National Jordan cancer Registry (JCR). 
 
 
 
Date Submitted : ...................................... 
 
Name : ........................................................................................................................................ 
 
Department : .............................................................................................................................. 
 
Institution : ............................................................................................................................... 
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Phone No : ........................... Fax No : .................... Email :........................................................ 
 
Information Requested : 
(Specify ,Time Period ,Site,Histology,Region,etc.) 
 
 
Purpose of Data Request: 
(Presentation / conference/assembly /publication/clinical,epidemiological study,etc.) 
 
 
Collaborators and Co-authors: 
 
Requester's affirmation statement: 
 
l hereby, supplicant of the above data affirm that the data given to me from the National Jordan Cancer 
Registry- JCR- will be treated with utmost confidentiality concerning  patient's identity, l also confirm 
that the data given to me will not be presented or published by me or any of my collaborators as an 
original work but rather can be cited in my presentation and/or publication with acknowledgement to 
the JCR .also confirm to provide copy of my work and feed-back to the JCR. 
 
Requester's Signature:……………………………..  Date:……………………….……………………………………. 
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For administrative  use only : 
 
Request:/  Approved : ……………………………Not Approved…………………………………………………….. 
 
 
Director of Jordan Cancer Registry………………………..….....Sign………...………………………………... 
 
 
Director of  Non-Communicable Disease Directorate…………………………..Sign………………………... 
 
Date:……………………………. 
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FORM A : Exempt IRB Review  
Version 1.1 
Date Approved February 2010
For IRB Use Only 
IRB Number  
Submission Date  
Research Title 
 
 
Principal 
Investigator 
 
Dr.Mohannad Al Nsour  
 
 
Check list for a complete submission 
 
A. The following documents must be submitted for the Exempt Review so that the 
application will be considered as complete and an IRB number will be then generated: 
 
CV(s) of Principal Investigator(s).  
Confidentiality Agreement for "Chart Reviewer(s)" only. 
Grant Application (if any) 
Consent Form (if any) or Request for Waiver of Consent Form. (Only for questionnaire/survey)  
Questionnaire or Survey (if any) 
Data Collection Sheet (if any) 
Other study related documents such as Investigator’s Brochure, other Institutional IRB 
Approvals, Flyers, Advertisement... etc (if any). This should be identified by version and issue 
date. 
 
B. Please NOTE the followings: 
 
- You must use the most updated IRB-form version. 
- The IRB form is to be electronically completed (it cannot be hand written). 
- The IRB form must be signed by ALL investigators and co-investigators properly. 
- Upon completion of the submission process, the study will be assigned an IRB-proposal 
number, without this number, the study will not undergo any review from the IRB.  
 
 
 
For more help, please contact the IRB office on: 
Tel     : (+9626) 5300460 Ext 1669 
Email: irboffice@khcc.jo 
 
 
Contents 
 
1. Study Team 
2. Exempt from IRB Review category 
3. Research Summary 
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 (1) Study team 
 
1.1 Principal Investigator(s): 
 
 
Principal Investigator from KHCC: Mr.Wael Shilbayah Department: CTR-CRRO 
Telephone Number:  Fax Number:  
E-mail address: wshilbayah@khcc.jo  
By signing, the PI assures that he/she will protect the privacy and the rights and welfare of 
human research subjects to the best of his/her ability. 
Signature of the KHCC PI:                                                 Date:  
KHCC Department Chairman Name: Signature:        Date:
 
Principal  Investigator from outside KHCC: 
DR.Mohannad Alnsour 
Signature: 
 
1.2 Co-Investigator(s) 
 
Co-Investigator Department Telephone E-mail Signature Date
Mr.Wael Shilbayah      
Dr.kamal Arqoob       
      
   
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
Signature of all Co-investigators acknowledges that they are thoroughly familiar with the contents 
of this research and pledge to assist the PI in protecting the privacy and the rights and welfare of 
human research subjects.   
 
1.2.1 Chart Reviewer(s): 
The PI must define a chart reviewer. He /she will be responsible for collecting patients' data from the 
medical records. 
Chart-Reviewer:  Mr.Wael Shilbayah                        Signature: 
Chart-Reviewer:  Dr.kamal Arqoob           Signature: 
Chart-Reviewer:                Signature: 
Chart-Reviewer:                Signature: 
Chart-Reviewer:                Signature: 
Chart-Reviewer:                Signature: 
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1.3 Research Office: Information about Research Staff is intended to facilitate communication. 
 
Clinical Research Coordinator CRC:  Telephone Number:  
E-mail address:  
Biostatistician:  Telephone Number:  
E-mail address:  
 
(2)Exempt from IRB review?  
 
2.1 Does the protocol include? 
 
2.1.1 - Children (Only for Interviews/Surveys)               Yes      No    
2.1.2 - Fetuses, pregnant women, or human in vitro fertilization           Yes      No
   
2.1.3 - Cognitively impaired                   Yes      No  
2.1.4 - Deception of subjects                  Yes      No 
 
If any one of the answers is Yes, then the protocol is NOT exempt, you need to complete 
Form-B  
 
2.2 Assessment of risk level of your project;  
 
Above than minimal risk      Yes      No 
At the level of minimal risk      Yes      No 
Lower than minimal risk     Yes      No 
If it qualifies at "level of" OR "more than" minimal risk, then the protocol is NOT 
exempt, you need to complete Form-B  
 
  
2.3 The protocol must qualify under one of the following categories: 
2.3.1  Surveys/ Interviews/ standardized educational tests/ observation of public 
behavior.   
Research involving the use of educational tests (cognitive, diagnostic, aptitude, achievement), survey 
procedures, interview procedures or observation of public behavior if:  (1) information obtained is 
recorded in such a manner that human subjects cannot be identified, directly or through identifiers linked 
to the subjects; or (2) and disclosure of human subjects’ responses outside research would not reasonably 
place the subjects at risk of criminal or civil liability or be damaging to the subjects’ financial standing, 
employability or reputation; AND children are not involved. 
  *Observation of public behavior in children may be exempt if the investigator does not participate in 
the activities being observed. 
 
2.3.2  Secondary use of pre-existing data.   
Research involving the collection or study of existing data, documents, records, pathological specimens, 
or diagnostic specimens (1) if these sources are publicly available, OR (2) if the information is recorded 
by the investigator in such a manner that subjects cannot be identified directly. “Existing data” means 
that the information or materials must already exist at the time of the research proposal, i.e. no on-going 
collection. If any of the above mentioned points (1 or 2) is not meet, then the project can not be exempt. 
It might be reviewed under expedited review.  
 
2.3.3 Research involving materials to be collected solely for non-research purposes. 
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Research involving materials (data, documents, records, or surplus specimens) that will be collected 
solely for non-research purposes (such as medical treatment or diagnosis). Some of these might be 
reviewed under expedited review. 
 
 
 
 
2.3.4  Taste and food quality evaluation.   
Taste and food quality evaluation and consumer acceptance studies: (1) if wholesome foods without 
additives are consumed; or (2) if food is consumed that contains a food ingredient at or below the level 
and for a use found to be safe, or agricultural chemical or environment contaminant at or below the level 
found to be safe, by the JFDA or approved by the Environmental Protection Agency or the Food Safety 
and Inspection Service of the Jordanian Ministry of Agriculture. 
 
4.3.5  Contract laboratory for de-identified sample analysis.  
Analyzing de-identified samples in a specialty laboratory or reading center if: (1) the investigator will 
never have access to the subject identifiers, and (2) the investigator is not a consultant, co-investigator, 
or author in the study, and (3) the investigator did not contribute to the protocol other than related to the 
assay or service provided by his/her laboratory. [Examples: serving as the ECG reading center or 
measuring plasma vasopressin on de-identified samples for a national trial with no other involvement in 
the trial.]  
 
(3) Research Summary 
 
3.1 Research Title: 
 
Colorectal cancer survival in Jordan 2003-2007 
3.2 Purpose of the Study: 
 Poster/ Oral Presentation at Conference.  
 Research Paper for Publication. 
 Master Degree 
 Ph.D. Degree  
 Others  
 
3.3 Study Design  
 Aims 
Explore observed and relative 5 years Survival rate of colorectal cancer in Jordan in 
patients diagnosed in 2003-2007 
 Identify the determinants (age, sex, site, grad, stage, treatment) of the Observed 5 years 
Survival rate of colorectal cancer in Jordan in patients diagnosed in 2003-2007 
 
Rational/Hypothesis: 
 
Our hypothesis is that there are differences in survival between Jordanian colorectal 
patients compared to colorectal patients in the developed countries; in addition to 
differences in survival between patients treated at different hospital services in Jordan 
(public health, teaching, and military hospitals) and that these differences could be 
explained by differences in patients’ management.  
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                                             Material and Methods:                                                                                           
Jordanian colorectal ll Our study will take place at national level including a                            
patients (aged 15 years and above) who were diagnosed with invasive primary Colorectal 
cancer (C18-C20.9) during the period 2003 (January 1st- 2007 (December 31st) and 
registered in Jordan cancer registry verified by histopathology report.  
 
The outcome of interest is the status of colorectal cancer cases (live, dead). The time at risk 
for each case will be measured by months from date of diagnosis to the last contact date. 
A special form was developed to collect the requested information. This information 
include 
1. Sociodemographic data: ID number, name, sex, age, date of birth, address 
(Governorate), main source of medical services, having health insurance,  the type of 
health insurance, and date of diagnosis.  
 2. Clinical data: site, grade, stage, and morphology.  
3. Type of treatment collected from medical records from main hospitals and pathological 
laboratories. 
4. Vital status data: if the patient alive or dead. The starting point is the date of patients’ 
diagnosis, as reported in files from 2003-2007.  
 
 
 Proposed Sample Size: 
 
The overall sample size for this study is 2,000 cases from different sites. The estimated 
sample size from King Hussein cancer center is 400.  
 
Statistical Consideration: 
   
Data collected will be analyzed in the following manner: 
 
1. Descriptive analysis (frequencies, and percentages and cross-tabulation) of the 
baseline characteristics. 
2. Kaplan Maier method will be used to determine the observed survival probability 
over the time.  
3. The effect of different predictors on survival rate (age at diagnosis, sex, stage, site, 
grade, and type of treatment) will be observed through survival graphs and using 
log rank test.  
4. Cox proportional hazard regression will be used to assess the net effect of each 
variable after simultaneously controlling the effects of potential confounders.    
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5. Life table for Jordanian population will be used to produce relative survivals (there 
is no available information on cause-specific mortality during the study time 
period, thus the calculation of cause-specific survival is not applicable).    
6. To compare the result with other countries, age-standardized relative survival will 
be calculated. 
7. Data will be analyzed using STATA (version 10). 
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